false
--12-31
Q3
0001642375
0001642375
2023-01-01
2023-09-30
0001642375
2023-11-09
0001642375
2023-09-30
0001642375
2022-12-31
0001642375
GHSI:SeriesCConvertibleRedeemablePreferredStockMember
2023-09-30
0001642375
GHSI:SeriesCConvertibleRedeemablePreferredStockMember
2022-12-31
0001642375
GHSI:SeriesDRedeemablePreferredStockMember
2023-09-30
0001642375
GHSI:SeriesDRedeemablePreferredStockMember
2022-12-31
0001642375
2023-07-01
2023-09-30
0001642375
2022-07-01
2022-09-30
0001642375
2022-01-01
2022-09-30
0001642375
GHSI:ClinicalNutritionMember
2023-07-01
2023-09-30
0001642375
GHSI:ClinicalNutritionMember
2022-07-01
2022-09-30
0001642375
GHSI:ClinicalNutritionMember
2023-01-01
2023-09-30
0001642375
GHSI:ClinicalNutritionMember
2022-01-01
2022-09-30
0001642375
GHSI:OtherMember
2023-07-01
2023-09-30
0001642375
GHSI:OtherMember
2022-07-01
2022-09-30
0001642375
GHSI:OtherMember
2023-01-01
2023-09-30
0001642375
GHSI:OtherMember
2022-01-01
2022-09-30
0001642375
us-gaap:CommonStockMember
2022-12-31
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001642375
us-gaap:RetainedEarningsMember
2022-12-31
0001642375
us-gaap:CommonStockMember
2023-03-31
0001642375
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001642375
us-gaap:RetainedEarningsMember
2023-03-31
0001642375
2023-03-31
0001642375
us-gaap:CommonStockMember
2023-06-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001642375
us-gaap:RetainedEarningsMember
2023-06-30
0001642375
2023-06-30
0001642375
us-gaap:CommonStockMember
2021-12-31
0001642375
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001642375
us-gaap:RetainedEarningsMember
2021-12-31
0001642375
2021-12-31
0001642375
us-gaap:CommonStockMember
2022-03-31
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001642375
us-gaap:RetainedEarningsMember
2022-03-31
0001642375
2022-03-31
0001642375
us-gaap:CommonStockMember
2022-06-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001642375
us-gaap:RetainedEarningsMember
2022-06-30
0001642375
2022-06-30
0001642375
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001642375
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001642375
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001642375
2023-01-01
2023-03-31
0001642375
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001642375
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001642375
2023-04-01
2023-06-30
0001642375
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001642375
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001642375
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001642375
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001642375
2022-01-01
2022-03-31
0001642375
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001642375
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001642375
2022-04-01
2022-06-30
0001642375
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001642375
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001642375
us-gaap:CommonStockMember
2023-09-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001642375
us-gaap:RetainedEarningsMember
2023-09-30
0001642375
us-gaap:CommonStockMember
2022-09-30
0001642375
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001642375
us-gaap:RetainedEarningsMember
2022-09-30
0001642375
2022-09-30
0001642375
2023-01-05
2023-01-06
0001642375
srt:MaximumMember
2023-01-06
0001642375
us-gaap:ShippingAndHandlingMember
2023-07-01
2023-09-30
0001642375
us-gaap:ShippingAndHandlingMember
2022-07-01
2022-09-30
0001642375
us-gaap:ShippingAndHandlingMember
2023-01-01
2023-09-30
0001642375
us-gaap:ShippingAndHandlingMember
2022-01-01
2022-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:TwoCustomerMember
2023-07-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:TwoCustomerMember
2023-01-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
2023-07-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:SecondLargestCustomerMember
2023-07-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
2023-01-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:SecondLargestCustomerMember
2023-01-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
2022-07-01
2022-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
2022-01-01
2022-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherCustomersMember
2023-07-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherCustomersMember
2022-07-01
2022-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherCustomersMember
2023-01-01
2023-09-30
0001642375
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherCustomersMember
2022-01-01
2022-09-30
0001642375
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
srt:MaximumMember
2023-01-01
2023-09-30
0001642375
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
srt:MinimumMember
2023-01-01
2023-09-30
0001642375
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneCustomerMember
2022-01-01
2022-12-31
0001642375
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherCustomersMember
srt:MinimumMember
2023-01-01
2023-09-30
0001642375
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherCustomersMember
srt:MinimumMember
2022-01-01
2022-12-31
0001642375
us-gaap:CostOfGoodsTotalMember
us-gaap:SupplierConcentrationRiskMember
GHSI:OneManufacturerMember
2023-07-01
2023-09-30
0001642375
us-gaap:CostOfGoodsTotalMember
us-gaap:SupplierConcentrationRiskMember
GHSI:OneManufacturerMember
2023-01-01
2023-09-30
0001642375
us-gaap:CostOfGoodsTotalMember
us-gaap:SupplierConcentrationRiskMember
GHSI:OneManufacturerMember
2022-07-01
2022-09-30
0001642375
us-gaap:CostOfGoodsTotalMember
us-gaap:SupplierConcentrationRiskMember
GHSI:OneManufacturerMember
2022-01-01
2022-09-30
0001642375
us-gaap:AccountsPayableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneVendorMember
2023-01-01
2023-09-30
0001642375
us-gaap:AccountsPayableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OneVendorMember
2022-01-01
2022-12-31
0001642375
us-gaap:AccountsPayableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherVendorMember
srt:MinimumMember
2023-01-01
2023-09-30
0001642375
us-gaap:AccountsPayableMember
us-gaap:CustomerConcentrationRiskMember
GHSI:OtherVendorMember
srt:MinimumMember
2022-01-01
2022-12-31
0001642375
srt:NorthAmericaMember
2023-07-01
2023-09-30
0001642375
srt:NorthAmericaMember
2022-07-01
2022-09-30
0001642375
srt:NorthAmericaMember
2023-01-01
2023-09-30
0001642375
srt:NorthAmericaMember
2022-01-01
2022-09-30
0001642375
srt:EuropeMember
2023-07-01
2023-09-30
0001642375
srt:EuropeMember
2022-07-01
2022-09-30
0001642375
srt:EuropeMember
2023-01-01
2023-09-30
0001642375
srt:EuropeMember
2022-01-01
2022-09-30
0001642375
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001642375
us-gaap:WarrantMember
2022-01-01
2022-09-30
0001642375
GHSI:OptionsMember
2023-01-01
2023-09-30
0001642375
GHSI:OptionsMember
2022-01-01
2022-09-30
0001642375
GHSI:UnvestedRestrictedCommonStockMember
2023-01-01
2023-09-30
0001642375
GHSI:UnvestedRestrictedCommonStockMember
2022-01-01
2022-09-30
0001642375
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001642375
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001642375
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001642375
us-gaap:FairValueInputsLevel1Member
GHSI:WarrantLiabilityMember
2023-09-30
0001642375
us-gaap:FairValueInputsLevel2Member
GHSI:WarrantLiabilityMember
2023-09-30
0001642375
us-gaap:FairValueInputsLevel3Member
GHSI:WarrantLiabilityMember
2023-09-30
0001642375
GHSI:WarrantLiabilityMember
2023-09-30
0001642375
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001642375
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001642375
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001642375
us-gaap:FairValueInputsLevel1Member
GHSI:WarrantLiabilityMember
2022-12-31
0001642375
us-gaap:FairValueInputsLevel2Member
GHSI:WarrantLiabilityMember
2022-12-31
0001642375
us-gaap:FairValueInputsLevel3Member
GHSI:WarrantLiabilityMember
2022-12-31
0001642375
GHSI:WarrantLiabilityMember
2022-12-31
0001642375
2022-01-01
2022-12-31
0001642375
2021-07-01
2021-07-31
0001642375
GHSI:SecuritiesPurchaseAgreementMember
us-gaap:CommonStockMember
2022-02-17
2022-02-18
0001642375
GHSI:SecuritiesPurchaseAgreementMember
GHSI:SeriesAWarrantMember
2022-02-18
0001642375
GHSI:SecuritiesPurchaseAgreementMember
GHSI:SeriesBWarrantMember
2022-02-18
0001642375
us-gaap:SeriesCPreferredStockMember
2022-11-28
2022-11-30
0001642375
GHSI:SecuritiesPurchaseAgreementMember
GHSI:SeriesAWarrantMember
2023-01-31
0001642375
GHSI:SecuritiesPurchaseAgreementMember
GHSI:SeriesBWarrantMember
2023-01-31
0001642375
GHSI:SeriesBWarrantMember
2023-09-30
0001642375
GHSI:SeriesBWarrantMember
2023-01-01
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputSharePriceMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputSharePriceMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputSharePriceMember
2023-09-30
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputSharePriceMember
2022-12-31
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputExercisePriceMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputExercisePriceMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputExercisePriceMember
2023-09-30
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputExercisePriceMember
2022-12-31
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputExpectedTermMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputExpectedTermMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputExpectedTermMember
2022-12-31
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputPriceVolatilityMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-09-30
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputPriceVolatilityMember
2022-12-31
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputExpectedDividendRateMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputExpectedDividendRateMember
2023-09-30
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-12-31
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001642375
GHSI:SeriesBWarrantsMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-12-31
0001642375
GHSI:SeriesAWarrantsMember
2023-09-30
0001642375
GHSI:SeriesAWarrantsMember
2022-12-31
0001642375
GHSI:SeriesBWarrantsMember
2023-09-30
0001642375
GHSI:SeriesBWarrantsMember
2022-12-31
0001642375
GHSI:SeriesCConvertibleRedeemablePreferredStockMember
us-gaap:PrivatePlacementMember
2022-11-28
2022-11-29
0001642375
GHSI:SeriesDRedeemablePreferredStockMember
us-gaap:PrivatePlacementMember
2022-11-28
2022-11-29
0001642375
2022-11-28
2022-11-29
0001642375
us-gaap:SeriesCPreferredStockMember
2022-01-01
2022-12-31
0001642375
us-gaap:SeriesDPreferredStockMember
2022-01-01
2022-12-31
0001642375
GHSI:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
us-gaap:WarrantMember
2022-02-17
2022-02-18
0001642375
GHSI:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
us-gaap:WarrantMember
2022-02-18
0001642375
GHSI:SeriesAWarrantsMember
GHSI:SecuritiesPurchaseAgreementMember
2022-02-18
0001642375
GHSI:SeriesBWarrantsMember
GHSI:SecuritiesPurchaseAgreementMember
2022-02-18
0001642375
GHSI:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
GHSI:SeriesBWarrantsMember
2022-02-18
0001642375
GHSI:SecuritiesPurchaseAgreementMember
us-gaap:InvestorMember
us-gaap:CommonStockMember
2022-02-18
0001642375
GHSI:FebruaryTwoThousandTwentyTwoOfferingMember
GHSI:PlacementAgencyAgreementMember
2022-02-17
2022-02-18
0001642375
GHSI:PlacementAgencyAgreementMember
GHSI:RothCapitalPartnersLLCMember
2022-02-17
2022-02-18
0001642375
GHSI:PlacementAgencyAgreementMember
GHSI:RothCapitalPartnersLLCMember
srt:MaximumMember
2022-02-18
0001642375
GHSI:PlacementAgencyAgreementMember
GHSI:RothCapitalPartnersLLCMember
2022-02-18
0001642375
GHSI:FebruaryTwoThousandTwentyTwoOfferingMember
us-gaap:InvestorMember
us-gaap:CommonStockMember
2022-02-22
2022-02-23
0001642375
GHSI:FebruaryTwoThousandTwentyTwoOfferingMember
GHSI:SeriesAWarrantMember
2022-02-23
0001642375
GHSI:FebruaryTwoThousandTwentyTwoOfferingMember
GHSI:SeriesBWarrantMember
2022-02-23
0001642375
us-gaap:InvestorMember
us-gaap:WarrantMember
GHSI:FebruaryTwoThousandTwentyTwoOfferingMember
2022-02-22
2022-02-23
0001642375
GHSI:FebruaryTwoThousandTwentyTwoOfferingMember
2022-11-22
2022-11-23
0001642375
GHSI:WarrantsMember
2023-01-01
2023-09-30
0001642375
GHSI:WarrantsMember
2023-09-30
0001642375
us-gaap:WarrantMember
2023-09-30
0001642375
srt:DirectorMember
2023-01-01
2023-09-30
0001642375
srt:DirectorMember
2022-01-01
2022-09-30
0001642375
srt:DirectorMember
2023-09-30
0001642375
srt:DirectorMember
2022-09-30
0001642375
srt:ChiefExecutiveOfficerMember
2023-01-01
2023-09-30
0001642375
srt:ChiefExecutiveOfficerMember
2023-07-01
2023-09-30
0001642375
us-gaap:RestrictedStockMember
2023-01-01
2023-09-30
0001642375
us-gaap:RestrictedStockMember
2022-01-01
2022-09-30
0001642375
us-gaap:RestrictedStockMember
2023-09-30
0001642375
us-gaap:WarrantMember
2022-12-31
0001642375
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001642375
GHSI:WarrantOneMember
2023-09-30
0001642375
GHSI:WarrantTwoMember
2023-09-30
0001642375
GHSI:ExercisePriceOneMember
2023-09-30
0001642375
GHSI:ExercisePriceTwoMember
2023-09-30
0001642375
GHSI:ExercisePriceThreeMember
2023-09-30
0001642375
GHSI:ExercisePriceFourMember
2023-09-30
0001642375
GHSI:ExercisePriceFiveMember
2023-09-30
0001642375
GHSI:ExercisePriceSixMember
2023-09-30
0001642375
GHSI:ExercisePriceSevenMember
2023-09-30
0001642375
GHSI:ExercisePriceEightMember
2023-09-30
0001642375
GHSI:ExercisePriceNineMember
2023-09-30
0001642375
GHSI:RestrictedCommonStockMember
2022-12-31
0001642375
GHSI:RestrictedCommonStockMember
2023-01-01
2023-09-30
0001642375
GHSI:RestrictedCommonStockMember
2023-09-30
0001642375
GHSI:EmploymentAgreementMember
GHSI:JanetHallMember
2023-06-18
2023-06-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
GHSI:Segment
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended September 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from ____ to ____
Commission
File Number: 001-38861
GUARDION
HEALTH SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
47-4428421 |
(State
or other jurisdiction
of
incorporation or organization) |
|
(I.R.S.
Employer
Identification
No.) |
|
|
|
2925
Richmond Avenue, Suite 1200, Houston, Texas |
|
77098 |
(Address
of principal executive offices) |
|
(Zip
Code) |
800-873-5141
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name, former address and former fiscal year, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
GHSI |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). ☒ Yes ☐ No
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
Emerging
growth company |
☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No
As
of November 9, 2023, there were 1,275,238 shares of the Company’s common stock, par value $0.001 per share, issued and outstanding.
TABLE
OF CONTENTS
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
This
Quarterly Report on Form 10-Q contains “forward-looking statements” which are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”). These forward-looking statements contain information about our expectations,
beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business,
financial condition, results of operations, strategies and prospects, and other similar matters. These forward-looking statements are
based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict. These statements may be identified by words such as “expects,”
“plans,” “projects,” “will,” “may,” “anticipates,” “believes,”
“should,” “intends,” “estimates,” “hopes” and other words of similar meaning.
Actual
results could differ materially from those contained in forward-looking statements. Many factors could cause actual results to differ
materially from those in forward-looking statements, including those matters discussed below. Readers are urged to read the risk factors
set forth in our recent filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report
on Form 10-K for the fiscal year ended December 31, 2022, and in other documents we file with the SEC from time to time.
Other
unknown or unpredictable factors that could also adversely affect our business, financial condition and results of operations may arise
from time to time. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and
uncertainties, the forward-looking statements discussed in this Quarterly Report on Form 10-Q may not prove to be accurate. Accordingly,
you should not place undue reliance on these forward-looking statements, which only reflect the views of our management as of the date
of this Quarterly Report on Form 10-Q. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify
or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede
such statements in this Quarterly Report on Form 10-Q. We undertake no obligation to update or revise forward-looking statements to reflect
changed assumptions, the occurrence of unanticipated events or changes to future operating results or expectations, except as required
by law. We qualify all of the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements,
by these cautionary statements.
This
Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company
surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications,
articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained
therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed.
While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party
sources.
PART
I – FINANCIAL INFORMATION
ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Guardion
Health Sciences, Inc.
Condensed
Consolidated Balance Sheets
| |
September 30, 2023 | | |
December 31, | |
| |
(Unaudited) | | |
2022 | |
Assets | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 7,657,309 | | |
$ | 10,655,490 | |
Restricted cash | |
| - | | |
| 5,250,000 | |
Accounts receivable | |
| 1,766,028 | | |
| 1,924,353 | |
Inventories | |
| 2,450,650 | | |
| 3,119,421 | |
Prepaid expenses and other current assets | |
| 965,644 | | |
| 687,933 | |
Total current assets | |
| 12,839,631 | | |
| 21,637,197 | |
Property and equipment, net | |
| 38,144 | | |
| 48,871 | |
Total assets | |
$ | 12,877,775 | | |
$ | 21,686,068 | |
| |
| | | |
| | |
Liabilities, Redeemable Preferred Stock and Stockholders’ Equity | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 881,600 | | |
$ | 1,518,052 | |
Accrued expenses | |
| 550,057 | | |
| 558,287 | |
Operating lease liability - current | |
| - | | |
| 3,807 | |
Warrant derivative liability – current | |
| - | | |
| 1,931,400 | |
Total current liabilities | |
| 1,431,657 | | |
| 4,011,546 | |
Warrant derivative liability – long-term | |
| 3,744,400 | | |
| 4,506,600 | |
Total liabilities | |
| 5,176,057 | | |
| 8,518,146 | |
| |
| | | |
| | |
Commitments and contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
Redeemable preferred stock | |
| | | |
| | |
Series C convertible redeemable preferred stock, no shares and 495,000 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| - | | |
| 5,197,500 | |
Series D redeemable preferred stock, no shares and 5,000 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| - | | |
| 52,500 | |
Total redeemable preferred stock | |
| - | | |
| 5,250,000 | |
| |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 2022 | |
| - | | |
| - | |
Common stock, $0.001 par value; 250,000,000 shares authorized; 1,275,239 shares and 1,267,340 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| 1,275 | | |
| 1,267 | |
Additional paid-in capital | |
| 101,691,430 | | |
| 101,640,955 | |
Accumulated deficit | |
| (93,990,987 | ) | |
| (93,724,300 | ) |
Total stockholders’ equity | |
| 7,701,718 | | |
| 7,917,922 | |
Total liabilities, redeemable preferred stock and stockholders’ equity | |
$ | 12,877,775 | | |
$ | 21,686,068 | |
See
accompanying notes to condensed consolidated financial statements.
Guardion
Health Sciences, Inc.
Condensed
Consolidated Statements of Operations (Unaudited)
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Revenue | |
| | | |
| | | |
| | | |
| | |
Clinical nutrition | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,663 | |
Other | |
| - | | |
| - | | |
| - | | |
| 18,719 | |
| |
| | | |
| | | |
| | | |
| | |
Total revenue | |
| 3,337,190 | | |
| 2,663,550 | | |
| 9,312,695 | | |
| 8,323,382 | |
| |
| | | |
| | | |
| | | |
| | |
Total cost of goods sold | |
| 1,876,938 | | |
| 1,575,366 | | |
| 5,267,874 | | |
| 4,739,197 | |
| |
| | | |
| | | |
| | | |
| | |
Gross profit | |
| 1,460,252 | | |
| 1,088,184 | | |
| 4,044,821 | | |
| 3,584,185 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 10,671 | | |
| 60,203 | | |
| 150,604 | | |
| 162,418 | |
Sales and marketing | |
| 318,734 | | |
| 526,193 | | |
| 1,332,469 | | |
| 1,583,349 | |
General and administrative | |
| 1,903,761 | | |
| 2,231,895 | | |
| 5,811,315 | | |
| 7,875,894 | |
Impairment of right-of-use asset | |
| - | | |
| - | | |
| - | | |
| 24,257 | |
Loss on disposal of fixed assets | |
| - | | |
| 9,287 | | |
| - | | |
| 9,287 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses | |
| 2,233,166 | | |
| 2,827,578 | | |
| 7,294,388 | | |
| 9,655,205 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (772,914 | ) | |
| (1,739,394 | ) | |
| (3,249,567 | ) | |
| (6,071,020 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Change in fair value of warrant derivative liability | |
| 1,050,800 | | |
| 873,200 | | |
| 2,693,600 | | |
| 3,548,300 | |
Interest income, net | |
| 94,747 | | |
| 43,282 | | |
| 289,280 | | |
| 54,458 | |
Other income (expense), net | |
| 1,145,547 | | |
| 916,482 | | |
| 2,982,880 | | |
| 3,602,758 | |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) | |
$ | 372,633 | | |
$ | (822,912 | ) | |
$ | (266,687 | ) | |
$ | (2,468,262 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) per common share - basic and diluted | |
$ | 0.29 | | |
$ | (0.67 | ) | |
$ | (0.21 | ) | |
$ | (2.27 | ) |
Weighted average common shares outstanding – basic and diluted | |
| 1,273,486 | | |
| 1,232,016 | | |
| 1,273,249 | | |
| 1,083,924 | |
See
accompanying notes to condensed consolidated financial statements.
Guardion
Health Sciences, Inc.
Condensed
Consolidated Statements of Stockholders’ Equity
(Unaudited)
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity | |
| |
Three Months and Nine Months Ended September 30, 2023 | |
| |
Common Stock | | |
Additional Paid-In | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity | |
Balance at December 31, 2022 | |
| 1,267,340 | | |
$ | 1,267 | | |
$ | 101,640,955 | | |
$ | (93,724,300 | ) | |
$ | 7,917,922 | |
Fair value of vested stock options | |
| - | | |
| - | | |
| 25,182 | | |
| - | | |
| 25,182 | |
Fair value of vested restricted stock | |
| - | | |
| - | | |
| 5,329 | | |
| - | | |
| 5,329 | |
Net income | |
| - | | |
| - | | |
| - | | |
| 533,091 | | |
| 533,091 | |
Balance at March 31, 2023 | |
| 1,267,340 | | |
| 1,267 | | |
| 101,671,466 | | |
| (93,191,209 | ) | |
| 8,481,524 | |
Fair value of vested stock options | |
| - | | |
| - | | |
| (73,456 | ) | |
| - | | |
| (73,456 | ) |
Fair value of vested restricted stock | |
| - | | |
| - | | |
| 5,388 | | |
| - | | |
| 5,388 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (1,172,411 | ) | |
| (1,172,411 | ) |
Balance at June 30, 2023 | |
| 1,267,340 | | |
| 1,267 | | |
| 101,603,398 | | |
| (94,363,620 | ) | |
| 7,241,045 | |
Fair value of vested stock options | |
| - | | |
| - | | |
| 27,943 | | |
| - | | |
| 27,943 | |
Fair value of vested restricted stock | |
| 250 | | |
| - | | |
| 2,194 | | |
| - | | |
| 2,194 | |
Common stock issued upon exercise of warrants | |
| 7,649 | | |
| 8 | | |
| 57,895 | | |
| - | | |
| 57,903 | |
Net income | |
| - | | |
| - | | |
| - | | |
| 372,633 | | |
| 372,633 | |
Balance at September 30, 2023 | |
| 1,275,239 | | |
$ | 1,275 | | |
$ | 101,691,430 | | |
$ | (93,990,987 | ) | |
$ | 7,701,718 | |
| |
Three Months and Nine Months Ended September 30, 2022 | |
| |
Common Stock | | |
Additional Paid-In | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity | |
Balance at December 31, 2021 | |
| 488,539 | | |
$ | 489 | | |
$ | 101,099,383 | | |
$ | (78,802,072 | ) | |
$ | 22,297,800 | |
Fair value of vested stock options | |
| - | | |
| - | | |
| 85,963 | | |
| - | | |
| 85,963 | |
Fair value of vested restricted stock | |
| - | | |
| - | | |
| 59,906 | | |
| - | | |
| 59,906 | |
Common stock issued for cash, net of offering costs | |
| 651,000 | | |
| 651 | | |
| 8,834,247 | | |
| - | | |
| 8,834,898 | |
Common stock issued upon exercise of warrants | |
| 89,000 | | |
| 89 | | |
| 1,133,951 | | |
| - | | |
| 1,134,040 | |
Recognition of fair value of warrant derivative liability issued in connection with issuance of common stock | |
| - | | |
| - | | |
| (8,783,800 | ) | |
| - | | |
| (8,783,800 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| (5,300,987 | ) | |
| (5,300,987 | ) |
Balance at March 31, 2022 | |
| 1,228,539 | | |
| 1,229 | | |
| 102,429,650 | | |
| (84,103,060 | ) | |
| 18,327,820 | |
Fair value of vested stock options | |
| - | | |
| - | | |
| 61,818 | | |
| - | | |
| 61,818 | |
Fair value of vested restricted stock | |
| - | | |
| - | | |
| 11,585 | | |
| - | | |
| 11,585 | |
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax | |
| 3,477 | | |
| 3 | | |
| (24,014 | ) | |
| - | | |
| (24,011 | ) |
Net income | |
| - | | |
| - | | |
| - | | |
| 3,655,637 | | |
| 3,655,637 | |
Balance at June 30, 2022 | |
| 1,232,016 | | |
| 1,232 | | |
| 102,479,039 | | |
| (80,447,422 | ) | |
| 22,032,849 | |
Balance, value | |
| 1,232,016 | | |
| 1,232 | | |
| 102,479,039 | | |
| (80,447,422 | ) | |
| 22,032,849 | |
Fair value of vested stock options | |
| - | | |
| - | | |
| 44,101 | | |
| | | |
| 44,101 | |
Fair value of vested restricted stock | |
| - | | |
| - | | |
| 5,447 | | |
| | | |
| 5,447 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (822,912 | ) | |
| (822,912 | ) |
Net Income (loss) | |
| - | | |
| - | | |
| - | | |
| (822,912 | ) | |
| (822,912 | ) |
Balance at September 30, 2022 | |
| 1,232,016 | | |
$ | 1,232 | | |
$ | 102,528,587 | | |
$ | (81,270,334 | ) | |
$ | 21,259,485 | |
Balance, value | |
| 1,232,016 | | |
$ | 1,232 | | |
$ | 102,528,587 | | |
$ | (81,270,334 | ) | |
$ | 21,259,485 | |
See
accompanying notes to condensed consolidated financial statements.
Guardion
Health Sciences, Inc.
Condensed
Consolidated Statements of Cash Flows
(Unaudited)
| |
2023 | | |
2022 | |
| |
Nine Months Ended | |
| |
September 30, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Operating Activities | |
| | | |
| | |
Net loss | |
$ | (266,687 | ) | |
$ | (2,468,262 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 14,518 | | |
| 946,397 | |
Loss on disposal of fixed assets | |
| - | | |
| 9,287 | |
Impairment of right-of-use asset | |
| - | | |
| 24,257 | |
Fair value of vested stock options | |
| (20,331 | ) | |
| 191,882 | |
Fair value of vested restricted common stock | |
| 12,911 | | |
| 76,938 | |
Change in fair value of warrant derivative liability | |
| (2,693,600 | ) | |
| (3,548,300 | ) |
Changes in operating assets and liabilities: | |
| | | |
| | |
(Increase) decrease in: | |
| | | |
| | |
Accounts receivable | |
| 158,325 | | |
| (41,679 | ) |
Inventories | |
| 668,771 | | |
| (1,585,240 | ) |
Prepaid expenses | |
| (277,711 | ) | |
| (258,560 | ) |
Increase (decrease) in: | |
| | | |
| | |
Accounts payable | |
| (636,452 | ) | |
| 799,249 | |
Operating lease liability | |
| (3,807 | ) | |
| (16,556 | ) |
Accrued expenses | |
| (8,230 | ) | |
| (212,319 | ) |
Net cash used in operating activities | |
| (3,052,293 | ) | |
| (6,082,906 | ) |
| |
| | | |
| | |
Investing Activities | |
| | | |
| | |
Purchase of equipment | |
| (3,791 | ) | |
| (5,569 | ) |
Purchase of US Treasury Bills | |
| - | | |
| (77,591,741 | ) |
Sale of US Treasury Bills | |
| - | | |
| 82,587,364 | |
Net cash (used in) provided by investing activities | |
| (3,791 | ) | |
| 4,990,054 | |
| |
| | | |
| | |
Financing Activities | |
| | | |
| | |
Redemption of preferred stock | |
| (5,250,000 | ) | |
| - | |
Proceeds from sale of common stock, net | |
| - | | |
| 8,834,899 | |
Proceeds from exercise of warrants | |
| 57,903 | | |
| 1,134,040 | |
Payment for employee withholding tax | |
| - | | |
| (24,011 | ) |
Net cash (used in) provided by financing activities | |
| (5,192,097 | ) | |
| 9,944,928 | |
| |
| | | |
| | |
Cash, cash equivalents and restricted cash | |
| | | |
| | |
Net (decrease) increase in cash, cash equivalents and restricted cash | |
| (8,248,181 | ) | |
| 8,852,076 | |
Balance at beginning of period | |
| 15,905,490 | | |
| 4,093,927 | |
Balance at end of period | |
$ | 7,657,309 | | |
$ | 12,946,003 | |
| |
| | | |
| | |
Supplemental disclosure of cash flow information: | |
| | | |
| | |
Cash paid for: | |
| | | |
| | |
Income taxes | |
$ | - | | |
$ | - | |
Interest | |
$ | - | | |
$ | - | |
Non-cash financing activities: | |
| | | |
| | |
Recognition of initial warrant derivative liability | |
$ | - | | |
$ | 8,783,800 | |
See
accompanying notes to condensed consolidated financial statements.
Guardion
Health Sciences, Inc.
Notes
to Condensed Consolidated Financial Statements
For
the Three Months and Nine Months Ended September 30, 2023 and 2022
(Unaudited)
1.
Organization and Business Operations
Business
Guardion
Health Sciences, Inc. (the “Company”) is a clinical nutrition company that develops and distributes clinically supported
nutrition, medical foods and dietary supplements. The Company offers a portfolio of science-based, clinically supported products designed
to support healthcare professionals and providers, and their patients and consumers. The Company was formed in 2009 as a California limited
liability company under the name P4L Health Sciences, LLC, and in 2015 converted from a California limited liability company to a Delaware
corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. In June 2021, the Company acquired
Activ Nutritional, LLC (“Activ”), the owner and distributor of the Viactiv® line of supplements for bone health and other
applications.
Liquidity
For
the nine months ended September 30, 2023, the Company recorded a loss from operations of $3,249,567 and used cash in operating activities
of $3,052,293. The Company has a history of operating losses and negative cash flows. Even though the Company’s management identified
certain indicators, including the current period loss from operations and the potential impact of inflation and general economic uncertainty,
management concluded these indicators do not raise substantial doubt regarding the Company’s ability to continue as a going concern
within one year after the date these financial statements are issued. As of September 30, 2023, the Company had $7,657,309 of cash and
cash equivalents, and management determined that it is probable that the Company will be able to fund its current operating plan and
meet all of its obligations due within one year from the date these financial statements are issued.
The
amount and timing of future cash requirements will depend, in part, on the Company’s ability to ultimately achieve operating profitability.
The Company expects to continue to incur net losses and negative operating cash flows in the near-term and will continue to incur significant
expenses for the development, commercialization and distribution of its clinical nutrition products (primarily the Viactiv® product
line) and the successful development and commercialization of new products and product lines. The Company may also utilize cash to fund
acquisitions of complementary businesses, product lines and/or brands.
The
Company may seek to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company
will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms
or at all. Over time, if the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to
reduce or discontinue its product development programs or curtail or cease operations.
Inflation
Higher
inflation, the actions by the Federal Reserve Bank to address inflation, most notably continuing increases in interest rates, and rising
food and energy prices in combination with higher labor costs create uncertainty about the future economic environment. The Company expects
that the impact of these issues will continue to evolve. The Company believes these factors impacted the Company’s business in
2022 and the first nine months of 2023, and will continue to impact the Company’s business for the remainder of 2023 and in 2024.
The implications of higher government deficits and debt, tighter monetary policy, and higher long-term interest rates may drive a higher
cost of capital for the business and an increase in the Company’s operating expenses.
2.
Summary of Significant Accounting Policies
Basis
of Presentation
The
unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the
United States of America (“GAAP”) pursuant to the applicable rules and regulations of the Securities and Exchange Commission
(“SEC”) for interim financial information. The unaudited condensed consolidated financial statements have been prepared on
the same basis as the Company’s annual financial statements for the year ended December 31, 2022, and, in the opinion of management,
reflect all adjustments, which consist of normal recurring adjustments, considered necessary for a fair presentation of the periods presented.
The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected
for the full fiscal year ending December 31, 2023.
These
unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial
statements and accompanying notes for the fiscal year ended December 31, 2022 included in the Company’s December 31, 2022 Annual
Report on Form 10-K, which was filed with the SEC on April 17, 2023. The condensed consolidated balance sheet as of December 31, 2022
was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes,
required by GAAP.
The
Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.
All inter-company transactions and balances have been eliminated in consolidation.
In
accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating
decision maker (the Company’s Chief Executive Officer) determined that the Company has only one reporting unit.
Reverse
Stock Split
On
January 6, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of
State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split of its outstanding common stock without any change
to its par value. The authorized number of shares of common stock was not affected by the reverse stock split. The Company issued 35,281
additional common shares in connection with this reverse stock split per the Company’s determination to round up all fractional
shares resulting from the reverse stock split to the nearest whole share.
Accordingly,
all common shares, stock options, stock warrants and per share amounts in these consolidated financial statements have been adjusted
retroactively to reflect the reverse stock split as if the split occurred at the beginning of the earliest period presented in this Quarterly
Report on Form 10-Q.
Use
of Estimates
The
preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions
that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities.
On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates
include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing the warrant derivative
liability, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets,
assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities,
and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.
Revenue
Recognition
Revenue
and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon delivery to the
customer. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts
with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause
revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of
the goods and therefore represent a fulfillment activity rather than a promised service to the customer.
All
products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance
obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives
or discounts that could cause revenue to be allocated or adjusted over time.
Shipping
and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity
rather than a promised service to the customer. Historically the Company has not experienced any significant payment delays from customers.
Due
to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products and assessment of
performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract
asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly
basis.
At
September 30, 2023 and December 31, 2022, the allowance for doubtful accounts was zero and $1,996, respectively.
The
Company’s revenues by product line for the three months and nine months ended September 30, 2023 and 2022 are as a follows:
Schedule of Revenues by Product
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Clinical Nutrition | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,663 | |
Other | |
| - | | |
| - | | |
| - | | |
| 18,719 | |
Revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
Substantially
all of the Company’s revenues earned during the three months and nine months ended September 30, 2023 and 2022 are derived from
sales of the Company’s clinical nutrition products primarily to retail customers in North America.
The
Company’s revenues by geographical area for the three months and nine months ended September 30, 2023 and 2022 are as follows:
Schedule of Revenue by Geographical Area
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,483 | |
Europe and other | |
| - | | |
| - | | |
| - | | |
| 18,899 | |
Total revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
Third-Party
Outsourcing
The
Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center which provides order
processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s
products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues.
In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional
services.
The
Company outsources the production of substantially all its products with a third-party that manufactures and packages the finished products
under a product supply agreement.
Costs
incurred related to third-party outsourcing, which includes manufacturing, order processing and fulfillment, customer invoicing, collections
and warehousing, were $1,759,260 and $1,876,259 for the three months ended September 30, 2023 and 2022, respectively, and $4,339,388
and $1,932,967 for the nine months ended September 30, 2023 and 2022, respectively.
Cost
of Goods Sold
Cost
of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees and in-bound freight charges.
Shipping
Costs
Shipping
costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense
totaled $135,059 and $209,804 for the three months ended September 30, 2023 and 2022, respectively, and $416,101 and $622,178 for the
nine months ended September 30, 2023 and 2022, respectively.
Advertising
Costs
Advertising
costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $279,457 and $385,010 for the
three months ended September 30, 2023 and 2022, respectively, and $1,109,310 and $1,264,740 for the nine months ended September 30, 2023
and 2022, respectively.
Concentrations
Revenue.
During the three months ended September 30, 2023, the Company had two customers that accounted for 68% of total revenue. During the
nine months ended September 30, 2023, the Company had two customers that accounted for 64% of total revenue. During the three months
ended September 30, 2023, the largest customer accounted for 47% of the Company’s total revenue, and the second largest customer
accounted for 21% of the Company’s total revenue. During the nine months ended September 30, 2023, the largest customer accounted
for 50% of the Company’s total revenue and the second largest customer accounted for 14%. During the three months ended September
30, 2022, the Company had one customer that accounted for 57% of total revenue. During the nine months ended September 30, 2022, the
Company had one customer that accounted for 56% of the Company’s total revenue. No other customer accounted for more than 10% of
revenue during the three months and nine months ended September 30, 2023 and 2022. The Company sells the majority of its products to
one of the largest retailers in the United States.
Accounts
receivable. As of September 30, 2023, the Company had accounts receivable from one customer which comprised approximately 61% of
its accounts receivable and one customer that accounted for approximately 13% of its accounts receivable. As of December 31, 2022, the
Company had accounts receivable from one customer which comprised approximately 88% of its accounts receivable. No other customer accounted
for more than 10% of accounts receivable as of September 30, 2023 and December 31, 2022.
Purchases
from vendors. During the three months and nine months ended September 30, 2023 and 2022, the Company utilized one manufacturer for
most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately
59% and 47% of all purchases during the three months and nine months ended September 30, 2023, respectively. Total purchases from this
manufacturer accounted for approximately 49% and 46% of all purchases during the three months and nine months ended September 30, 2022,
respectively.
Accounts
payable. As of September 30, 2023, one vendor accounted for 84% of total accounts payable. As of December 31, 2022, one vendor accounted
for 88% of the total accounts payable. One other vendor accounted for 13% of total accounts payable as of September 30, 2023. No other
vendor accounted for more than 10% of accounts payable as of December 31, 2022.
Cash
and cash equivalents. Cash and cash equivalents consist of funds deposited with BMO Harris Bank (“BMO”), which is a major,
established, high quality financial institution, in short-term (original maturity of generally 60 days or less) liquid investments in
money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net
asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with
BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests
solely in high quality U.S. government issued securities. As of September 30, 2023, $7,657,309 included in cash and cash equivalents
was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance
Corporation (the “FDIC”).
The
Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000,
respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because
of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced
any losses to date resulting from this policy.
Stock-Based
Compensation
Stock-based
awards for stock options and restricted stock awards to employees and non-employees are accounted for by using the fair value method
in accordance with ASC 718, Share-Compensation – Stock Compensation. The estimated fair value of stock options granted to
employees in exchange for services is measured at the grant date, using a fair value-based method, such as a Black-Scholes option valuation
model, and is recognized as an expense on a straight-line basis over the requisite service periods. The assumptions used in the Black-Scholes
option pricing model could materially affect compensation expense recorded in future periods. The fair value of restricted stock units
is measured at the grant date based on the closing market price of the Company’s common stock on the date of grant and is recognized
as an expense on a straight-line basis over the requisite service periods. Recognition of compensation expense for non-employees is accounted
for in the same period and manner as if the Company had paid cash for the services.
Warrants
The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s
specific terms and applicable authoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities
from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance
outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of
professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be
recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the
criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on
the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants
are recognized as a non-cash gain or loss on the statements of operations. The Company has determined that the warrants issued in the
February 18, 2022 equity financing (see Note 6) meet the requirements for liability classification.
Income
(Loss) per Common Share
Basic
earnings (loss) per share (“EPS” or “LPS”) is computed by dividing net loss by the weighted-average common
shares outstanding during the period, excluding shares of unvested restricted common stock outstanding. Diluted EPS/LPS is computed
based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the
period calculated using the treasury stock method. Shares of vested restricted stock are included in the diluted weighted average
number of common shares outstanding from the date they are vested. In addition, net earnings (loss) for diluted EPS/LPS is adjusted
for the impact of the assumed exercise of the
outstanding warrants, to the extent they are dilutive. For the three months ended September 30, 2022, and the nine months ended
September 30, 2023 and 2022, the Company recorded a net loss, as a result of which warrants, options, and unvested restricted shares
of common stock were excluded from the computation of diluted EPS/LPS because they were considered anti-dilutive. For the three
months ended September 30, 2023, the Company recorded net income, and it was determined that the applicable warrants and options
were out-of-the-money. For the three months ended September 30, 2023, the treasury stock method was not applied to options or
warrants that were out-of-the-money, and accordingly, the warrants, options, and unvested restricted shares of common stock were
excluded from the computation of diluted EPS/LPS because they were considered anti-dilutive.
The
following potentially dilutive shares were excluded from the shares used to calculate diluted earnings (loss) per share:
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share
| |
2023 | | |
2022 | |
| |
September 30, | |
| |
2023 | | |
2022 | |
Warrants | |
| 779,052 | | |
| 1,489,702 | |
Options | |
| 20,577 | | |
| 14,470 | |
Unvested restricted common stock | |
| 417 | | |
| 667 | |
Anti-dilutive securities | |
| 800,046 | | |
| 1,504,839 | |
Fair
Value of Financial Instruments
Accounting
standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for
establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer
a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers
the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing
the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques
used to measure fair value:
Level
1 – Quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the
measurement date.
Level
2 – Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.
Level
3 – Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting
entity to develop its own assumptions.
The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.
The
following table sets forth by level, within the fair value hierarchy, the Company’s financial assets and liabilities at fair value
as of September 30, 2023, and December 31, 2022:
Schedule of Assets and Liabilities at Fair Value
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
September 30, 2023 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
December 31, 2022 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
The
following table provides a roll-forward of the warrant derivative liability measured at fair value on a recurring basis using unobservable
Level 3 inputs for the nine months ended September 30, 2023:
Schedule of Warrant Derivative Liability Measured at Fair Value
Warrant derivative liability | |
| | |
Balance as of beginning of period – December 31, 2022 | |
$ | 6,438,000 | |
Change in fair value of warrant derivative liability, during the period | |
| (2,693,600 | ) |
Balance as of end of period – September 30, 2023 | |
$ | 3,744,400 | |
As
of September 30, 2023, and December 31, 2022, the Company’s outstanding warrants were treated as derivative liabilities and changes
in the fair value were recognized in earnings (see Note 6). As of September 30, 2023, the current warrant derivative liability was zero
and the long-term warrant derivative liability was $3,744,400. As of December 31, 2022, the current warrant derivative liability was
$1,931,400 and the long-term warrant derivative liability was $4,506,600.
The
Company believes the carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, and
accounts payable and accrued liabilities, approximate fair value due to the short-term nature of such instruments and are excluded from
the fair value tables above.
Recent
Accounting Pronouncements
In
September 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly
changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. ASU 2016-13 replaces
the “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based
on expected rather than incurred losses. Entities will apply the ASU 2016-13’s provisions as a cumulative-effect adjustment to
retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company,
ASU 2016-13 was effective for and adopted by the Company effective January 1, 2023. The adoption of ASU 2016-13 did not have any material
impact on the Company’s financial statement presentation or and related disclosures.
In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications
and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts
in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification
of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified
after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of
a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant
immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the
corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated
to equity issuance and debt origination or modification). ASU 2021-04 was effective for all entities for fiscal years beginning after
December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively
to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The
adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or related disclosures.
In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement — Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation — Stock Compensation
(Topic 718) Presentation of Financial Statements (“ASU 2023-03”). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 — General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company’s consolidated financial statement presentation or related disclosures.
Other
recent accounting pronouncements and guidance issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future
financial statements.
3.
Inventories
Inventories
consist of the following:
Schedule of Inventories
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Raw materials | |
$ | 35,405 | | |
$ | 49,637 | |
Finished goods | |
| 2,415,245 | | |
| 3,069,784 | |
Inventories, net | |
$ | 2,450,650 | | |
$ | 3,119,421 | |
The
Company’s inventories are stated at the lower of cost or net realizable value calculated on a first-in, first-out basis.
4.
Intangible Assets, Net
At
December 31, 2021, the gross amount of the Company’s amortizable finite-lived identifiable intangible assets, consisting of a trade
name and customer relationships, totaled $11,900,000. Effective December 31, 2022, the Company performed an impairment analysis of its
intangible assets and determined that the asset group’s fair value was zero, as a result of which the Company recorded an impairment
loss of $10,065,833 for the net book balance of the intangible assets at that date.
For
the three months and nine months ended September 30, 2022, amortization expense was $297,500 and $892,500, respectively.
5.
Operating Leases
In
July 2021, the Company entered into a month-to-month lease for its primary corporate office space located in Houston, Texas, with lease
payments of approximately $2,700 per month. Leases with the duration of less than 12 months are not recognized on the balance sheet and
are expensed on a straight-line basis over the lease term.
As
of December 31, 2022, the Company’s VectorVision subsidiary leased a warehouse space in Ohio under an operating lease that expired
in February 2023. During the year ended December 31, 2022, the Company recorded an impairment of the operating lease right-of-use asset
of $24,257 and made payments of $22,221 on the operating lease liability. At December 31, 2022, the balance of the operating lease liability
was $3,807, which was paid in full and extinguished in February 2023.
6.
Warrant Derivative Liability
On
February 18, 2022, the Company sold in a best-efforts public offering, 651,000 shares of the Company’s common stock (see Note 8)
and 740,000 Series A warrants (the “Series A Warrants”) and 740,000 Series B warrants (the “Series B Warrants”).
The Series A and Series B Warrants had an initial exercise price of $18.50 per share. The Series A Warrants expire in February 2027 and
the Series B Warrants expired in August 2023.
The
Series A and Series B Warrants contain certain anti-dilution provisions, including a down round provision and certain cash redemption
rights. On November 30, 2022, the exercise price of the Series A and Series B Warrants was adjusted downward to $7.88 per share to equal
the Series C Convertible Redeemable Preferred Stock conversion price (see Note 8).
In
addition, the Series A Warrants and Series B Warrants contain a provision which requires that the exercise price of such warrants be
adjusted to the volume weighted average price of the Company’s common stock for the five trading days immediately following effectiveness
of a reverse stock split if such calculation resulted in an exercise price below the then-current exercise price. The Company determined
that this provision represented a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined
under ASC 815-40, and thus the Series A and Series B Warrants are not considered indexed to the Company’s own stock and not eligible
for an exception from derivative accounting. Accordingly, the Series A and Series B warrants are classified as a derivative liability.
In January 2023, in conjunction with the completion of the Company’s reverse stock split (see Note 2), the exercise price of the
Series A and Series B warrants was further adjusted to $7.57 per share.
The
fair value of the warrant liability on September 30, 2023, and at December 31, 2022, was $3,744,400 and $6,438,000, respectively. The
estimated fair value of the warrants is determined using Level 3 inputs. Inherent in a binomial lattice model are assumptions related
to expected probability of event occurrence, including stock splits, stock-price volatility, expected life, risk-free interest rate and
dividend yield. The Company estimates the volatility of its common stock warrants based on the Company’s historical volatility.
The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant or valuation date for a maturity similar
to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual
term. The dividend rate is based on the Company’s historical rate, which the Company anticipates remaining at zero. The derivative
liabilities were valued using a binomial lattice model with the following assumptions:
Schedule of Warrant Derivative Liability
| |
Series A Warrants | | |
Series B Warrants | |
| |
September 30, 2023 | | |
December 31, 2022 | | |
September 30, 2023 | | |
December 31, 2022 | |
Common stock market price | |
$ | 7.38 | | |
$ | 7.26 | | |
$ | - | | |
$ | 7.26 | |
Exercise price | |
| 7.57 | | |
| 7.88 | | |
| - | | |
| 7.88 | |
Expected term (in years) | |
| 3.40 | | |
| 4.15 | | |
| - | | |
| 0.65 | |
Expected volatility | |
| 102.40 | % | |
| 131.20 | % | |
| - | | |
| 104.50 | % |
Expected dividend yield | |
| - | | |
| - | | |
| - | | |
| - | |
Risk-free interest rate | |
| 4.75 | % | |
| 4.11 | % | |
| - | | |
| 4.75 | % |
Total fair value | |
$ | 3,744,400 | | |
$ | 4,506,600 | | |
$ | - | | |
$ | 1,931,400 | |
The
740,000 Series B Warrants expired on August 24, 2023. On the expiration date, the Series B Warrants were marked to a fair value of zero
with such change being recorded as part of the change in fair value of warrant derivative included in the statement of operations.
7.
Redeemable Preferred Stock (Temporary Equity, redeemed in full in February 2023)
On
November 29, 2022, the Company issued and sold, in a private placement, 495,000 shares of the Company’s Series C Convertible Redeemable
Preferred Stock (the “Series C Preferred Stock”), and 5,000 shares of the Company’s Series D Redeemable Preferred Stock
(the “Series D Preferred Stock,” and together with the Series C Preferred Stock, the “Preferred Stock”).
The
Series C Preferred Stock had the right to vote on an amendment (the “Amendment”) to the Company’s Certificate of Incorporation,
as amended, to authorize a reverse split of the Common Stock on an as-converted to common stock basis (see Note 2). The shares of the
Series D Preferred Stock were automatically voted in a manner that “mirrored” the proportions on which the shares of Common
Stock (excluding any shares of Common Stock that were not voted) and Series C Preferred Stock were voted on the Amendment. The Certificates
of Designation for the Preferred Stock provided that the Preferred Stock had no voting rights other than the right to vote on the Amendment
and as a class on certain other specified matters, and, with respect to the Series D Certificate of Designation, the right to cast 1,000,000
votes per share of Series D Preferred Stock on the Reverse Stock Split proposal. The Amendment required the approval of the majority
of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. On January 5, 2023, the Amendment
to authorize a reverse split of the Common Stock was approved at a special meeting of the Company’s stockholders. Following the
meeting, the board of directors approved a one-for-fifty (1-for-50) reverse split of the Company’s issued and outstanding shares
of common stock (see Note 2).
The
following table reconciles the Series C and Series D Preferred Stock reflected on the balance sheet at December 31, 2022:
Schedule of Preferred Stock
| |
Series C Preferred
Stock | | |
Series D Preferred
Stock | |
Gross Proceeds | |
$ | 4,702,500 | | |
$ | 47,500 | |
Less: | |
| | | |
| | |
Preferred stock issuance costs | |
| (437,169 | ) | |
| (4,416 | ) |
Plus: | |
| | | |
| | |
Accretion of carrying value to redemption value | |
| 932,169 | | |
| 9,416 | |
Preferred stock subject to possible redemption | |
$ | 5,197,500 | | |
$ | 52,500 | |
At
December 31, 2022, $4,750,000 in gross proceeds received from the issuance of the Preferred Stock, plus an additional $500,000, which
was required to fund the 105% redemption price for the Preferred Stock, was held in an escrow account and presented as restricted cash
on the Company’s December 31, 2022 consolidated balance sheet. The Preferred Stock was redeemed in full for cash through February
8, 2023, the escrow account was closed, and as of September 30, 2023, there were no shares of Preferred Stock outstanding.
8.
Stockholders’ Equity
February
2022 Offering
On
February 18, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the
Company issued and sold in a best-efforts public offering, (i) 651,000 units, at $15.00 per unit, with each unit consisting of one share
of the Company’s common stock, one warrant to purchase one share of the Company’s common stock at an exercise price of $18.50
per share that expires on the fifth anniversary of the date of issuance (“Series A Warrant”) and one warrant to purchase
one share of the Company’s common stock at an exercise price of $18.50 per share that expired on the 18-month anniversary of the
date of issuance (“Series B Warrant”), and (ii) 89,000 pre-funded units, at $14.995 per unit, with each unit consisting of
one pre-funded warrant to purchase one share of the Company’s common stock at an exercise price of $0.005 per share (a “Pre-Funded
Warrant” and together with the Series A Warrants and Series B Warrants, the “Warrants”), one Series A Warrant and one
Series B Warrant (collectively, the “February 2022 Offering”).
The
exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock
splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. In addition,
in the event the Company effects a reverse stock split during the term of the Warrants, the exercise price of the Warrants following
such reverse split will be subject to further adjustment in the event the volume-weighted average trading price of our common stock for
the five days following such reverse stock split is lower than the exercise price of the Warrants. Also, subject to customary exceptions,
the exercise price of the Warrants is subject to adjustment in the event of issuances of the Company’s common stock or common stock
equivalents at a price below the exercise price of the Warrants. In such event, the exercise price of the Warrants will be reduced to
the price of the securities issued in such transactions. In the event of a fundamental transaction, as defined, the holder of a warrant
shall have the option, exercisable at any time concurrently with, or within 30 days after, the consummation of the fundamental transaction
to cause the Company to purchase such warrant from the holder for cash in an amount equal to the Black Scholes value of such warrant
calculated in accordance with the terms of Warrant.
On
February 18, 2022, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital
Partners LLC (“Roth”) and Maxim Group LLC, as co-agents (collectively, the “Agents”), pursuant to which the Company
paid the Agents an aggregate fee equal to 7.0% of the gross proceeds from the units sold in the February 2022 Offering and reimbursed
the Agents $100,000 for expenses incurred in connection with the February 2022 Offering. In addition, the Company issued warrants (the
“Placement Agent Warrants”) to Roth to purchase up to 37,000 shares of the Company’s common stock exercisable at an
exercise price of $18.50 per share. The Placement Agent Warrants were immediately exercisable and expire on the fifth anniversary of
the date of the issuance.
On
February 23, 2022, the Company closed the February 2022 Offering, and issued (i) 651,000 shares of common stock, (ii) Series A Warrants
to purchase 740,000 shares of common stock, (iii) Series B Warrants to purchase 740,000 shares of common stock, and (iv) Pre-Funded Warrants
to purchase 89,000 shares of common stock. The gross proceeds from the February 2022 Offering were $11,100,000 and the net proceeds,
after deducting the placement agent fees and offering expenses payable by us, were approximately $9,969,000. Included in the proceeds
were net proceeds of approximately $1,134,000 from the exercise of warrants exercised in connection with the February 2022 Offering.
Warrants
A
summary of the Company’s warrant activity is as follows:
Schedule of Warrants Activity
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (Years) | |
December 31, 2022 | |
| 1,526,701 | | |
$ | 8.67 | | |
| 2.39 | |
Granted | |
| - | | |
| - | | |
| - | |
Forfeitures | |
| - | | |
| - | | |
| - | |
Expirations | |
| (740,000 | ) | |
| 7.57 | | |
| - | |
Exercised | |
| (7,649 | ) | |
| - | | |
| - | |
September 30, 2023, all exercisable | |
| 779,052 | | |
$ | 8.95 | | |
| 2.14 | |
The
exercise prices of warrants outstanding and exercisable as of September 30, 2023, are as follows:
Schedule of Exercise Price of Warrants Outstanding and Exercisable
Warrants Outstanding and Exercisable (Shares) | |
Exercise Prices | |
769,351 | |
| 7.57 | |
9,701 | |
| 120.00 | |
779,052 | |
| | |
During
the nine months ended September 30, 2023, warrants exercisable into 7,649 shares of common stock were exercised for total proceeds of
$57,903. Based on the closing price of the Company’s common stock on September 30, 2023 of $7.38 per share, the intrinsic value
of the warrants as of September 30, 2023 was $318,570.
Stock
Options
A
summary of the Company’s stock option activity is as follows:
Schedule of Share-based Compensation, Stock Options, Activity
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (Years) | |
December 31, 2022 | |
| 13,294 | | |
$ | 217.05 | | |
| 6.80 | |
Granted | |
| 11,336 | | |
| 6.22 | | |
| 9.05 | |
Forfeitures | |
| (595 | ) | |
| 197.70 | | |
| 7.50 | |
Expirations | |
| (3,458 | ) | |
| 357.53 | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
September 30, 2023, outstanding | |
| 20,577 | | |
| 77.72 | | |
| 7.89 | |
September 30, 2023, exercisable | |
| 10,096 | | |
| 149.26 | | |
| 6.80 | |
The
exercise prices of options outstanding and exercisable as of September 30, 2023 are as follows:
Schedule of Exercise Price of Options Outstanding and Exercisable
Options Outstanding (Shares) | | |
Options Exercisable (Shares) | | |
Exercise Prices | |
10,000 | | |
| 1,250 | | |
$ | 6.01 | |
1,344 | | |
| 1,176 | | |
| 7.35 | |
1,344 | | |
| 168 | | |
| 7.78 | |
841 | | |
| 788 | | |
| 45.50 | |
1,002 | | |
| 668 | | |
| 80.50 | |
1,008 | | |
| 1,008 | | |
| 88.00 | |
840 | | |
| 840 | | |
| 116.70 | |
336 | | |
| 336 | | |
| 162.33 | |
3,862 | | |
| 3,862 | | |
| 300.00 | |
20,577 | | |
| 10,096 | | |
| | |
The
Company accounts for share-based payments in accordance with ASC 718 wherein grants are measured at the grant date fair value and charged
to operations over the vesting periods.
During
the nine months ended September 30, 2023 and 2022, the Company granted options to purchase an aggregate of 1,344 shares of common stock
to the independent members of the Company’s Board of Directors in connection with the compensation plan for such directors with
grant date fair values of $8,454 and $7,793, respectively, using a Black-Scholes option pricing model based on the following assumptions:
(i) a volatility rate of 146%, (ii) a discount rate of 3.81% and 3.35%, respectively, (iii) zero expected dividend yield, and (iv) an
expected life of 3 years. The options have an exercise price of $7.78 and $7.35 per share, respectively. The options vest on a quarterly
basis over two years from the grant date, with the first tranche vesting on September 30, 2023.
During
the nine months ended September 30, 2023, the Company granted options to purchase 10,000 shares of common stock to the Company’s
new Chief Executive Officer (“CEO”) with a grant date fair value of $65,000 using a Black-Scholes option pricing model based
on the following assumptions: (i) a volatility rate of 146%, (ii) a discount rate of 3.80%, (iii) zero expected dividend yield, and (iv)
an expected life of 6 years. The options vest on a quarterly basis thereafter over two years.
The
Company’s former CEO resigned effective June 9, 2023. All options issued to the former CEO that were not vested at the time of
resignation were forfeited. Compensation expense previously recorded related to the unvested options was reversed, resulting in a reduction
of stock compensation expense of $(92,412) during the three months and nine months ended September 30, 2023.
The
Company computes stock price volatility over expected terms based on its historical common stock trading prices. The risk-free interest
rate was based on rates established by the Federal Reserve Bank. The expected dividend yield was based on the fact that the Company has
not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.
The expected life of the stock options granted is estimated using the “simplified” method, whereby the expected term equals
the average of the vesting term and the original contractual term of the stock option.
For
the nine months ended September 30, 2023 and 2022, the Company recognized aggregate stock-compensation expense of $(20,331) and $191,882,
respectively, related to the fair value of vested options, net of the impact of forfeitures.
As
of September 30, 2023, the Company had an aggregate of 10,096 remaining unvested options outstanding, with a remaining grant date fair
value of approximately $153,000 to be amortized over an average of 5 years. Based on the closing price of the Company’s common
stock on September 30, 2023 of $7.38 per share, the aggregate intrinsic value of unvested options outstanding as of September 30, 2023
was approximately $13,700.
Restricted
Common Stock
During
the nine months ended September 30, 2023 and 2022, there were no grants of restricted common stock.
During
the nine months ended September 30, 2023 and 2022, the Company recognized share-based compensation expense of $12,911 and $76,938, respectively,
related to vested restricted shares. At September 30, 2023, there was $6,534 of unvested compensation related to the non-vested shares
that will be amortized over a remaining vesting period of one year.
The
following table summarizes restricted common stock activity for the nine months ended September 30, 2023:
Schedule of Non Vested Restricted Common Stock Activity
| |
Number of shares | | |
Fair value of shares | |
Non-vested shares, December 31, 2022 | |
| 667 | | |
$ | 80.50 | |
Granted | |
| - | | |
| - | |
Vested | |
| 250 | | |
| - | |
Forfeited | |
| - | | |
| - | |
Non-vested shares, September 30, 2023 | |
| 417 | | |
| 80.50 | |
9.
Commitments and Contingencies
Employment
Agreement
On
June 19, 2023, the Board of Directors appointed Jan Hall as President and Chief Executive Officer of the Company. The Company and Ms.
Hall entered into an employment agreement pursuant to which Ms. Halls’ annual base salary is $370,000 and provides that Ms. Hall
shall have an annual target cash bonus of no less than her base salary based on performance objectives determined by the Compensation
Committee of the Board of Directors. With respect to the 2023 performance period, Ms. Hall’s annual bonus will be equal to either
(i) her full target bonus, prorated based on a period commencing on June 19, 2023, or (ii) in the event there is a change in control
of the Company that is consummated on or before March 31, 2024, $200,000, subject to remaining employed through the payment of her bonus
(which may be up to 90 days following the change in control), compliance with her restrictive covenants, her execution and non-revocation
of a general release of claims against the Company, and if requested, entering into any offer letter, restrictive covenant agreement
and/or employment agreement with the buyer after being offered an opportunity to negotiate such agreements in good faith; provided, however,
that in no event will she be entitled to both payments with respect to the 2023 performance period. In the event the Company terminates
Ms. Hall’s employment without cause, she resigns for good reason or her employment is terminated by the Company following a change
in control of the Company, subject to executing and not revoking a general release of claims against the Company and complying with her
restrictive covenants, she will be entitled to (a) nine months of salary continuation, which is to be increased to twelve months if the
qualifying termination of her employment occurs on or after June 19, 2024; (b) any unpaid annual bonus for the year prior to the year
in which the termination of her employment occurs; (c) a prorated bonus for the year in which the termination of her employment occurs,
based on actual performance; and (d) any salary earned and vested benefits accrued prior to Ms. Hall’s termination of employment.
10.
Subsequent Events
The
Company performed an evaluation of subsequent events through the date of filing of these condensed consolidated financial statements
with the SEC. Other than those matters described elsewhere in the footnotes, there were no material subsequent events which affected,
or could affect, the amounts or disclosures in the condensed consolidated financial statements.
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You
should read the following discussion and analysis of our financial condition and results of operations together with and our financial
statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this
discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may
differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited
to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form
10-K for the fiscal year ended December 31, 2022, as may be amended, supplemented or superseded from time to time by other reports we
file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted.
As
used in this Quarterly Report on Form 10-Q, the terms “we,” “us” “our” and the “Company”
mean Guardion Health Sciences, Inc., individually, or as the context requires, collectively with
its subsidiaries.
Overview
We
are a clinical nutrition company that develops and distributes clinically supported nutritional medical foods and dietary supplements.
The Company offers a portfolio of science-based, clinically supported products designed to support retail consumers, healthcare professionals
and providers, and their patients by supporting bone health, eye health, cardiovascular health, and brain health through nutrients such
as Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s.
Our
profile and focus fundamentally changed with the acquisition of Activ Nutritional, LLC (“Activ” or “Viactiv”
as the context requires) in June 2021, the owner and distributor of the Viactiv® line of supplements for bone health and other applications.
As a result of the Activ acquisition, our commercial efforts changed to its current focus on the development and marketing of science-based
clinical nutrition and supplements.
The
acquisition and integration of the Viactiv® line of products has changed our financial position, market profile and brand and operating
focus. In order to leverage the Viactiv® platform, the Company has searched for additional complementary business opportunities.
Additionally, the Company is focusing on new product development that it can launch under the Viactiv® brand and in the year ended
December 31, 2022, the Company launched its new Omega Boost Gel Bites product.
In
June 2023, Bret Scholtes, the Company’s former President and Chief Executive Officer and a member of the Board of Directors, resigned
as an officer and as a member of the Board of Directors. In June 2023, we appointed former Neutrogena and Coca-Cola executive, Jan Hall,
as our new President and Chief Executive Officer. Ms. Hall is a highly regarded veteran of big consumer health and consumables, including
dietary supplements. Ms. Hall has an extensive array of commercial experience and a proven track record of growing well-known consumer
and healthcare brands at leading global companies. Ms. Hall is instrumental in building out the Company’s capability to drive growth
with the existing Viactiv® line of products and accelerate the development of new complementary products. In addition, in July 2023,
we appointed Katie Cox as our new Chief Accounting Officer, replacing Jeffrey Benjamin.
We
believe the Activ acquisition added valuable attributes, which have contributed to achieving our goals including (1) Viactiv’s
brand awareness and acceptance from the consumer; (2) experienced management; (3) established distribution and supply networks and relationships;
(4) product development potential; and (5) a consistent track record of financial performance.
|
● |
Brand
awareness – Viactiv® was initially launched by industry leaders Mead Johnson/Johnson & Johnson approximately twenty
years ago, and we believe this history, along with the product’s marketing campaigns, taste profile and receipt of consistently
positive consumer reviews, have led to strong consumer awareness and acceptance. We are leveraging this strong consumer awareness
to expand the Viactiv® brand beyond calcium chews. We launched an Omega-3 product during the year ended December 31, 2022, called
Omega Boost Gel Bites, and we are marketing it to a similar target audience as the calcium chews. This along with cross selling across
products are important actions we are taking to take advantage of the Viactiv® brand awareness to help us grow our business. |
|
|
|
|
● |
Experienced
management – As part of the Activ acquisition, we hired the senior executive responsible for the Viactiv® brand at Adare
Pharmaceuticals, Inc. (“Adare”) as our Chief Commercial Officer. This senior executive was a member of the executive
leadership team of Adare, and contributes strong sales, marketing and research and development skills and experiences to our leadership
team. Since the acquisition of Activ, we assembled other professionals that have additional and complementary skills, including manufacturing,
logistics, financial management and medical education. |
|
|
|
|
● |
Established
distribution – Viactiv’s products are currently marketed through many of the nation’s largest retailers, including
Walmart (retail and online), Target and Amazon. We added a direct-to-consumer eCommerce capability on our website viactiv.com in
2022 to expand our sales channels. The Viactiv® calcium chews can now be purchased through any of these channels, and we subsequently
added our ocular products to this platform. We are also working to leverage our distribution and supply networks to grow our Omega
Boost Gel Bites product which is currently sold on our direct-to-consumer site as well as one online retailer. We are evaluating
additional channel expansion for Omega Boost Gel Bites in addition to offering bundles with our other products to our customers.
The product has been listed for distribution at The Vitamin Shoppe and Rite Aid. |
|
|
|
|
● |
Track
record of financial performance – The Viactiv® brand has a strong history of financial success both before and after our
acquisition of the brand. For the nine months ended September 30, 2023, Viactiv® generated net revenues of $9,054,305, which
accounted for 97% of our total revenues for the period. For the nine months ended September 30, 2022, Viactiv® generated net
revenues of $8,006,229, which accounted for 96% of our total revenues for the period. Over time, we expect the acquisition of Viactiv®
to contribute increasing revenue and consistent operating margins, as well as a multitude of growth opportunities to our Company. |
Viactiv®
Calcium Fortified Soft Chew
Viactiv®
was first introduced to the market over 20 years ago as a calcium-fortified soft chew intended to deliver clinical nutrition to women
in a product form that has an enjoyable taste and is easy to consume. The chews are available in chocolate and caramel flavors, each
delivering nutrition to help consumers maintain health goals, such as strong bones and immune support. The calcium chews contain 650
mg of calcium that deliver benefits of hard-to swallow pills in a chewable form with the great taste you expect from a gummy. Compared
to the leading gummies, we believe our calcium chews are one of the only products with both Vitamin D and K1 to boost calcium absorption
and help support bone mineral density.
Viactiv®
Omega Boost Gel Bites
In
February 2022, we began the marketing of our Viactiv® Omega Boost Gel Bites product, our first expansion of the Viactiv® brand
since we acquired the business in June 2021. The 1,200 mg Omega-3 gel bites are designed to provide valuable health benefits, including
the support of cardiovascular, brain, joint and eye health. The gel bite dosage form has been shown to have better absorption and fewer
digestive issues than regular soft gel formulas, as well as without the unpleasant fishy aftertaste and sugar, which is associated with
many other Omega-3 products.
The
Omega Boost Gel Bites also represent an expansion of the Viactiv® brand beyond calcium products. We are focusing on the potential
of the product as we increase consumer awareness, receive additional clinical support for the efficacy of the product, refine our marketing
activities and increase distribution.
Launch
of Direct-to-Consumer Online Store for Viactiv® Products
During
January 2022, we launched our e-commerce venue through a Shopify store for our Viactiv® line of products (which can be found at www.activ.com).
The e-commerce platform offers Viactiv® customers the option of shopping via retail outlets (e.g., grocery, pharmacy, etc.) or online
through those same retail websites or directly through our branded website. We derived approximately 1% of our sales revenue from this
channel during the three months and nine months ended September 30, 2023 and 2022. We hope to increase this revenue segment through a
targeted marketing effort to attract existing and new customers through a digital marketing strategy which entails mobile optimization,
performance marketing, and brand awareness.
Strategic
Objectives, Goals and Initiatives
We
believe that our ability to maximize stockholder value requires that we continue to build a solid corporate foundation and demonstrate
growth and commercial success on top of that foundation. We have taken a number of steps over the last two years to strengthen our corporate
foundation, including acquiring Viactiv®, winding down and reevaluating VectorVision, hiring key team members, launching a new product,
strengthening our eCommerce capabilities and streamlining operations.
Our
three primary objectives are:
|
● |
Demonstrate
Commercial Success: We are focused on growing sales of our existing Viactiv® product portfolio, growing sales of new products
introduced in 2022 and positioning the other clinical nutrition products to maximize results. In 2022, we launched the new Omega
Boost Gel Bites, which adds a key product to our portfolio. We believe that new products are also important to reduce the risk of
customer and supplier concentrations. We have worked with our manufacturing partners to rebuild inventories which were negatively
impacted by the supply chain constraints we experienced in 2021 and 2022. Lack of inventory was the biggest impediment to our ability
to grow sales of our calcium products in the first three fiscal quarters of 2022, but we have since rebuilt our inventory levels
and inventory is not currently an impediment. We also implemented a targeted retail price increase that went into effect during the
second half of 2022 and the first nine months of 2023 that were driven by retailers’ timelines. Our sales increased in the
nine months ended September 30, 2023, to $9,312,695, which we believe was a result of these actions. This sales increase was also
a result of various commercial and operational improvements that we implemented for our Viactiv® line of products, including
the increased inventory levels we maintained in the first nine months of 2023. |
|
● |
Strengthen
our Commercial Engine: We believe we need to effectively implement several strategies to improve our commercial engine. We intend
to expand our product distribution within our existing sales channels, strengthen our Viactiv® brand and related marketing, build
our innovation pipeline and strengthen our management team. During the nine months ended September 30, 2023, we continued to explore
new distribution opportunities with new and existing customers as well as enhance our direct-to-consumer capability on viactiv.com.
We continue to monitor customer trends and identify opportunities for new product development. As we refine our plans for 2023, we
plan to focus our efforts on supporting our core calcium chew products with a new digital advertising campaign called “Bold
Age”, and further commercializing the Omega Boost Gel Bites product that was introduced in 2022. During the nine months ended
September 30, 2023, we maintained our inventory levels at a satisfactory level, which is required in order to increase our marketing
trials. We also made progress toward our goal of regaining consistent selling levels with Amazon.com and, as result, net sales have
grown on the site by approximately 68% for the three months ended September 30, 2023. We also continue to pursue additional marketing
strategies to increase the distribution of all Viactiv® products across our existing sales channels, such as targeted digital
advertising of the new advertising campaign driving customer purchases of Viactiv® calcium chews at Walmart, Target and Kroger. |
|
● |
Strengthen
our Clinical Nutrition Strategy: We are strengthening our clinical nutrition strategy by advancing clinical evidence regarding
our existing and future products, partnering with specialty manufacturers and suppliers to leverage innovations, and working to increase
awareness of our products within the healthcare community. In 2022, we announced interim results of an independent clinical study
designed to evaluate the effectiveness of new Viactiv® Omega Boost Gel Bite Gummies at increasing Omega-3s, EPA and DHA saturation
levels on red blood cells in comparison to a leading gummy and soft gel product. According to this study, Viactiv® Omega Boost
Gel Bites provided a greater and faster increase of the omega-3 index when compared to the soft gel and gummy groups. Our clinical
results showed a 50% improvement in Omega-3 levels in just 4 weeks and a 63% increase in 12 weeks in healthy participants. Finally,
we continue to consult with our manufacturing partners to research the supply of science-based ingredients and new formats that could
be incorporated into our future products |
Evaluation
of Strategic Alternatives
The
Company is also evaluating alternative strategic paths focused on maximizing stockholder value, and we have hired Alantra, LLC (“Alantra”)
as the Company’s exclusive financial advisor to implement a strategic review to evaluate alternatives to maximize stockholder value
in the near-term, which could include, among other alternatives, a sale of the Company or the Viactiv brand, or a merger, acquisition,
reverse acquisition, or other strategic transaction, which review was ongoing at September 30, 2023.
The Company is continuing to explore a diverse range of strategic options
to help grow the Company and enhance stockholder value. There can be no assurances, however, that this process will result in a transaction,
or that if a transaction is completed, it will ultimately enhance stockholder value. There is no set timetable for the strategic review
process and the Company does not intend to provide periodic updates until the Board of Directors makes a formal decision and determines
that disclosure is appropriate and/or necessary under the circumstances.
Availability
of Capital
We
may continue to seek to raise additional debt and/or equity capital to fund future operations and acquisitions as necessary, but there
can be no assurances that we will be able to secure such additional financing in the amounts necessary to fully fund our operating requirements
on acceptable terms or at all. Over time, if we are unable to access sufficient capital resources on a timely basis, we may be forced
to reduce or discontinue our product development programs and/or curtail or cease operations.
We
will continue to incur significant expenses related to the commercialization and development of our products and with respect to our
efforts to build our infrastructure, expand our operations, and execute our business plans. Even if profitability is achieved in the
future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative
cash flow from operations for the foreseeable future.
We
do not have any credit facilities as a source of present or future capital. If we raise additional capital through the issuance of equity
or convertible debt securities, the percentage ownership of our stockholders could be significantly diluted, and these newly issued securities
may have rights, preferences or privileges senior to those of existing stockholders. Debt financing, if obtained, may involve agreements
that include covenants limiting or restricting the ability to take specific actions, such as incurring additional debt, would increase
expenses and may require that our assets secure such debt.
Reverse
Stock Split
On
January 6, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of
State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split of its outstanding common stock without any change
to its par value. The authorized number of shares of common stock was not affected by the reverse stock split. The Company issued 35,281
additional common shares in connection with this reverse stock split per the Company’s determination to round up all fractional
shares resulting from the reverse stock split to the nearest whole share.
Accordingly,
all common shares, stock options, stock warrants and per share amounts in these consolidated financial statements have been adjusted
retroactively to reflect the reverse stock split as if the split occurred at the beginning of the earliest period presented in this Quarterly
Report on Form 10-Q.
Concentration
of Risk
Information
with respect to concentration of risk is provided at Note 2 to the condensed consolidated financial statements for the nine months ended
September 30, 2023 and 2022, included elsewhere in this Quarterly Report on Form 10-Q.
Critical
Accounting Policies and Estimates
The
preparation of our consolidated financial statements in conformity with generally accepted accounting principles in the United States
(“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can
be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or
conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in
relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates
the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances,
historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly.
Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing inventories
at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other
long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for
potential liabilities, the classification and valuation of warrants, and assumptions used in the determination of the Company’s
liquidity. There were no changes to our critical accounting policies described in the consolidated financial statements included in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2022 that impacted our condensed consolidated financial statements
and related notes included herein.
Recent
Trends – Market Conditions
Beginning
in December 2021 and through the third quarter of 2022, we experienced supply chain constraints due to the COVID-19 pandemic. These supply
chain issues constrained our ability to obtain inventory to fulfill customer orders for our Viactiv® brand products on a timely basis.
The constraints began to abate during the fourth quarter of 2022, and we have not experienced any disruptions since that time. We are
subject to out-of-stock fees to certain retailers in the event that we are unable to adequately maintain certain inventory levels of
our Viactiv® products.
We,
along with our suppliers, continue to experience significant broad-based inflation and labor cost pressures. We expect input cost inflation
to continue through the remainder of 2023 and 2024. There are signs that unit volume consumption is softening in recent vitamins, minerals,
and supplements syndicated industry data. We believe that the impact of inflation-based cost increases on consumers’ purchasing
power in combination with the implementation of higher retail prices across brands in the vitamins, minerals and supplements category
is contributing to the softness.
Store traffic in the drug channel has declined due to a decrease in the
number of people choosing to have a COVID-19 shot. Lower footfall has reduced chainwide sales, including vitamins, minerals, and supplements.
The legal cost of opioid settlements has also impacted drug retailers. In October 2023, Rite Aid filed for protection under Chapter 11
of the United States Bankruptcy Code and disclosed a restructuring plan which includes a phased approach to a significant store-closure
program. We have adjusted our sales forecast to account for the changes to the number of Rite Aid stores and will continue to identify
new distribution opportunities to bridge the gap and accelerate brand sales.
Inflation
The
continuing impact of higher inflation, the actions by the Federal Reserve Bank to address inflation, most notably continuing increases
in interest rates, and rising food and energy prices in combination with higher labor costs create uncertainty about the future economic
environment which will continue to evolve. The Company believes these factors impacted the Company’s business in 2022 and the first
nine months of and will continue for the remainder of 2023 and, and we believe, in 2024. The consequences of higher government deficits
and debt, tighter monetary policy, and potentially higher long-term interest rates may result in a higher cost of capital for the business
and an increase in our operating expenses.
Recent
Accounting Pronouncements
Information
with respect to recent accounting pronouncements is provided at Note 2 to the condensed consolidated financial statements for the nine
months ended September 30, 2023 and 2022 included elsewhere in this Quarterly Report on Form 10-Q.
Plan
of Operations
General
Overview
We
are a clinical nutrition company that develops and distributes clinically supported nutritional medical foods and dietary supplements.
The Company offers a portfolio of science-based, clinically supported products designed to support retail consumers, healthcare professionals
and providers, and their patients by supporting bone health, eye health, cardiovascular health, and brain health through nutrients such
as Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s.
We
believe that our ability to maximize stockholder value requires that we build a solid corporate foundation and demonstrate growth and
commercial success on top of that foundation. In the last two years we have taken numerous steps to strengthen our corporate foundation,
including acquiring Viactiv® winding down and reevaluating VectorVision, hiring key team members, including, more recently, hiring
Ms. Hall as the Company’s President and Chief Executive Officer, launching a new product, strengthening our eCommerce capabilities,
and streamlining operations.
We
are working on several initiatives we believe will help achieve the long-term goals as described above under “Strategic Objectives,
Goals and Strategies” and below.
|
● |
We
intend to focus on growing Viactiv® to become a profitable broad-based destination health and wellness brand with a foundation
in clinically supported efficacy. |
|
|
|
|
● |
We
hope to strengthen the core functional benefits and emotional attributes that set the brand apart from other products in the market
that do not have the benefit of a legacy of more than 20 years driving consumer awareness and product acceptance. Effective advertising
combined with targeted marketing initiatives, product innovations in existing and new product segments, plus expanded retail and
online distribution will be the engine of future growth. |
|
|
|
|
● |
We
plan to focus on increasing market share of the Viactiv® brand among current users of calcium supplements in current channels
and customers, and by driving product trial and loyalty among new calcium users entering the category. By offering more appealing
and differentiated products with clinically supported claims in combination with powerful, insight-driven advertising that brings
the brand to life in a meaningful and personal way, we hope to ignite a deeper level of relevance and resonance among our target
consumer groups. The new “Bold Age” advertising campaign launched in the second quarter of 2023, is an example of consumer
insight-driven brand communication that has proved to be successful versus key category metrics. As we learn more from in-market
performance analytics, we will continue to optimize the impact of the creative and effectively deploy media spend across social media
channels and eCommerce, including customer websites and Viactiv.com. |
|
|
|
|
● |
We
believe Viactiv® holds significant potential for brand extension in the health and wellness space. In parallel with strengthening
the core pillars of the current calcium business, we intend to continue to take Viactiv® beyond where it is today by expanding
the appeal and reach of the brand to a broader base of dietary supplement and health and wellness consumers. We are focused on product
formulations that offer superior product taste, compelling product formats, and competitive cost structures. The launch of Viactiv®
Omega Boost Gel Bites is an example of the growth potential of this strategy. The product was recently accepted by The Vitamin Shoppe
in the specialty channel and became available to shoppers in stores and online in the third quarter of 2023. Future innovations to
extend Viactiv® into new product segments will continue to spearhead penetration of trade channels and customers that the brand
does not leverage today. |
|
● |
We
hope to strengthen our clinical nutrition strategy by continuing to advance clinical evidence regarding our products, working with
manufacturers and suppliers to leverage our partner’s innovations and increasing awareness of our products and efforts within
the healthcare community. Product efficacy is a cornerstone of the Viactiv® brand promise. We will actively seek out further
opportunities to participate in clinical studies that demonstrate the effectiveness of our products, following the example of the
independent clinical study involving Omega Boost Gel Bites referenced earlier in this report. |
|
|
|
|
● |
To
enable us to achieve the initiatives we believe will help deliver our long-term objectives, we hope to strengthen the consumer-packaged
goods and science-based capabilities of our management team and the network of external partners we work with. As we grow, we intend
to optimize our go-to-market sales and marketing structure and strengthen our internal and external operations and support functions
capability and capacity in alignment with business goals and regulatory requirements. |
|
|
|
|
● |
We
intend to focus on smart use of financial resources through cross-functional collaboration, effective financial planning, analysis
and disciplined management in alignment with pre-approved metrics that tie to the achievement of short and long-term business goals.
We will continue our efforts to make cost improvements and drive efficiencies to reduce cash burn and improve profitability to drive
shareholder value. |
Results
of Operations
Through
September 30, 2023, we have primarily been engaged in product development and marketing, commercialization of our products and improving
our operating efficiencies. We have incurred, and will continue to incur, significant expenditures for the commercialization and development
of our products. With the acquisition of the Viactiv® brand and its successful integration into our operations, we believe we have
established a significant baseline level of revenue from which to grow.
Comparison
of Three Months Ended September 30, 2023 and 2022
| |
Three Months Ended September 30, | | |
Change | |
| |
2023 | | |
2022 | | |
$ | | |
% | |
Revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 673,640 | | |
| 25 | % |
Cost of goods sold | |
| 1,876,938 | | |
| 1,575,366 | | |
| 301,572 | | |
| 19 | % |
Gross Profit | |
| 1,460,252 | | |
| 1,088,184 | | |
| 372,068 | | |
| 34 | % |
Operating Expenses: | |
| | | |
| | | |
| | | |
| | |
Sales and marketing | |
| 318,734 | | |
| 526,193 | | |
| (207,459 | ) | |
| (39 | )% |
General and administrative and other | |
| 1,903,761 | | |
| 2,241,182 | | |
| (337,421 | ) | |
| (15 | )% |
Research and development | |
| 10,671 | | |
| 60,203 | | |
| (49,532 | ) | |
| (82 | )% |
Total Operating Expenses | |
| 2,233,166 | | |
| 2,827,578 | | |
| (594,412 | ) | |
| (21 | )% |
Loss from Operations | |
| (772,914 | ) | |
| (1,739,394 | ) | |
| (966,480 | ) | |
| (56 | )% |
Other Income (Expense): | |
| | | |
| | | |
| | | |
| | |
Change in fair value of warrant derivative liability | |
| 1,050,800 | | |
| 873,200 | | |
| 177,600 | | |
| 20 | % |
Interest income | |
| 94,747 | | |
| 43,282 | | |
| 51,465 | | |
| 119 | % |
Net Income (Loss) | |
$ | 372,633 | | |
$ | (822,912 | ) | |
$ | 1,195,545 | | |
| 145 | % |
Revenue
For
the three months ended September 30, 2023, revenue was $3,337,190 as compared to $2,663,550 for the three months ended September 30,
2022, an increase of $673,640 or 25%. This increase is primarily attributable to $3,252,673 of revenue generated during the three months
ended September 30, 2023, from sales of our Viactiv® product line as compared to $2,563,398 of revenue generated from sales of our
Viactiv® product line for the three months ended September 30, 2022. During the three months ended September 30, 2023, we experienced
positive phasing for orders previously delayed in the prior three months by our carrier’s warehouse expansion plan, which was resolved
in July 2023.
Cost
of Goods Sold
For
the three months ended September 30, 2023, cost of goods sold was $1,876,938, as compared to $1,575,366 for the three months ended September
30, 2022, an increase of $301,572 or 19%. This increase is primarily attributable to the increase in revenues for the three months ended
September 30, 2023, as compared to the three months ended September 30, 2022, and a result of lower transportation costs negotiated during
the period.
Gross
Profit
For
the three months ended September 30, 2023, gross profit was $1,460,252, as compared to $1,088,184 for the three months ended September
30, 2022, an increase of $372,068 or 34%. This increase is primarily the result of the additional gross profit generated by sales of
our Viactiv® products during the three months ended September 30, 2023, as compared to the three months ended September 30, 2022.
Gross margin for the three months ended September 30, 2023, was 43.8%, as compared to 40.9% for the three months ended September 30,
2022.
Sales
and Marketing
For
the three months ended September 30, 2023, sales and marketing expenses were $318,734, as compared to $526,193 for the three months ended
September 30, 2022, a decrease of $207,459, or 39%. The decrease is attributable to expenditures in marketing and advertising during
the three months ended September 30, 2023, related to our Viactiv® line of products. Sales and marketing costs are primarily attributable
to the Viactiv® product line and consist primarily of advertising expenses related to support for our calcium chews, and Omega Boost
Gel Bites products. During the three months ended September 30, 2023, we ran digital advertising campaigns to support the core calcium
chew business with new creative focusing on the benefits of Viactiv® to strengthen bones and help protect against osteoporosis and
implemented a separate marketing campaign for pregnancy. Both performed well against industry benchmarks and compared with prior brand
advertising. In addition to advertising for the calcium products, we also ran a specific digital advertising campaign to support Omega
Boost Gel Bites focusing on their unique benefits of enhanced absorption, quantity of Omega-3, no sugar and no fishy taste. Like the
calcium chews, the campaign also worked well against industry metrics. Based on the consumer learning, we will continue to optimize the
campaigns in 2023.
General
and Administrative and other
For
the three months ended September 30, 2023, general and administrative and other expenses were $1,903,761, as compared to $2,241,182 for
the three months ended September 30, 2022, a decrease of $337,421 or 15%. The decrease was primarily driven by decreases of approximately
$298,000 in the amortization of intangibles, and $112,000 in payroll costs, partially offset by an increase of approximately $96,000
in insurance fees. We continue to focus our efforts and resources on lowering the ratio of general and administrative and other expense
to net sales. The ratio has decreased from 84% to 57% in the three months ended September 30, 2023, as compared to the three months ended
September 30, 2022.
Change
in Fair Value of Warrant Derivative Liability
For
the three months ended September 30, 2023, the change in the fair value of warrant derivative liabilities related to the issuance of
the Series A warrants and Series B warrants in November 2022 was a gain of $1,050,800, as compared to a gain of $873,200 for the three
months ended September 30, 2022.
Loss
from Operations
For
the three months ended September 30, 2023, we incurred a loss of $772,914, as compared to a loss of $1,739,394 for the three months ended
September 30, 2022. The reduction in operating loss was attributable to an increase of gross profit due to an increase in sales of $673,640
or 25%. In addition, the decrease of $337,421 or 15% in the general and administrative expense category and the decrease of $207,459
or 39% in the sales and marketing expense category for the three months ended September 30, 2023, as compared to the three months ended
September 30, 2022.
Net
Income (Loss)
For
the three months ended September 30, 2023, net income was $372,633, as compared to a net loss of $822,912 for the three months ended
September 30, 2022. Net income was impacted by a change in value of the warrant derivative liability, which was a gain of $1,050,800
for the three months ended September 30, 2023, as compared to a gain from the change in fair value of the warrant derivative liability
of $873,200 for the three months ended September 30, 2022.
Comparison
of Nine Months Ended September 30, 2023 and 2022
| |
Nine Months Ended September 30, | | |
Change | |
| |
2023 | | |
2022 | | |
$ | | |
% | |
Revenue | |
$ | 9,312,695 | | |
$ | 8,323,382 | | |
| 989,313 | | |
| 12 | % |
Cost of goods sold | |
| 5,267,874 | | |
| 4,739,197 | | |
| 528,677 | | |
| 11 | % |
Gross Profit | |
| 4,044,821 | | |
| 3,584,185 | | |
| 460,636 | | |
| 13 | % |
Operating Expenses: | |
| | | |
| | | |
| | | |
| | |
Sales and marketing | |
| 1,332,469 | | |
| 1,583,349 | | |
| (250,880 | ) | |
| (16 | )% |
General and administrative and other | |
| 5,811,315 | | |
| 7,885,181 | | |
| (2,073,867 | ) | |
| (26 | )% |
Research and development | |
| 150,604 | | |
| 162,418 | | |
| (11,814 | ) | |
| (7 | )% |
Impairment loss right-of-use asset | |
| - | | |
| 24,257 | | |
| (24,257 | ) | |
| (100 | )% |
Total operating expense | |
| 7,294,388 | | |
| 9,655,205 | | |
| (2,360,817 | ) | |
| (24 | )% |
Loss from Operations | |
| (3,249,567 | ) | |
| (6,071,020 | ) | |
| (2,821,453 | ) | |
| (46 | )% |
Other Income (Expense): | |
| | | |
| | | |
| | | |
| | |
Change in fair value of warrant derivative liability | |
| 2,693,600 | | |
| 3,548,300 | | |
| (854,700 | ) | |
| (24 | )% |
Interest income | |
| 289,280 | | |
| 54,458 | | |
| 234,822 | | |
| 431 | % |
Total Other Income (Expense) | |
| 2,982,880 | | |
| 3,602,758 | | |
| (619,878 | ) | |
| (17 | )% |
Net Loss | |
$ | (266,687 | ) | |
$ | (2,468,262 | ) | |
| (2,201,575 | ) | |
| (89 | )% |
Revenue
For
the nine months ended September 30, 2023, revenue was $9,312,695, as compared to $8,323,382 for the nine months ended September 30, 2022,
an increase of $989,313 or 12%. We experienced supply chain delays for inventory in the quarter ended September 30, 2022, which reduced
revenues. In the nine months ended September 30,2023, we were able to successfully mitigate the inventory supply challenges experienced
during the nine months ended September 30, 2022, which enabled us to meet increased customer demand for our Viactiv® line of products
and grow sales by 12% as compared to the nine months ended September 30, 2022.
Cost
of Goods Sold
For
the nine months ended September 30, 2023, cost of goods sold was $5,267,874, as compared to $4,739,197 for the nine months ended September
30, 2022, an increase of $528,677 or 11%. This increase was primarily driven by our 12% growth in revenue primarily from our Viactiv®
line of products for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022.
Gross
Profit
For
the nine months ended September 30, 2023, gross profit was $4,044,821, as compared to $3,584,185 for the nine months ended September
30, 2022, an increase of $460,636 or 13%. This increase was primarily driven by the increase in sales during the nine months ended September
30, 2023. In addition, during the nine months ended September 30, 2023, we paid out-of-stock fees of approximately $5,126, as compared
to out-of-stock fees paid during the nine months ended September 30, 2022, of approximately $88,000, which fees were due to our inability
to maintain contractually agreed upon levels of inventory with certain retailers. We solved these challenges in 2022 and have realized
a measurable benefit as a result. During the nine months ended September 30, 2023, we had a gross profit percentage of 43.4%, as compared
to a gross profit percentage of 43.1% for the nine months ended September 30, 2022.
Sales
and Marketing
For
the nine months ended September 30, 2023, sales and marketing expenses were $1,332,469, as compared to $1,583,349 for the nine months
ended September 30, 2022, a decrease of $250,880 or 16%. The decrease was primarily attributable to our reduced expenditures in marketing
and advertising during the nine months ended September 30, 2023, as we reduced expenses across the product line. We incurred additional
expense in the nine months ended September 30, 2022, related to the launch of our Viactiv® Omega Boost Gel Bites product, including
creative development, testimonial advertising, account management and social media related costs.
General
and Administrative and Other
For
the nine months ended September 30, 2023, general and administrative and other expenses were $5,811,314, as compared to $7,885,181 for
the nine months ended September 30, 2022, a decrease of $2,073,867 or 26%. The decrease in 2023 was primarily driven by decreases of
approximately $892,500 in amortization expense, $397,000 in payroll expense, $242,000 in consulting fees, $276,000 in stock-based compensation,
$157,000 in recruiting fees, and $128,000 in insurance expense, partially offset by an increase in legal fees of approximately $93,000.
Loss
from Operations
Loss
from operations for the nine months ended September 30, 2023, was $(3,249,567), as compared to $(6,071,020) for the nine months ended
September 30, 2022, a decrease of $2,821,453 or 46%. The reduction in operating loss was primarily attributable to a decrease of $2,073,867
or 26% in the general and administrative expense category for the nine months ended September 30, 2023, as compared to the nine months
ended September 30, 2022.
Change
in Fair Value of Warrant Derivative Liability
For
the nine months ended September 30, 2023, the change in the fair value of warrant derivative liabilities related to the issuance of the
Series A Warrants and Series B Warrants in November 2022 was a gain of $2,693,600, as compared to a gain of $3,548,300 for the nine months
ended September 30, 2022.
Net
Income (Loss)
For
the nine months ended September 30, 2023, we generated a net loss of $266,687, as compared to a net loss of $2,468,262 for the nine months
ended September 30, 2022. Net loss for the nine months ended September 30, 2023 was attributable to the operating loss that was partially
offset by the non-cash gain on the change in fair value of the warrant derivative liability described above.
Liquidity
and Capital Resources
For
the nine months ended September 30, 2023, we generated a net loss of $266,687 and used cash in operating activities of $3,052,293. At
September 30, 2023, we had cash and cash equivalents of $7,657,309 and working capital of $11,407,975.
Notwithstanding
the net operating loss for the nine months ended September 30, 2023, management believes that our current cash balance and short-term
investments are sufficient to fund operations for at least one year from the date that this Quarterly Report on Form 10-Q is filed with
the SEC.
We
will continue to incur significant expenses for continued commercialization activities related to our clinical nutrition product lines
and building our infrastructure. Development and commercialization of clinical nutrition products involves a lengthy and complex process.
Additionally, our long-term viability and growth may depend upon the successful development and commercialization of new complementary
products or product lines.
Our
financing has historically come from the sale of common stock and securities convertible into common stock. We may continue to seek to
raise additional debt and/or equity capital to fund future operations and acquisitions as necessary, but there can be no assurances that
we will be able to secure such additional financing in the amounts necessary to fully fund our operating requirements and strategic initiatives
on acceptable terms or at all. Over time, if we are unable to access sufficient capital resources on a timely basis, we may be forced
to reduce or discontinue our product development programs and/or curtail or cease operations.
Sources
and Uses of Cash and Cash Equivalents
The
following table sets forth the Company’s major sources and uses of cash and cash equivalents for each of the following periods:
| |
Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
Net cash used in operating activities | |
$ | (3,052,293 | ) | |
$ | (6,082,906 | ) |
Net cash (used in) provided by investing activities | |
| (3,791 | ) | |
| 4,990,054 | |
Net cash (used in) provided by financing activities | |
| (5,192,097 | ) | |
| 9,944,928 | |
Net (decrease) increase in cash and cash equivalents | |
$ | (8,248,181 | ) | |
$ | 8,852,076 | |
Operating
Activities
Net
cash used in operating activities was $3,052,293 during the nine months ended September 30, 2023, as compared to $6,082,906 for the nine
months ended September 30, 2022. The decrease of $3,030,613 in cash used by operating activities was primarily due to a reduction in
general and administrative expenses.
Investing
Activities
Net
cash used in investing activities was $3,791 for the nine months ended September 30, 2023, as compared to net cash provided by investing
activities in the amount of $4,990,054 for the nine months ended September 30, 2022. Cash used in investing activities for the nine months
ended September 30, 2023 was for the purchase of property and equipment. Cash used in investing activities during the nine months ended
September 30, 2022 was primarily attributable to the net of purchases and sales of US Treasury Bills.
Financing
Activities
Net
cash used in financing activities was $5,250,000 for the nine months ended September 30, 2023. The entire amount was used to repay in
full the holders of the Preferred Stock, originally issued in November 2022, during January and February 2023. Cash provided by financing
activities for the nine months ended September 30, 2022 was $9,944,928 and consisted primarily of the sale of common stock resulting
in net proceeds of $8,834,899 and warrant exercises resulting in net proceeds of $1,134,040.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As
we are a “smaller reporting company”, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide this information.
ITEM
4. CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
Under
the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Accounting Officer,
we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Securities and Exchange Act of 1934
Rules 13a-15(f). Based on this evaluation, our Chief Executive Officer and our Chief Accounting Officer concluded that the Company’s
disclosure controls and procedures were not effective as of September 30, 2023. As of September 30, 2023, management’s assessment
identified the following material weaknesses in the Company’s internal control over financial reporting:
We
continue to have a material weakness in our internal control over financial reporting as disclosed in the December 31, 2022 Annual Report
on Form 10-K, in that the Company did not design and maintain effective controls over the preparation and review of accounting for complex
financial transactions, mainly due to the lack of adequate technical expertise to ensure the proper application, at inception, of ASC
815-15 Embedded Derivatives related to certain stock warrants issued in February 2022.
Remediation
Plan
As
of September 30, 2023, management has designed and implemented the following measures to remediate the material weakness related to the
accounting for the preparation and review of accounting for complex financial transactions, mainly due to the lack of adequate technical
expertise to ensure proper application, as described in the preceding paragraph. As part of the remediation process, the Company has
engaged a third party to review the Company’s accounting for complex financial transactions on a quarterly basis, or when any significant
unusual transaction has been entered into.
While
management believes that the measures already designed and implemented in the accounting for the preparation and review of accounting
for complex financial transactions are effective, the material weakness will not be considered fully remediated until the associated
controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
The Company will monitor the effectiveness of its remediation plan and will refine its remediation plan as appropriate.
Changes
in Internal Control Over Financial Reporting
There
have been no changes in our internal control over financial reporting during the nine months ended September 30, 2023 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations
on Effectiveness of Controls and Procedures
In
designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of
controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management
is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
PART
II – OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
The
Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding or
claim against the Company that the Company believes could have a material adverse effect on its business, operating results, cash flows
or financial condition. The Company is periodically the subject of various pending or threatened legal actions and claims arising out
of its operations in the normal course of business. Regardless of the outcome, such proceedings or claims can have a material adverse
impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances
that favorable outcomes will be obtained.
ITEM
1A. RISK FACTORS
Risk
factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report
on Form 10-K for the year ended December 31, 2022, as filed with the SEC on April 17, 2023 (“Annual Report”). There have
been no material changes in our risk factors from those previously disclosed in our Annual Report, other than as described herein and
below. You should carefully consider the risks described in our Annual Report, which could materially affect our business, financial
condition or future results. The risks described in our Annual Report are not the only risks we face. Additional risks and uncertainties
not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition,
and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be
negatively affected.
We
have identified material weaknesses in our disclosure controls and procedures and internal control over financial reporting. If not remediated,
our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could
result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which
could have a material adverse effect on our financial condition and the trading price of our common stock.
Maintaining
effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce
reliable financial statements. As discussed in Part I, Item 4 – “Controls and Procedures” of this Quarterly Report
on Form 10-Q, we have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded
that they were not effective as of September 30, 2023.
A
material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that
there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or
detected on a timely basis. The material weaknesses we identified are (1) ineffective controls over outsourced Information Technology
systems and business processes and (2) inadequate segregation of duties within accounting processes.
As
discussed in Part I, Item 4 – “Controls and Procedures” of this Quarterly Report on Form 10-Q as of September 30, 2023,
management has designed and implemented measures to remediate the material weakness related to the accounting for the preparation and
review of accounting for complex financial transactions. The execution of our remediation is ongoing and will require validation and
testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles. Management
expects to complete its remediation plan by December 31, 2023.
Risks
Related to the Company’s Business
Supply
Chain Constraints; Inflationary Pressures
We
experienced supply chain constraints due to the COVID-19 pandemic and its aftermath. These constraints began in approximately December
2021 and continued through approximately the third quarter of 2022. These constraints had impacted the Company’s ability to obtain
inventory to fulfill customer orders for its Viactiv® branded products and may continue to impact its ability to fulfill customer
orders going forward which would have a material adverse effect on the Company’s business and results of operations. A resurgence
of COVID-19 could impact the Company’s operations. The Company is subject to out-of-stock fees to certain retailers in the event
that the Company is unable to adequately maintain certain inventory levels of our Viactiv® products. The Company paid approximately
$5,126 and $88,000 in such fees for the nine months ended September 30, 2023 and 2022, respectively, to certain of these retailers. Additionally,
the Company and its suppliers are experiencing significant broad-based inflation of manufacturing and distribution costs as well as transportation
challenges. The Company expects input cost inflation to continue throughout 2023 and 2024. If we are unable to successfully manage the
effects of inflation, our business, operating results, cash flows and financial condition may be adversely affected. Additionally, there
have been various economic indicators that the United States economy may be entering a recession in upcoming quarters. An economic recession
could potentially impact the general business environment and the capital markets, which may have a material negative impact on our financial
results.
Risks
Related to the Company’s Common Stock
We
are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange,
our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and
it may be more difficult for our shareholders to sell their securities.
Although
our common stock is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange’s minimum
continued listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid
market for our common stock does not develop or is sustained, our common stock may remain thinly traded.
The
Listing Rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If, for any
reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from trading on its
exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may
occur, each of which could have a material adverse effect on our shareholders:
|
● |
the
liquidity of our common stock; |
|
|
|
|
● |
the
market price of our common stock; |
|
|
|
|
● |
our
ability to obtain financing for the continuation of our operations; |
|
|
|
|
● |
the
number of investors that will consider investing in our common stock; |
|
|
|
|
● |
the
number of market makers in our common stock; |
|
|
|
|
● |
the
availability of information concerning the trading prices and volume of our common stock; and |
|
|
|
|
● |
the
number of broker-dealers willing to execute trades in shares of our common stock. |
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM
4. MINE SAFETY DISCLOSURES
Not
applicable.
ITEM
5. OTHER INFORMATION
During
the three months ended September 30, 2023, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company
adopted or terminated a “Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K.
ITEM
6. EXHIBITS
Exhibit
No. |
|
Description |
3.1 |
|
Delaware Certificate of Incorporation and amendment thereto (filed with the Company’s Registration Statement on Form S-1 filed with the SEC on February 11, 2016 and incorporated herein by reference) |
|
|
|
3.2 |
|
Certificate of Amendment to Certificate of Incorporation (filed with the Company’s Current Report Form 8-K on February 1, 2019 and incorporated herein by reference) |
|
|
|
3.3 |
|
Certificate of Amendment to Certificate of Incorporation (filed with the Company’s Current Report on Form 8-K filed with the SEC on December 10, 2019 and incorporated herein by reference) |
|
|
|
3.4 |
|
Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 22, 2019) |
|
|
|
3.5 |
|
Amendment No. 1 to Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 14, 2022) |
|
|
|
3.6 |
|
Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 6, 2023) |
|
|
|
3.7 |
|
Certificate of Designation of Series C Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 2, 2022) |
|
|
|
3.8 |
|
Certificate of Designation of Series D Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 2, 2022) |
|
|
|
10.1 |
|
Employment Agreement by and between the Company and Janet Hall dated May 28, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 27, 2023) |
|
|
|
10.2 |
|
Retention Agreement dated as of May 18, 2023 by and between the Company and Katherine Cox (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 31, 2023) |
|
|
|
31.1* |
|
Certification of Principal Executive Officer pursuant to Rule 13a – 14(a) and 15d-14(a), under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
31.2* |
|
Certification of Principal Financial and Accounting Officer pursuant to Rule 13a – 14(a) and 15d-14(a), under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
32.1** |
|
Certification of Principal Executive Officer and Principal Financial and Accounting Officer pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 |
|
|
|
101.INS* |
|
Inline
XBRL Instance Document |
|
|
|
101.SCH* |
|
Inline
XBRL Taxonomy Extension Schema Document |
|
|
|
101.CAL* |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
101.DEF* |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
101.LAB* |
|
Inline
XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
101.PRE* |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
104* |
|
Cover
Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September
30, 2023, is formatted in Inline XBRL |
*
|
Filed
herewith. |
|
|
** |
Furnished
herewith. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Guardion
Health Sciences, Inc. |
|
(Registrant) |
|
|
|
Date:
November 13, 2023 |
By: |
/s/
Jan Hall |
|
|
Jan
Hall |
|
|
President
and Chief Executive Officer |
|
|
(Principal
Executive Officer) |
|
|
|
Date:
November 13, 2023 |
By: |
/s/
Katie Cox |
|
|
Katie
Cox |
|
|
(Chief
Accounting Officer) |
|
|
(Principal
Financial and Accounting Officer) |
Exhibit
31.1
CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER OF GUARDION HEALTH SCIENCES, INC.
PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Jan Hall, certify that:
1. |
I
have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.; |
|
|
2. |
Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; |
|
|
3. |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
|
4. |
The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
(b) |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
(c) |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
|
|
|
|
(d) |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions): |
|
(a) |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
|
|
|
(b) |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
Date:
November 13, 2023 |
/s/
Jan Hall |
|
Jan
Hall |
|
President
and Chief Executive Officer
(Principal
Executive Officer) |
Exhibit
31.2
CERTIFICATION
OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER OF GUARDION HEALTH SCIENCES, INC. PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002
I,
Katie Cox, certify that:
1. |
I
have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.; |
|
|
2. |
Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; |
|
|
3. |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
|
4. |
The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
(b) |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
(c) |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
|
|
|
|
(d) |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions): |
|
(a) |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
|
|
|
(b) |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
Date:
November 13, 2023 |
/s/
Katie Cox |
|
Katie
Cox |
|
Chief
Accounting Officer |
|
(Principal
Financial and Accounting Officer) |
Exhibit
32.1
CERTIFICATIONS
OF
PRINCIPAL
EXECUTIVE OFFICER
AND
PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
PURSUANT
TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of Guardion Health Sciences, Inc. (the “Company”) on Form 10-Q for the period ended
September 30, 2023 (the “Report”) as filed with the Securities and Exchange Commission on the date hereof, each of Jan Hall,
Chief Executive Officer of the Company, and Katie Cox, Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §
1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
|
(2) |
The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company. |
Date:
November 13, 2023 |
/s/
Jan Hall |
|
Jan
Hall |
|
President
and Chief Executive Officer |
|
(Principal
Executive Officer) |
|
|
Date:
November 13, 2023 |
/s/
Katie Cox |
|
Katie
Cox |
|
Chief
Accounting Officer |
|
(Principal
Financial and Accounting Officer) |
v3.23.3
Cover - shares
|
9 Months Ended |
|
Sep. 30, 2023 |
Nov. 09, 2023 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Sep. 30, 2023
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2023
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
001-38861
|
|
Entity Registrant Name |
GUARDION
HEALTH SCIENCES, INC.
|
|
Entity Central Index Key |
0001642375
|
|
Entity Tax Identification Number |
47-4428421
|
|
Entity Incorporation, State or Country Code |
DE
|
|
Entity Address, Address Line One |
2925
Richmond Avenue
|
|
Entity Address, Address Line Two |
Suite 1200
|
|
Entity Address, City or Town |
Houston
|
|
Entity Address, State or Province |
TX
|
|
Entity Address, Postal Zip Code |
77098
|
|
City Area Code |
800
|
|
Local Phone Number |
873-5141
|
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
|
Trading Symbol |
GHSI
|
|
Security Exchange Name |
NASDAQ
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
true
|
|
Elected Not To Use the Extended Transition Period |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
1,275,238
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Current assets |
|
|
Cash and cash equivalents |
$ 7,657,309
|
$ 10,655,490
|
Restricted cash |
|
5,250,000
|
Accounts receivable |
1,766,028
|
1,924,353
|
Inventories |
2,450,650
|
3,119,421
|
Prepaid expenses and other current assets |
965,644
|
687,933
|
Total current assets |
12,839,631
|
21,637,197
|
Property and equipment, net |
38,144
|
48,871
|
Total assets |
12,877,775
|
21,686,068
|
Current liabilities |
|
|
Accounts payable |
881,600
|
1,518,052
|
Accrued expenses |
550,057
|
558,287
|
Operating lease liability - current |
|
3,807
|
Warrant derivative liability – current |
|
1,931,400
|
Total current liabilities |
1,431,657
|
4,011,546
|
Warrant derivative liability – long-term |
3,744,400
|
4,506,600
|
Total liabilities |
5,176,057
|
8,518,146
|
Commitments and contingencies |
|
|
Redeemable preferred stock |
|
|
Total redeemable preferred stock |
|
5,250,000
|
Stockholders’ equity |
|
|
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 2022 |
|
|
Common stock, $0.001 par value; 250,000,000 shares authorized; 1,275,239 shares and 1,267,340 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively |
1,275
|
1,267
|
Additional paid-in capital |
101,691,430
|
101,640,955
|
Accumulated deficit |
(93,990,987)
|
(93,724,300)
|
Total stockholders’ equity |
7,701,718
|
7,917,922
|
Total liabilities, redeemable preferred stock and stockholders’ equity |
12,877,775
|
21,686,068
|
Series C Convertible Redeemable Preferred Stock [Member] |
|
|
Redeemable preferred stock |
|
|
Total redeemable preferred stock |
|
5,197,500
|
Series D Redeemable Preferred Stock [Member] |
|
|
Redeemable preferred stock |
|
|
Total redeemable preferred stock |
|
$ 52,500
|
X |
- DefinitionWarrant derivative liability current.
+ References
+ Details
Name: |
GHSI_WarrantDerivativeLiabilityCurrent |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionWarrant derivative liability non current.
+ References
+ Details
Name: |
GHSI_WarrantDerivativeLiabilityNonCurrent |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_RestrictedCash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_TemporaryEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
+ Details
Name: |
us-gaap_TemporaryEquityCarryingAmountAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesCConvertibleRedeemablePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesDRedeemablePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Preferred stock, par value |
$ 0.001
|
$ 0.001
|
Preferred stock, shares authorized |
10,000,000
|
10,000,000
|
Preferred stock, shares issued |
0
|
0
|
Preferred stock, shares outstanding |
0
|
0
|
Common stock, par value |
$ 0.001
|
$ 0.001
|
Common stock, shares authorized |
250,000,000
|
250,000,000
|
Common stock, shares issued |
1,275,239
|
1,267,340
|
Common stock, shares outstanding |
1,275,239
|
1,267,340
|
Series C Convertible Redeemable Preferred Stock [Member] |
|
|
Preferred stock, shares issued |
0
|
495,000
|
Preferred stock, shares outstanding |
0
|
495,000
|
Series D Redeemable Preferred Stock [Member] |
|
|
Preferred stock, shares issued |
0
|
5,000
|
Preferred stock, shares outstanding |
0
|
5,000
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesCConvertibleRedeemablePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesDRedeemablePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Revenue |
|
|
|
|
Total revenue |
$ 3,337,190
|
$ 2,663,550
|
$ 9,312,695
|
$ 8,323,382
|
Total cost of goods sold |
1,876,938
|
1,575,366
|
5,267,874
|
4,739,197
|
Gross profit |
1,460,252
|
1,088,184
|
4,044,821
|
3,584,185
|
Operating expenses |
|
|
|
|
Research and development |
10,671
|
60,203
|
150,604
|
162,418
|
Sales and marketing |
318,734
|
526,193
|
1,332,469
|
1,583,349
|
General and administrative |
1,903,761
|
2,231,895
|
5,811,315
|
7,875,894
|
Impairment of right-of-use asset |
|
|
|
24,257
|
Loss on disposal of fixed assets |
|
9,287
|
|
9,287
|
Total operating expenses |
2,233,166
|
2,827,578
|
7,294,388
|
9,655,205
|
Loss from operations |
(772,914)
|
(1,739,394)
|
(3,249,567)
|
(6,071,020)
|
Other income (expense) |
|
|
|
|
Change in fair value of warrant derivative liability |
1,050,800
|
873,200
|
2,693,600
|
3,548,300
|
Interest income, net |
94,747
|
43,282
|
289,280
|
54,458
|
Other income (expense), net |
1,145,547
|
916,482
|
2,982,880
|
3,602,758
|
Net income (loss) |
$ 372,633
|
$ (822,912)
|
$ (266,687)
|
$ (2,468,262)
|
Net income (loss) per common share - basic |
$ 0.29
|
$ (0.67)
|
$ (0.21)
|
$ (2.27)
|
Net income (loss) per common share - diluted |
$ 0.29
|
$ (0.67)
|
$ (0.21)
|
$ (2.27)
|
Weighted average common shares outstanding - basic |
1,273,486
|
1,232,016
|
1,273,249
|
1,083,924
|
Weighted average common shares outstanding - diluted |
1,273,486
|
1,232,016
|
1,273,249
|
1,083,924
|
Clinical Nutrition [Member] |
|
|
|
|
Revenue |
|
|
|
|
Total revenue |
$ 3,337,190
|
$ 2,663,550
|
$ 9,312,695
|
$ 8,304,663
|
Other [Member] |
|
|
|
|
Revenue |
|
|
|
|
Total revenue |
|
|
|
$ 18,719
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfPropertyPlantEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest income earned from interest bearing assets classified as other.
+ References
+ Details
Name: |
us-gaap_InterestIncomeOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.
+ References
+ Details
Name: |
us-gaap_LiabilitiesFairValueAdjustment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from impairment of right-of-use asset from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6
+ Details
Name: |
us-gaap_OperatingLeaseImpairmentLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_RevenuesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
+ Details
Name: |
us-gaap_SellingAndMarketingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=GHSI_ClinicalNutritionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=GHSI_OtherMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
Balance, value at Dec. 31, 2021 |
$ 489
|
$ 101,099,383
|
$ (78,802,072)
|
$ 22,297,800
|
Balance, shares at Dec. 31, 2021 |
488,539
|
|
|
|
Fair value of vested stock options |
|
85,963
|
|
85,963
|
Fair value of vested restricted stock |
|
59,906
|
|
59,906
|
Net Income (loss) |
|
|
(5,300,987)
|
(5,300,987)
|
Common stock issued upon exercise of warrants |
$ 89
|
1,133,951
|
|
1,134,040
|
Common stock issued upon exercise of warrants, shares |
89,000
|
|
|
|
Common stock issued for cash, net of offering costs |
$ 651
|
8,834,247
|
|
8,834,898
|
Common stock issued for cash, net of offering costs, shares |
651,000
|
|
|
|
Recognition of fair value of warrant derivative liability issued in connection with issuance of common stock |
|
(8,783,800)
|
|
(8,783,800)
|
Balance, value at Mar. 31, 2022 |
$ 1,229
|
102,429,650
|
(84,103,060)
|
18,327,820
|
Balance, shares at Mar. 31, 2022 |
1,228,539
|
|
|
|
Balance, value at Dec. 31, 2021 |
$ 489
|
101,099,383
|
(78,802,072)
|
22,297,800
|
Balance, shares at Dec. 31, 2021 |
488,539
|
|
|
|
Net Income (loss) |
|
|
|
(2,468,262)
|
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax |
|
|
|
24,011
|
Balance, value at Sep. 30, 2022 |
$ 1,232
|
102,528,587
|
(81,270,334)
|
21,259,485
|
Balance, shares at Sep. 30, 2022 |
1,232,016
|
|
|
|
Balance, value at Mar. 31, 2022 |
$ 1,229
|
102,429,650
|
(84,103,060)
|
18,327,820
|
Balance, shares at Mar. 31, 2022 |
1,228,539
|
|
|
|
Fair value of vested stock options |
|
61,818
|
|
61,818
|
Fair value of vested restricted stock |
|
11,585
|
|
11,585
|
Net Income (loss) |
|
|
3,655,637
|
3,655,637
|
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax |
$ 3
|
(24,014)
|
|
(24,011)
|
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax, shares |
3,477
|
|
|
|
Balance, value at Jun. 30, 2022 |
$ 1,232
|
102,479,039
|
(80,447,422)
|
22,032,849
|
Balance, shares at Jun. 30, 2022 |
1,232,016
|
|
|
|
Fair value of vested stock options |
|
44,101
|
|
44,101
|
Fair value of vested restricted stock |
|
5,447
|
|
5,447
|
Net Income (loss) |
|
|
(822,912)
|
(822,912)
|
Balance, value at Sep. 30, 2022 |
$ 1,232
|
102,528,587
|
(81,270,334)
|
21,259,485
|
Balance, shares at Sep. 30, 2022 |
1,232,016
|
|
|
|
Balance, value at Dec. 31, 2022 |
$ 1,267
|
101,640,955
|
(93,724,300)
|
7,917,922
|
Balance, shares at Dec. 31, 2022 |
1,267,340
|
|
|
|
Fair value of vested stock options |
|
25,182
|
|
25,182
|
Fair value of vested restricted stock |
|
5,329
|
|
5,329
|
Fair value of vested restricted stock, shares |
|
|
|
|
Net Income (loss) |
|
|
533,091
|
533,091
|
Balance, value at Mar. 31, 2023 |
$ 1,267
|
101,671,466
|
(93,191,209)
|
8,481,524
|
Balance, shares at Mar. 31, 2023 |
1,267,340
|
|
|
|
Balance, value at Dec. 31, 2022 |
$ 1,267
|
101,640,955
|
(93,724,300)
|
7,917,922
|
Balance, shares at Dec. 31, 2022 |
1,267,340
|
|
|
|
Net Income (loss) |
|
|
|
(266,687)
|
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax |
|
|
|
|
Balance, value at Sep. 30, 2023 |
$ 1,275
|
101,691,430
|
(93,990,987)
|
7,701,718
|
Balance, shares at Sep. 30, 2023 |
1,275,239
|
|
|
|
Balance, value at Mar. 31, 2023 |
$ 1,267
|
101,671,466
|
(93,191,209)
|
8,481,524
|
Balance, shares at Mar. 31, 2023 |
1,267,340
|
|
|
|
Fair value of vested stock options |
|
(73,456)
|
|
(73,456)
|
Fair value of vested restricted stock |
|
5,388
|
|
5,388
|
Net Income (loss) |
|
|
(1,172,411)
|
(1,172,411)
|
Balance, value at Jun. 30, 2023 |
$ 1,267
|
101,603,398
|
(94,363,620)
|
7,241,045
|
Balance, shares at Jun. 30, 2023 |
1,267,340
|
|
|
|
Fair value of vested stock options |
|
27,943
|
|
27,943
|
Fair value of vested restricted stock |
|
2,194
|
|
2,194
|
Fair value of vested restricted stock, shares |
250
|
|
|
|
Net Income (loss) |
|
|
372,633
|
372,633
|
Common stock issued upon exercise of warrants |
$ 8
|
57,895
|
|
57,903
|
Common stock issued upon exercise of warrants, shares |
7,649
|
|
|
|
Balance, value at Sep. 30, 2023 |
$ 1,275
|
$ 101,691,430
|
$ (93,990,987)
|
$ 7,701,718
|
Balance, shares at Sep. 30, 2023 |
1,275,239
|
|
|
|
X |
- DefinitionAdjustments to additional paid in capital other shares.
+ References
+ Details
Name: |
GHSI_AdjustmentsToAdditionalPaidInCapitalOtherShares |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIssuance of vested restricted stock net.
+ References
+ Details
Name: |
GHSI_IssuanceOfVestedRestrictedStockNet |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of vested restricted stock share.
+ References
+ Details
Name: |
GHSI_IssuanceOfVestedRestrictedStockShare |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period as a result of warrants exercised.
+ References
+ Details
Name: |
GHSI_StockIssuedDuringPeriodSharesWarrantsExercised |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of new stock issued during the period as a result of warrants exercised.
+ References
+ Details
Name: |
GHSI_StockIssuedDuringPeriodValueWarrantsExercised |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of other increase (decrease) in additional paid in capital (APIC).
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Operating Activities |
|
|
|
|
|
|
|
Net loss |
$ 372,633
|
$ 533,091
|
$ (822,912)
|
$ (5,300,987)
|
$ (266,687)
|
$ (2,468,262)
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
14,518
|
946,397
|
|
Loss on disposal of fixed assets |
|
|
9,287
|
|
|
9,287
|
|
Impairment of right-of-use asset |
|
|
|
|
|
24,257
|
$ 24,257
|
Fair value of vested stock options |
|
|
|
|
(20,331)
|
191,882
|
|
Fair value of vested restricted common stock |
|
|
|
|
12,911
|
76,938
|
|
Change in fair value of warrant derivative liability |
|
|
|
|
(2,693,600)
|
(3,548,300)
|
|
Increase (decrease) in: |
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
158,325
|
(41,679)
|
|
Inventories |
|
|
|
|
668,771
|
(1,585,240)
|
|
Prepaid expenses |
|
|
|
|
(277,711)
|
(258,560)
|
|
Accounts payable |
|
|
|
|
(636,452)
|
799,249
|
|
Operating lease liability |
|
|
|
|
(3,807)
|
(16,556)
|
|
Accrued expenses |
|
|
|
|
(8,230)
|
(212,319)
|
|
Net cash used in operating activities |
|
|
|
|
(3,052,293)
|
(6,082,906)
|
|
Investing Activities |
|
|
|
|
|
|
|
Purchase of equipment |
|
|
|
|
(3,791)
|
(5,569)
|
|
Purchase of US Treasury Bills |
|
|
|
|
|
(77,591,741)
|
|
Sale of US Treasury Bills |
|
|
|
|
|
82,587,364
|
|
Net cash (used in) provided by investing activities |
|
|
|
|
(3,791)
|
4,990,054
|
|
Financing Activities |
|
|
|
|
|
|
|
Redemption of preferred stock |
|
|
|
|
(5,250,000)
|
|
|
Proceeds from sale of common stock, net |
|
|
|
|
|
8,834,899
|
|
Proceeds from exercise of warrants |
|
|
|
|
57,903
|
1,134,040
|
|
Payment for employee withholding tax |
|
|
|
|
|
(24,011)
|
|
Net cash (used in) provided by financing activities |
|
|
|
|
(5,192,097)
|
9,944,928
|
|
Cash, cash equivalents and restricted cash |
|
|
|
|
|
|
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
|
|
(8,248,181)
|
8,852,076
|
|
Balance at beginning of period |
|
$ 15,905,490
|
|
$ 4,093,927
|
15,905,490
|
4,093,927
|
4,093,927
|
Balance at end of period |
$ 7,657,309
|
|
$ 12,946,003
|
|
7,657,309
|
12,946,003
|
$ 15,905,490
|
Cash paid for: |
|
|
|
|
|
|
|
Income taxes |
|
|
|
|
|
|
|
Interest |
|
|
|
|
|
|
|
Non-cash financing activities: |
|
|
|
|
|
|
|
Recognition of initial warrant derivative liability |
|
|
|
|
|
$ 8,783,800
|
|
X |
- References
+ Details
Name: |
GHSI_CashPaidForAbstract |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value of vested restricted common stock.
+ References
+ Details
Name: |
GHSI_FairValueOfVestedRestrictedCommonStock |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value of vested stock options.
+ References
+ Details
Name: |
GHSI_FairValueOfVestedStockOptions |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of vested restricted stock net.
+ References
+ Details
Name: |
GHSI_IssuanceOfVestedRestrictedStockNet |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPayments to acquire treasury bills.
+ References
+ Details
Name: |
GHSI_PaymentsToAcquireTreasuryBills |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from sale of treasury bills.
+ References
+ Details
Name: |
GHSI_ProceedsFromSaleOfTreasuryBills |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRecording of initial warrant derivative liability.
+ References
+ Details
Name: |
GHSI_RecordingOfInitialWarrantDerivativeLiability |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfPropertyPlantEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingAssetsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from impairment of right-of-use asset from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6
+ Details
Name: |
us-gaap_OperatingLeaseImpairmentLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to reacquire preferred stock during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.3
Pay vs Performance Disclosure - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
Net Income (Loss) Attributable to Parent |
$ 372,633
|
$ (1,172,411)
|
$ 533,091
|
$ (822,912)
|
$ 3,655,637
|
$ (5,300,987)
|
$ (266,687)
|
$ (2,468,262)
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1
+ Details
Name: |
ecd_PvpTable |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.3
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a
+ Details
Name: |
ecd_InsiderTradingArrLineItems |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_NonRule10b51ArrAdoptedFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_NonRule10b51ArrTrmntdFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_Rule10b51ArrAdoptedFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1
+ Details
Name: |
ecd_Rule10b51ArrTrmntdFlag |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Organization and Business Operations
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Organization and Business Operations |
1.
Organization and Business Operations
Business
Guardion
Health Sciences, Inc. (the “Company”) is a clinical nutrition company that develops and distributes clinically supported
nutrition, medical foods and dietary supplements. The Company offers a portfolio of science-based, clinically supported products designed
to support healthcare professionals and providers, and their patients and consumers. The Company was formed in 2009 as a California limited
liability company under the name P4L Health Sciences, LLC, and in 2015 converted from a California limited liability company to a Delaware
corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. In June 2021, the Company acquired
Activ Nutritional, LLC (“Activ”), the owner and distributor of the Viactiv® line of supplements for bone health and other
applications.
Liquidity
For
the nine months ended September 30, 2023, the Company recorded a loss from operations of $3,249,567 and used cash in operating activities
of $3,052,293. The Company has a history of operating losses and negative cash flows. Even though the Company’s management identified
certain indicators, including the current period loss from operations and the potential impact of inflation and general economic uncertainty,
management concluded these indicators do not raise substantial doubt regarding the Company’s ability to continue as a going concern
within one year after the date these financial statements are issued. As of September 30, 2023, the Company had $7,657,309 of cash and
cash equivalents, and management determined that it is probable that the Company will be able to fund its current operating plan and
meet all of its obligations due within one year from the date these financial statements are issued.
The
amount and timing of future cash requirements will depend, in part, on the Company’s ability to ultimately achieve operating profitability.
The Company expects to continue to incur net losses and negative operating cash flows in the near-term and will continue to incur significant
expenses for the development, commercialization and distribution of its clinical nutrition products (primarily the Viactiv® product
line) and the successful development and commercialization of new products and product lines. The Company may also utilize cash to fund
acquisitions of complementary businesses, product lines and/or brands.
The
Company may seek to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company
will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms
or at all. Over time, if the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to
reduce or discontinue its product development programs or curtail or cease operations.
Inflation
Higher
inflation, the actions by the Federal Reserve Bank to address inflation, most notably continuing increases in interest rates, and rising
food and energy prices in combination with higher labor costs create uncertainty about the future economic environment. The Company expects
that the impact of these issues will continue to evolve. The Company believes these factors impacted the Company’s business in
2022 and the first nine months of 2023, and will continue to impact the Company’s business for the remainder of 2023 and in 2024.
The implications of higher government deficits and debt, tighter monetary policy, and higher long-term interest rates may drive a higher
cost of capital for the business and an increase in the Company’s operating expenses.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
Summary of Significant Accounting Policies |
2.
Summary of Significant Accounting Policies
Basis
of Presentation
The
unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the
United States of America (“GAAP”) pursuant to the applicable rules and regulations of the Securities and Exchange Commission
(“SEC”) for interim financial information. The unaudited condensed consolidated financial statements have been prepared on
the same basis as the Company’s annual financial statements for the year ended December 31, 2022, and, in the opinion of management,
reflect all adjustments, which consist of normal recurring adjustments, considered necessary for a fair presentation of the periods presented.
The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected
for the full fiscal year ending December 31, 2023.
These
unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial
statements and accompanying notes for the fiscal year ended December 31, 2022 included in the Company’s December 31, 2022 Annual
Report on Form 10-K, which was filed with the SEC on April 17, 2023. The condensed consolidated balance sheet as of December 31, 2022
was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes,
required by GAAP.
The
Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.
All inter-company transactions and balances have been eliminated in consolidation.
In
accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating
decision maker (the Company’s Chief Executive Officer) determined that the Company has only one reporting unit.
Reverse
Stock Split
On
January 6, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of
State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split of its outstanding common stock without any change
to its par value. The authorized number of shares of common stock was not affected by the reverse stock split. The Company issued 35,281
additional common shares in connection with this reverse stock split per the Company’s determination to round up all fractional
shares resulting from the reverse stock split to the nearest whole share.
Accordingly,
all common shares, stock options, stock warrants and per share amounts in these consolidated financial statements have been adjusted
retroactively to reflect the reverse stock split as if the split occurred at the beginning of the earliest period presented in this Quarterly
Report on Form 10-Q.
Use
of Estimates
The
preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions
that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities.
On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates
include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing the warrant derivative
liability, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets,
assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities,
and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.
Revenue
Recognition
Revenue
and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon delivery to the
customer. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts
with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause
revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of
the goods and therefore represent a fulfillment activity rather than a promised service to the customer.
All
products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance
obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives
or discounts that could cause revenue to be allocated or adjusted over time.
Shipping
and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity
rather than a promised service to the customer. Historically the Company has not experienced any significant payment delays from customers.
Due
to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products and assessment of
performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract
asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly
basis.
At
September 30, 2023 and December 31, 2022, the allowance for doubtful accounts was zero and $1,996, respectively.
The
Company’s revenues by product line for the three months and nine months ended September 30, 2023 and 2022 are as a follows:
Schedule of Revenues by Product
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Clinical Nutrition | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,663 | |
Other | |
| - | | |
| - | | |
| - | | |
| 18,719 | |
Revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
Substantially
all of the Company’s revenues earned during the three months and nine months ended September 30, 2023 and 2022 are derived from
sales of the Company’s clinical nutrition products primarily to retail customers in North America.
The
Company’s revenues by geographical area for the three months and nine months ended September 30, 2023 and 2022 are as follows:
Schedule of Revenue by Geographical Area
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,483 | |
Europe and other | |
| - | | |
| - | | |
| - | | |
| 18,899 | |
Total revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
Third-Party
Outsourcing
The
Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center which provides order
processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s
products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues.
In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional
services.
The
Company outsources the production of substantially all its products with a third-party that manufactures and packages the finished products
under a product supply agreement.
Costs
incurred related to third-party outsourcing, which includes manufacturing, order processing and fulfillment, customer invoicing, collections
and warehousing, were $1,759,260 and $1,876,259 for the three months ended September 30, 2023 and 2022, respectively, and $4,339,388
and $1,932,967 for the nine months ended September 30, 2023 and 2022, respectively.
Cost
of Goods Sold
Cost
of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees and in-bound freight charges.
Shipping
Costs
Shipping
costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense
totaled $135,059 and $209,804 for the three months ended September 30, 2023 and 2022, respectively, and $416,101 and $622,178 for the
nine months ended September 30, 2023 and 2022, respectively.
Advertising
Costs
Advertising
costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $279,457 and $385,010 for the
three months ended September 30, 2023 and 2022, respectively, and $1,109,310 and $1,264,740 for the nine months ended September 30, 2023
and 2022, respectively.
Concentrations
Revenue.
During the three months ended September 30, 2023, the Company had two customers that accounted for 68% of total revenue. During the
nine months ended September 30, 2023, the Company had two customers that accounted for 64% of total revenue. During the three months
ended September 30, 2023, the largest customer accounted for 47% of the Company’s total revenue, and the second largest customer
accounted for 21% of the Company’s total revenue. During the nine months ended September 30, 2023, the largest customer accounted
for 50% of the Company’s total revenue and the second largest customer accounted for 14%. During the three months ended September
30, 2022, the Company had one customer that accounted for 57% of total revenue. During the nine months ended September 30, 2022, the
Company had one customer that accounted for 56% of the Company’s total revenue. No other customer accounted for more than 10% of
revenue during the three months and nine months ended September 30, 2023 and 2022. The Company sells the majority of its products to
one of the largest retailers in the United States.
Accounts
receivable. As of September 30, 2023, the Company had accounts receivable from one customer which comprised approximately 61% of
its accounts receivable and one customer that accounted for approximately 13% of its accounts receivable. As of December 31, 2022, the
Company had accounts receivable from one customer which comprised approximately 88% of its accounts receivable. No other customer accounted
for more than 10% of accounts receivable as of September 30, 2023 and December 31, 2022.
Purchases
from vendors. During the three months and nine months ended September 30, 2023 and 2022, the Company utilized one manufacturer for
most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately
59% and 47% of all purchases during the three months and nine months ended September 30, 2023, respectively. Total purchases from this
manufacturer accounted for approximately 49% and 46% of all purchases during the three months and nine months ended September 30, 2022,
respectively.
Accounts
payable. As of September 30, 2023, one vendor accounted for 84% of total accounts payable. As of December 31, 2022, one vendor accounted
for 88% of the total accounts payable. One other vendor accounted for 13% of total accounts payable as of September 30, 2023. No other
vendor accounted for more than 10% of accounts payable as of December 31, 2022.
Cash
and cash equivalents. Cash and cash equivalents consist of funds deposited with BMO Harris Bank (“BMO”), which is a major,
established, high quality financial institution, in short-term (original maturity of generally 60 days or less) liquid investments in
money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net
asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with
BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests
solely in high quality U.S. government issued securities. As of September 30, 2023, $7,657,309 included in cash and cash equivalents
was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance
Corporation (the “FDIC”).
The
Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000,
respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because
of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced
any losses to date resulting from this policy.
Stock-Based
Compensation
Stock-based
awards for stock options and restricted stock awards to employees and non-employees are accounted for by using the fair value method
in accordance with ASC 718, Share-Compensation – Stock Compensation. The estimated fair value of stock options granted to
employees in exchange for services is measured at the grant date, using a fair value-based method, such as a Black-Scholes option valuation
model, and is recognized as an expense on a straight-line basis over the requisite service periods. The assumptions used in the Black-Scholes
option pricing model could materially affect compensation expense recorded in future periods. The fair value of restricted stock units
is measured at the grant date based on the closing market price of the Company’s common stock on the date of grant and is recognized
as an expense on a straight-line basis over the requisite service periods. Recognition of compensation expense for non-employees is accounted
for in the same period and manner as if the Company had paid cash for the services.
Warrants
The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s
specific terms and applicable authoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities
from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance
outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of
professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be
recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the
criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on
the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants
are recognized as a non-cash gain or loss on the statements of operations. The Company has determined that the warrants issued in the
February 18, 2022 equity financing (see Note 6) meet the requirements for liability classification.
Income
(Loss) per Common Share
Basic
earnings (loss) per share (“EPS” or “LPS”) is computed by dividing net loss by the weighted-average common
shares outstanding during the period, excluding shares of unvested restricted common stock outstanding. Diluted EPS/LPS is computed
based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the
period calculated using the treasury stock method. Shares of vested restricted stock are included in the diluted weighted average
number of common shares outstanding from the date they are vested. In addition, net earnings (loss) for diluted EPS/LPS is adjusted
for the impact of the assumed exercise of the
outstanding warrants, to the extent they are dilutive. For the three months ended September 30, 2022, and the nine months ended
September 30, 2023 and 2022, the Company recorded a net loss, as a result of which warrants, options, and unvested restricted shares
of common stock were excluded from the computation of diluted EPS/LPS because they were considered anti-dilutive. For the three
months ended September 30, 2023, the Company recorded net income, and it was determined that the applicable warrants and options
were out-of-the-money. For the three months ended September 30, 2023, the treasury stock method was not applied to options or
warrants that were out-of-the-money, and accordingly, the warrants, options, and unvested restricted shares of common stock were
excluded from the computation of diluted EPS/LPS because they were considered anti-dilutive.
The
following potentially dilutive shares were excluded from the shares used to calculate diluted earnings (loss) per share:
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share
| |
2023 | | |
2022 | |
| |
September 30, | |
| |
2023 | | |
2022 | |
Warrants | |
| 779,052 | | |
| 1,489,702 | |
Options | |
| 20,577 | | |
| 14,470 | |
Unvested restricted common stock | |
| 417 | | |
| 667 | |
Anti-dilutive securities | |
| 800,046 | | |
| 1,504,839 | |
Fair
Value of Financial Instruments
Accounting
standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for
establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer
a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers
the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing
the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques
used to measure fair value:
Level
1 – Quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the
measurement date.
Level
2 – Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.
Level
3 – Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting
entity to develop its own assumptions.
The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.
The
following table sets forth by level, within the fair value hierarchy, the Company’s financial assets and liabilities at fair value
as of September 30, 2023, and December 31, 2022:
Schedule of Assets and Liabilities at Fair Value
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
September 30, 2023 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
December 31, 2022 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
The
following table provides a roll-forward of the warrant derivative liability measured at fair value on a recurring basis using unobservable
Level 3 inputs for the nine months ended September 30, 2023:
Schedule of Warrant Derivative Liability Measured at Fair Value
Warrant derivative liability | |
| | |
Balance as of beginning of period – December 31, 2022 | |
$ | 6,438,000 | |
Change in fair value of warrant derivative liability, during the period | |
| (2,693,600 | ) |
Balance as of end of period – September 30, 2023 | |
$ | 3,744,400 | |
As
of September 30, 2023, and December 31, 2022, the Company’s outstanding warrants were treated as derivative liabilities and changes
in the fair value were recognized in earnings (see Note 6). As of September 30, 2023, the current warrant derivative liability was zero
and the long-term warrant derivative liability was $3,744,400. As of December 31, 2022, the current warrant derivative liability was
$1,931,400 and the long-term warrant derivative liability was $4,506,600.
The
Company believes the carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, and
accounts payable and accrued liabilities, approximate fair value due to the short-term nature of such instruments and are excluded from
the fair value tables above.
Recent
Accounting Pronouncements
In
September 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly
changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. ASU 2016-13 replaces
the “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based
on expected rather than incurred losses. Entities will apply the ASU 2016-13’s provisions as a cumulative-effect adjustment to
retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company,
ASU 2016-13 was effective for and adopted by the Company effective January 1, 2023. The adoption of ASU 2016-13 did not have any material
impact on the Company’s financial statement presentation or and related disclosures.
In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications
and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts
in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification
of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified
after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of
a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant
immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the
corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated
to equity issuance and debt origination or modification). ASU 2021-04 was effective for all entities for fiscal years beginning after
December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively
to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The
adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or related disclosures.
In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement — Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation — Stock Compensation
(Topic 718) Presentation of Financial Statements (“ASU 2023-03”). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 — General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company’s consolidated financial statement presentation or related disclosures.
Other
recent accounting pronouncements and guidance issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future
financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Inventories
|
9 Months Ended |
Sep. 30, 2023 |
Inventory Disclosure [Abstract] |
|
Inventories |
3.
Inventories
Inventories
consist of the following:
Schedule of Inventories
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Raw materials | |
$ | 35,405 | | |
$ | 49,637 | |
Finished goods | |
| 2,415,245 | | |
| 3,069,784 | |
Inventories, net | |
$ | 2,450,650 | | |
$ | 3,119,421 | |
The
Company’s inventories are stated at the lower of cost or net realizable value calculated on a first-in, first-out basis.
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Intangible Assets, Net
|
9 Months Ended |
Sep. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
Intangible Assets, Net |
4.
Intangible Assets, Net
At
December 31, 2021, the gross amount of the Company’s amortizable finite-lived identifiable intangible assets, consisting of a trade
name and customer relationships, totaled $11,900,000. Effective December 31, 2022, the Company performed an impairment analysis of its
intangible assets and determined that the asset group’s fair value was zero, as a result of which the Company recorded an impairment
loss of $10,065,833 for the net book balance of the intangible assets at that date.
For
the three months and nine months ended September 30, 2022, amortization expense was $297,500 and $892,500, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Operating Leases
|
9 Months Ended |
Sep. 30, 2023 |
Operating Leases |
|
Operating Leases |
5.
Operating Leases
In
July 2021, the Company entered into a month-to-month lease for its primary corporate office space located in Houston, Texas, with lease
payments of approximately $2,700 per month. Leases with the duration of less than 12 months are not recognized on the balance sheet and
are expensed on a straight-line basis over the lease term.
As
of December 31, 2022, the Company’s VectorVision subsidiary leased a warehouse space in Ohio under an operating lease that expired
in February 2023. During the year ended December 31, 2022, the Company recorded an impairment of the operating lease right-of-use asset
of $24,257 and made payments of $22,221 on the operating lease liability. At December 31, 2022, the balance of the operating lease liability
was $3,807, which was paid in full and extinguished in February 2023.
|
X |
- References
+ Details
Name: |
GHSI_DisclosureOperatingLeasesAbstract |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Warrant Derivative Liability
|
9 Months Ended |
Sep. 30, 2023 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
|
Warrant Derivative Liability |
6.
Warrant Derivative Liability
On
February 18, 2022, the Company sold in a best-efforts public offering, 651,000 shares of the Company’s common stock (see Note 8)
and 740,000 Series A warrants (the “Series A Warrants”) and 740,000 Series B warrants (the “Series B Warrants”).
The Series A and Series B Warrants had an initial exercise price of $18.50 per share. The Series A Warrants expire in February 2027 and
the Series B Warrants expired in August 2023.
The
Series A and Series B Warrants contain certain anti-dilution provisions, including a down round provision and certain cash redemption
rights. On November 30, 2022, the exercise price of the Series A and Series B Warrants was adjusted downward to $7.88 per share to equal
the Series C Convertible Redeemable Preferred Stock conversion price (see Note 8).
In
addition, the Series A Warrants and Series B Warrants contain a provision which requires that the exercise price of such warrants be
adjusted to the volume weighted average price of the Company’s common stock for the five trading days immediately following effectiveness
of a reverse stock split if such calculation resulted in an exercise price below the then-current exercise price. The Company determined
that this provision represented a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined
under ASC 815-40, and thus the Series A and Series B Warrants are not considered indexed to the Company’s own stock and not eligible
for an exception from derivative accounting. Accordingly, the Series A and Series B warrants are classified as a derivative liability.
In January 2023, in conjunction with the completion of the Company’s reverse stock split (see Note 2), the exercise price of the
Series A and Series B warrants was further adjusted to $7.57 per share.
The
fair value of the warrant liability on September 30, 2023, and at December 31, 2022, was $3,744,400 and $6,438,000, respectively. The
estimated fair value of the warrants is determined using Level 3 inputs. Inherent in a binomial lattice model are assumptions related
to expected probability of event occurrence, including stock splits, stock-price volatility, expected life, risk-free interest rate and
dividend yield. The Company estimates the volatility of its common stock warrants based on the Company’s historical volatility.
The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant or valuation date for a maturity similar
to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual
term. The dividend rate is based on the Company’s historical rate, which the Company anticipates remaining at zero. The derivative
liabilities were valued using a binomial lattice model with the following assumptions:
Schedule of Warrant Derivative Liability
| |
Series A Warrants | | |
Series B Warrants | |
| |
September 30, 2023 | | |
December 31, 2022 | | |
September 30, 2023 | | |
December 31, 2022 | |
Common stock market price | |
$ | 7.38 | | |
$ | 7.26 | | |
$ | - | | |
$ | 7.26 | |
Exercise price | |
| 7.57 | | |
| 7.88 | | |
| - | | |
| 7.88 | |
Expected term (in years) | |
| 3.40 | | |
| 4.15 | | |
| - | | |
| 0.65 | |
Expected volatility | |
| 102.40 | % | |
| 131.20 | % | |
| - | | |
| 104.50 | % |
Expected dividend yield | |
| - | | |
| - | | |
| - | | |
| - | |
Risk-free interest rate | |
| 4.75 | % | |
| 4.11 | % | |
| - | | |
| 4.75 | % |
Total fair value | |
$ | 3,744,400 | | |
$ | 4,506,600 | | |
$ | - | | |
$ | 1,931,400 | |
The
740,000 Series B Warrants expired on August 24, 2023. On the expiration date, the Series B Warrants were marked to a fair value of zero
with such change being recorded as part of the change in fair value of warrant derivative included in the statement of operations.
|
X |
- References
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//815/tableOfContent
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Redeemable Preferred Stock (Temporary Equity, redeemed in full in February 2023)
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
Redeemable Preferred Stock (Temporary Equity, redeemed in full in February 2023) |
7.
Redeemable Preferred Stock (Temporary Equity, redeemed in full in February 2023)
On
November 29, 2022, the Company issued and sold, in a private placement, 495,000 shares of the Company’s Series C Convertible Redeemable
Preferred Stock (the “Series C Preferred Stock”), and 5,000 shares of the Company’s Series D Redeemable Preferred Stock
(the “Series D Preferred Stock,” and together with the Series C Preferred Stock, the “Preferred Stock”).
The
Series C Preferred Stock had the right to vote on an amendment (the “Amendment”) to the Company’s Certificate of Incorporation,
as amended, to authorize a reverse split of the Common Stock on an as-converted to common stock basis (see Note 2). The shares of the
Series D Preferred Stock were automatically voted in a manner that “mirrored” the proportions on which the shares of Common
Stock (excluding any shares of Common Stock that were not voted) and Series C Preferred Stock were voted on the Amendment. The Certificates
of Designation for the Preferred Stock provided that the Preferred Stock had no voting rights other than the right to vote on the Amendment
and as a class on certain other specified matters, and, with respect to the Series D Certificate of Designation, the right to cast 1,000,000
votes per share of Series D Preferred Stock on the Reverse Stock Split proposal. The Amendment required the approval of the majority
of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. On January 5, 2023, the Amendment
to authorize a reverse split of the Common Stock was approved at a special meeting of the Company’s stockholders. Following the
meeting, the board of directors approved a one-for-fifty (1-for-50) reverse split of the Company’s issued and outstanding shares
of common stock (see Note 2).
The
following table reconciles the Series C and Series D Preferred Stock reflected on the balance sheet at December 31, 2022:
Schedule of Preferred Stock
| |
Series C Preferred
Stock | | |
Series D Preferred
Stock | |
Gross Proceeds | |
$ | 4,702,500 | | |
$ | 47,500 | |
Less: | |
| | | |
| | |
Preferred stock issuance costs | |
| (437,169 | ) | |
| (4,416 | ) |
Plus: | |
| | | |
| | |
Accretion of carrying value to redemption value | |
| 932,169 | | |
| 9,416 | |
Preferred stock subject to possible redemption | |
$ | 5,197,500 | | |
$ | 52,500 | |
At
December 31, 2022, $4,750,000 in gross proceeds received from the issuance of the Preferred Stock, plus an additional $500,000, which
was required to fund the 105% redemption price for the Preferred Stock, was held in an escrow account and presented as restricted cash
on the Company’s December 31, 2022 consolidated balance sheet. The Preferred Stock was redeemed in full for cash through February
8, 2023, the escrow account was closed, and as of September 30, 2023, there were no shares of Preferred Stock outstanding.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
+ Details
Name: |
us-gaap_PreferredStockTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stockholders’ Equity
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
Stockholders’ Equity |
8.
Stockholders’ Equity
February
2022 Offering
On
February 18, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the
Company issued and sold in a best-efforts public offering, (i) 651,000 units, at $15.00 per unit, with each unit consisting of one share
of the Company’s common stock, one warrant to purchase one share of the Company’s common stock at an exercise price of $18.50
per share that expires on the fifth anniversary of the date of issuance (“Series A Warrant”) and one warrant to purchase
one share of the Company’s common stock at an exercise price of $18.50 per share that expired on the 18-month anniversary of the
date of issuance (“Series B Warrant”), and (ii) 89,000 pre-funded units, at $14.995 per unit, with each unit consisting of
one pre-funded warrant to purchase one share of the Company’s common stock at an exercise price of $0.005 per share (a “Pre-Funded
Warrant” and together with the Series A Warrants and Series B Warrants, the “Warrants”), one Series A Warrant and one
Series B Warrant (collectively, the “February 2022 Offering”).
The
exercise prices of the Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock
splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. In addition,
in the event the Company effects a reverse stock split during the term of the Warrants, the exercise price of the Warrants following
such reverse split will be subject to further adjustment in the event the volume-weighted average trading price of our common stock for
the five days following such reverse stock split is lower than the exercise price of the Warrants. Also, subject to customary exceptions,
the exercise price of the Warrants is subject to adjustment in the event of issuances of the Company’s common stock or common stock
equivalents at a price below the exercise price of the Warrants. In such event, the exercise price of the Warrants will be reduced to
the price of the securities issued in such transactions. In the event of a fundamental transaction, as defined, the holder of a warrant
shall have the option, exercisable at any time concurrently with, or within 30 days after, the consummation of the fundamental transaction
to cause the Company to purchase such warrant from the holder for cash in an amount equal to the Black Scholes value of such warrant
calculated in accordance with the terms of Warrant.
On
February 18, 2022, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital
Partners LLC (“Roth”) and Maxim Group LLC, as co-agents (collectively, the “Agents”), pursuant to which the Company
paid the Agents an aggregate fee equal to 7.0% of the gross proceeds from the units sold in the February 2022 Offering and reimbursed
the Agents $100,000 for expenses incurred in connection with the February 2022 Offering. In addition, the Company issued warrants (the
“Placement Agent Warrants”) to Roth to purchase up to 37,000 shares of the Company’s common stock exercisable at an
exercise price of $18.50 per share. The Placement Agent Warrants were immediately exercisable and expire on the fifth anniversary of
the date of the issuance.
On
February 23, 2022, the Company closed the February 2022 Offering, and issued (i) 651,000 shares of common stock, (ii) Series A Warrants
to purchase 740,000 shares of common stock, (iii) Series B Warrants to purchase 740,000 shares of common stock, and (iv) Pre-Funded Warrants
to purchase 89,000 shares of common stock. The gross proceeds from the February 2022 Offering were $11,100,000 and the net proceeds,
after deducting the placement agent fees and offering expenses payable by us, were approximately $9,969,000. Included in the proceeds
were net proceeds of approximately $1,134,000 from the exercise of warrants exercised in connection with the February 2022 Offering.
Warrants
A
summary of the Company’s warrant activity is as follows:
Schedule of Warrants Activity
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (Years) | |
December 31, 2022 | |
| 1,526,701 | | |
$ | 8.67 | | |
| 2.39 | |
Granted | |
| - | | |
| - | | |
| - | |
Forfeitures | |
| - | | |
| - | | |
| - | |
Expirations | |
| (740,000 | ) | |
| 7.57 | | |
| - | |
Exercised | |
| (7,649 | ) | |
| - | | |
| - | |
September 30, 2023, all exercisable | |
| 779,052 | | |
$ | 8.95 | | |
| 2.14 | |
The
exercise prices of warrants outstanding and exercisable as of September 30, 2023, are as follows:
Schedule of Exercise Price of Warrants Outstanding and Exercisable
Warrants Outstanding and Exercisable (Shares) | |
Exercise Prices | |
769,351 | |
| 7.57 | |
9,701 | |
| 120.00 | |
779,052 | |
| | |
During
the nine months ended September 30, 2023, warrants exercisable into 7,649 shares of common stock were exercised for total proceeds of
$57,903. Based on the closing price of the Company’s common stock on September 30, 2023 of $7.38 per share, the intrinsic value
of the warrants as of September 30, 2023 was $318,570.
Stock
Options
A
summary of the Company’s stock option activity is as follows:
Schedule of Share-based Compensation, Stock Options, Activity
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (Years) | |
December 31, 2022 | |
| 13,294 | | |
$ | 217.05 | | |
| 6.80 | |
Granted | |
| 11,336 | | |
| 6.22 | | |
| 9.05 | |
Forfeitures | |
| (595 | ) | |
| 197.70 | | |
| 7.50 | |
Expirations | |
| (3,458 | ) | |
| 357.53 | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
September 30, 2023, outstanding | |
| 20,577 | | |
| 77.72 | | |
| 7.89 | |
September 30, 2023, exercisable | |
| 10,096 | | |
| 149.26 | | |
| 6.80 | |
The
exercise prices of options outstanding and exercisable as of September 30, 2023 are as follows:
Schedule of Exercise Price of Options Outstanding and Exercisable
Options Outstanding (Shares) | | |
Options Exercisable (Shares) | | |
Exercise Prices | |
10,000 | | |
| 1,250 | | |
$ | 6.01 | |
1,344 | | |
| 1,176 | | |
| 7.35 | |
1,344 | | |
| 168 | | |
| 7.78 | |
841 | | |
| 788 | | |
| 45.50 | |
1,002 | | |
| 668 | | |
| 80.50 | |
1,008 | | |
| 1,008 | | |
| 88.00 | |
840 | | |
| 840 | | |
| 116.70 | |
336 | | |
| 336 | | |
| 162.33 | |
3,862 | | |
| 3,862 | | |
| 300.00 | |
20,577 | | |
| 10,096 | | |
| | |
The
Company accounts for share-based payments in accordance with ASC 718 wherein grants are measured at the grant date fair value and charged
to operations over the vesting periods.
During
the nine months ended September 30, 2023 and 2022, the Company granted options to purchase an aggregate of 1,344 shares of common stock
to the independent members of the Company’s Board of Directors in connection with the compensation plan for such directors with
grant date fair values of $8,454 and $7,793, respectively, using a Black-Scholes option pricing model based on the following assumptions:
(i) a volatility rate of 146%, (ii) a discount rate of 3.81% and 3.35%, respectively, (iii) zero expected dividend yield, and (iv) an
expected life of 3 years. The options have an exercise price of $7.78 and $7.35 per share, respectively. The options vest on a quarterly
basis over two years from the grant date, with the first tranche vesting on September 30, 2023.
During
the nine months ended September 30, 2023, the Company granted options to purchase 10,000 shares of common stock to the Company’s
new Chief Executive Officer (“CEO”) with a grant date fair value of $65,000 using a Black-Scholes option pricing model based
on the following assumptions: (i) a volatility rate of 146%, (ii) a discount rate of 3.80%, (iii) zero expected dividend yield, and (iv)
an expected life of 6 years. The options vest on a quarterly basis thereafter over two years.
The
Company’s former CEO resigned effective June 9, 2023. All options issued to the former CEO that were not vested at the time of
resignation were forfeited. Compensation expense previously recorded related to the unvested options was reversed, resulting in a reduction
of stock compensation expense of $(92,412) during the three months and nine months ended September 30, 2023.
The
Company computes stock price volatility over expected terms based on its historical common stock trading prices. The risk-free interest
rate was based on rates established by the Federal Reserve Bank. The expected dividend yield was based on the fact that the Company has
not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.
The expected life of the stock options granted is estimated using the “simplified” method, whereby the expected term equals
the average of the vesting term and the original contractual term of the stock option.
For
the nine months ended September 30, 2023 and 2022, the Company recognized aggregate stock-compensation expense of $(20,331) and $191,882,
respectively, related to the fair value of vested options, net of the impact of forfeitures.
As
of September 30, 2023, the Company had an aggregate of 10,096 remaining unvested options outstanding, with a remaining grant date fair
value of approximately $153,000 to be amortized over an average of 5 years. Based on the closing price of the Company’s common
stock on September 30, 2023 of $7.38 per share, the aggregate intrinsic value of unvested options outstanding as of September 30, 2023
was approximately $13,700.
Restricted
Common Stock
During
the nine months ended September 30, 2023 and 2022, there were no grants of restricted common stock.
During
the nine months ended September 30, 2023 and 2022, the Company recognized share-based compensation expense of $12,911 and $76,938, respectively,
related to vested restricted shares. At September 30, 2023, there was $6,534 of unvested compensation related to the non-vested shares
that will be amortized over a remaining vesting period of one year.
The
following table summarizes restricted common stock activity for the nine months ended September 30, 2023:
Schedule of Non Vested Restricted Common Stock Activity
| |
Number of shares | | |
Fair value of shares | |
Non-vested shares, December 31, 2022 | |
| 667 | | |
$ | 80.50 | |
Granted | |
| - | | |
| - | |
Vested | |
| 250 | | |
| - | |
Forfeited | |
| - | | |
| - | |
Non-vested shares, September 30, 2023 | |
| 417 | | |
| 80.50 | |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Commitments and Contingencies
|
9 Months Ended |
Sep. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
Commitments and Contingencies |
9.
Commitments and Contingencies
Employment
Agreement
On
June 19, 2023, the Board of Directors appointed Jan Hall as President and Chief Executive Officer of the Company. The Company and Ms.
Hall entered into an employment agreement pursuant to which Ms. Halls’ annual base salary is $370,000 and provides that Ms. Hall
shall have an annual target cash bonus of no less than her base salary based on performance objectives determined by the Compensation
Committee of the Board of Directors. With respect to the 2023 performance period, Ms. Hall’s annual bonus will be equal to either
(i) her full target bonus, prorated based on a period commencing on June 19, 2023, or (ii) in the event there is a change in control
of the Company that is consummated on or before March 31, 2024, $200,000, subject to remaining employed through the payment of her bonus
(which may be up to 90 days following the change in control), compliance with her restrictive covenants, her execution and non-revocation
of a general release of claims against the Company, and if requested, entering into any offer letter, restrictive covenant agreement
and/or employment agreement with the buyer after being offered an opportunity to negotiate such agreements in good faith; provided, however,
that in no event will she be entitled to both payments with respect to the 2023 performance period. In the event the Company terminates
Ms. Hall’s employment without cause, she resigns for good reason or her employment is terminated by the Company following a change
in control of the Company, subject to executing and not revoking a general release of claims against the Company and complying with her
restrictive covenants, she will be entitled to (a) nine months of salary continuation, which is to be increased to twelve months if the
qualifying termination of her employment occurs on or after June 19, 2024; (b) any unpaid annual bonus for the year prior to the year
in which the termination of her employment occurs; (c) a prorated bonus for the year in which the termination of her employment occurs,
based on actual performance; and (d) any salary earned and vested benefits accrued prior to Ms. Hall’s termination of employment.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Subsequent Events
|
9 Months Ended |
Sep. 30, 2023 |
Subsequent Events [Abstract] |
|
Subsequent Events |
10.
Subsequent Events
The
Company performed an evaluation of subsequent events through the date of filing of these condensed consolidated financial statements
with the SEC. Other than those matters described elsewhere in the footnotes, there were no material subsequent events which affected,
or could affect, the amounts or disclosures in the condensed consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies (Policies)
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
Basis of Presentation |
Basis
of Presentation
The
unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the
United States of America (“GAAP”) pursuant to the applicable rules and regulations of the Securities and Exchange Commission
(“SEC”) for interim financial information. The unaudited condensed consolidated financial statements have been prepared on
the same basis as the Company’s annual financial statements for the year ended December 31, 2022, and, in the opinion of management,
reflect all adjustments, which consist of normal recurring adjustments, considered necessary for a fair presentation of the periods presented.
The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected
for the full fiscal year ending December 31, 2023.
These
unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial
statements and accompanying notes for the fiscal year ended December 31, 2022 included in the Company’s December 31, 2022 Annual
Report on Form 10-K, which was filed with the SEC on April 17, 2023. The condensed consolidated balance sheet as of December 31, 2022
was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes,
required by GAAP.
The
Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.
All inter-company transactions and balances have been eliminated in consolidation.
In
accordance with the “Segment Reporting” Topic of the Accounting Standards Codification, the Company’s chief operating
decision maker (the Company’s Chief Executive Officer) determined that the Company has only one reporting unit.
|
Reverse Stock Split |
Reverse
Stock Split
On
January 6, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of
State of the State of Delaware to effectuate a one-for-fifty (1:50) reverse stock split of its outstanding common stock without any change
to its par value. The authorized number of shares of common stock was not affected by the reverse stock split. The Company issued 35,281
additional common shares in connection with this reverse stock split per the Company’s determination to round up all fractional
shares resulting from the reverse stock split to the nearest whole share.
Accordingly,
all common shares, stock options, stock warrants and per share amounts in these consolidated financial statements have been adjusted
retroactively to reflect the reverse stock split as if the split occurred at the beginning of the earliest period presented in this Quarterly
Report on Form 10-Q.
|
Use of Estimates |
Use
of Estimates
The
preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions
that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities.
On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates
include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing the warrant derivative
liability, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets,
assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities,
and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.
|
Revenue Recognition |
Revenue
Recognition
Revenue
and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon delivery to the
customer. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts
with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause
revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of
the goods and therefore represent a fulfillment activity rather than a promised service to the customer.
All
products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance
obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives
or discounts that could cause revenue to be allocated or adjusted over time.
Shipping
and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity
rather than a promised service to the customer. Historically the Company has not experienced any significant payment delays from customers.
Due
to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products and assessment of
performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract
asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly
basis.
At
September 30, 2023 and December 31, 2022, the allowance for doubtful accounts was zero and $1,996, respectively.
The
Company’s revenues by product line for the three months and nine months ended September 30, 2023 and 2022 are as a follows:
Schedule of Revenues by Product
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Clinical Nutrition | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,663 | |
Other | |
| - | | |
| - | | |
| - | | |
| 18,719 | |
Revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
Substantially
all of the Company’s revenues earned during the three months and nine months ended September 30, 2023 and 2022 are derived from
sales of the Company’s clinical nutrition products primarily to retail customers in North America.
The
Company’s revenues by geographical area for the three months and nine months ended September 30, 2023 and 2022 are as follows:
Schedule of Revenue by Geographical Area
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,483 | |
Europe and other | |
| - | | |
| - | | |
| - | | |
| 18,899 | |
Total revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
Third-Party
Outsourcing
The
Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center which provides order
processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s
products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues.
In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional
services.
The
Company outsources the production of substantially all its products with a third-party that manufactures and packages the finished products
under a product supply agreement.
Costs
incurred related to third-party outsourcing, which includes manufacturing, order processing and fulfillment, customer invoicing, collections
and warehousing, were $1,759,260 and $1,876,259 for the three months ended September 30, 2023 and 2022, respectively, and $4,339,388
and $1,932,967 for the nine months ended September 30, 2023 and 2022, respectively.
|
Cost of Goods Sold |
Cost
of Goods Sold
Cost
of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees and in-bound freight charges.
|
Shipping Costs |
Shipping
Costs
Shipping
costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense
totaled $135,059 and $209,804 for the three months ended September 30, 2023 and 2022, respectively, and $416,101 and $622,178 for the
nine months ended September 30, 2023 and 2022, respectively.
|
Advertising Costs |
Advertising
Costs
Advertising
costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $279,457 and $385,010 for the
three months ended September 30, 2023 and 2022, respectively, and $1,109,310 and $1,264,740 for the nine months ended September 30, 2023
and 2022, respectively.
|
Concentrations |
Concentrations
Revenue.
During the three months ended September 30, 2023, the Company had two customers that accounted for 68% of total revenue. During the
nine months ended September 30, 2023, the Company had two customers that accounted for 64% of total revenue. During the three months
ended September 30, 2023, the largest customer accounted for 47% of the Company’s total revenue, and the second largest customer
accounted for 21% of the Company’s total revenue. During the nine months ended September 30, 2023, the largest customer accounted
for 50% of the Company’s total revenue and the second largest customer accounted for 14%. During the three months ended September
30, 2022, the Company had one customer that accounted for 57% of total revenue. During the nine months ended September 30, 2022, the
Company had one customer that accounted for 56% of the Company’s total revenue. No other customer accounted for more than 10% of
revenue during the three months and nine months ended September 30, 2023 and 2022. The Company sells the majority of its products to
one of the largest retailers in the United States.
Accounts
receivable. As of September 30, 2023, the Company had accounts receivable from one customer which comprised approximately 61% of
its accounts receivable and one customer that accounted for approximately 13% of its accounts receivable. As of December 31, 2022, the
Company had accounts receivable from one customer which comprised approximately 88% of its accounts receivable. No other customer accounted
for more than 10% of accounts receivable as of September 30, 2023 and December 31, 2022.
Purchases
from vendors. During the three months and nine months ended September 30, 2023 and 2022, the Company utilized one manufacturer for
most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately
59% and 47% of all purchases during the three months and nine months ended September 30, 2023, respectively. Total purchases from this
manufacturer accounted for approximately 49% and 46% of all purchases during the three months and nine months ended September 30, 2022,
respectively.
Accounts
payable. As of September 30, 2023, one vendor accounted for 84% of total accounts payable. As of December 31, 2022, one vendor accounted
for 88% of the total accounts payable. One other vendor accounted for 13% of total accounts payable as of September 30, 2023. No other
vendor accounted for more than 10% of accounts payable as of December 31, 2022.
Cash
and cash equivalents. Cash and cash equivalents consist of funds deposited with BMO Harris Bank (“BMO”), which is a major,
established, high quality financial institution, in short-term (original maturity of generally 60 days or less) liquid investments in
money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net
asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with
BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests
solely in high quality U.S. government issued securities. As of September 30, 2023, $7,657,309 included in cash and cash equivalents
was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance
Corporation (the “FDIC”).
The
Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000,
respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because
of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced
any losses to date resulting from this policy.
|
Stock-Based Compensation |
Stock-Based
Compensation
Stock-based
awards for stock options and restricted stock awards to employees and non-employees are accounted for by using the fair value method
in accordance with ASC 718, Share-Compensation – Stock Compensation. The estimated fair value of stock options granted to
employees in exchange for services is measured at the grant date, using a fair value-based method, such as a Black-Scholes option valuation
model, and is recognized as an expense on a straight-line basis over the requisite service periods. The assumptions used in the Black-Scholes
option pricing model could materially affect compensation expense recorded in future periods. The fair value of restricted stock units
is measured at the grant date based on the closing market price of the Company’s common stock on the date of grant and is recognized
as an expense on a straight-line basis over the requisite service periods. Recognition of compensation expense for non-employees is accounted
for in the same period and manner as if the Company had paid cash for the services.
|
Warrants |
Warrants
The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s
specific terms and applicable authoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities
from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the
Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance
outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of
professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are
outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be
recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the
criteria for equity classification, the warrants are required to be liability classified and recorded at their initial fair value on
the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants
are recognized as a non-cash gain or loss on the statements of operations. The Company has determined that the warrants issued in the
February 18, 2022 equity financing (see Note 6) meet the requirements for liability classification.
|
Income (Loss) per Common Share |
Income
(Loss) per Common Share
Basic
earnings (loss) per share (“EPS” or “LPS”) is computed by dividing net loss by the weighted-average common
shares outstanding during the period, excluding shares of unvested restricted common stock outstanding. Diluted EPS/LPS is computed
based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the
period calculated using the treasury stock method. Shares of vested restricted stock are included in the diluted weighted average
number of common shares outstanding from the date they are vested. In addition, net earnings (loss) for diluted EPS/LPS is adjusted
for the impact of the assumed exercise of the
outstanding warrants, to the extent they are dilutive. For the three months ended September 30, 2022, and the nine months ended
September 30, 2023 and 2022, the Company recorded a net loss, as a result of which warrants, options, and unvested restricted shares
of common stock were excluded from the computation of diluted EPS/LPS because they were considered anti-dilutive. For the three
months ended September 30, 2023, the Company recorded net income, and it was determined that the applicable warrants and options
were out-of-the-money. For the three months ended September 30, 2023, the treasury stock method was not applied to options or
warrants that were out-of-the-money, and accordingly, the warrants, options, and unvested restricted shares of common stock were
excluded from the computation of diluted EPS/LPS because they were considered anti-dilutive.
The
following potentially dilutive shares were excluded from the shares used to calculate diluted earnings (loss) per share:
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share
| |
2023 | | |
2022 | |
| |
September 30, | |
| |
2023 | | |
2022 | |
Warrants | |
| 779,052 | | |
| 1,489,702 | |
Options | |
| 20,577 | | |
| 14,470 | |
Unvested restricted common stock | |
| 417 | | |
| 667 | |
Anti-dilutive securities | |
| 800,046 | | |
| 1,504,839 | |
|
Fair Value of Financial Instruments |
Fair
Value of Financial Instruments
Accounting
standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for
establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer
a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers
the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing
the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques
used to measure fair value:
Level
1 – Quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the
measurement date.
Level
2 – Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.
Level
3 – Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting
entity to develop its own assumptions.
The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the
lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company
performs an analysis of the assets and liabilities at each reporting period end.
The
following table sets forth by level, within the fair value hierarchy, the Company’s financial assets and liabilities at fair value
as of September 30, 2023, and December 31, 2022:
Schedule of Assets and Liabilities at Fair Value
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
September 30, 2023 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
December 31, 2022 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
The
following table provides a roll-forward of the warrant derivative liability measured at fair value on a recurring basis using unobservable
Level 3 inputs for the nine months ended September 30, 2023:
Schedule of Warrant Derivative Liability Measured at Fair Value
Warrant derivative liability | |
| | |
Balance as of beginning of period – December 31, 2022 | |
$ | 6,438,000 | |
Change in fair value of warrant derivative liability, during the period | |
| (2,693,600 | ) |
Balance as of end of period – September 30, 2023 | |
$ | 3,744,400 | |
As
of September 30, 2023, and December 31, 2022, the Company’s outstanding warrants were treated as derivative liabilities and changes
in the fair value were recognized in earnings (see Note 6). As of September 30, 2023, the current warrant derivative liability was zero
and the long-term warrant derivative liability was $3,744,400. As of December 31, 2022, the current warrant derivative liability was
$1,931,400 and the long-term warrant derivative liability was $4,506,600.
The
Company believes the carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, and
accounts payable and accrued liabilities, approximate fair value due to the short-term nature of such instruments and are excluded from
the fair value tables above.
|
Recent Accounting Pronouncements |
Recent
Accounting Pronouncements
In
September 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly
changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. ASU 2016-13 replaces
the “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based
on expected rather than incurred losses. Entities will apply the ASU 2016-13’s provisions as a cumulative-effect adjustment to
retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company,
ASU 2016-13 was effective for and adopted by the Company effective January 1, 2023. The adoption of ASU 2016-13 did not have any material
impact on the Company’s financial statement presentation or and related disclosures.
In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications
and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts
in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification
of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified
after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of
a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant
immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the
corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated
to equity issuance and debt origination or modification). ASU 2021-04 was effective for all entities for fiscal years beginning after
December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively
to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The
adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or related disclosures.
In
July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement — Reporting Comprehensive
Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation — Stock Compensation
(Topic 718) Presentation of Financial Statements (“ASU 2023-03”). ASU 2023-03 amends the FASB Accounting Standards Codification
to include Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022
EITF Meeting, and SEC Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 — General Revision of Regulation S-X:
Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new guidance, there was no transition or effective date
associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03
did not have any impact on the Company’s consolidated financial statement presentation or related disclosures.
Other
recent accounting pronouncements and guidance issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future
financial statements.
|
X |
- DefinitionReverse Stock Split [Policy Text Block]
+ References
+ Details
Name: |
GHSI_ReverseStockSplitPolicyTextBlock |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for warrants.
+ References
+ Details
Name: |
GHSI_WarrantsPolicyTextBlock |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for advertising cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_CompensationRelatedCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for credit risk.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
+ Details
Name: |
us-gaap_ConcentrationRiskCreditRisk |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cost of product sold and service rendered.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 705 -Publisher FASB -URI https://asc.fasb.org//705/tableOfContent
+ Details
Name: |
us-gaap_CostOfSalesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 60 -Paragraph 1 -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1
+ Details
Name: |
us-gaap_FairValueOfFinancialInstrumentsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue from contract with customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.
+ References
+ Details
Name: |
us-gaap_ShippingAndHandlingCostPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
Schedule of Revenues by Product |
The
Company’s revenues by product line for the three months and nine months ended September 30, 2023 and 2022 are as a follows:
Schedule of Revenues by Product
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Clinical Nutrition | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,663 | |
Other | |
| - | | |
| - | | |
| - | | |
| 18,719 | |
Revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
|
Schedule of Revenue by Geographical Area |
The
Company’s revenues by geographical area for the three months and nine months ended September 30, 2023 and 2022 are as follows:
Schedule of Revenue by Geographical Area
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
North America | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,304,483 | |
Europe and other | |
| - | | |
| - | | |
| - | | |
| 18,899 | |
Total revenue | |
$ | 3,337,190 | | |
$ | 2,663,550 | | |
$ | 9,312,695 | | |
$ | 8,323,382 | |
|
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share |
The
following potentially dilutive shares were excluded from the shares used to calculate diluted earnings (loss) per share:
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share
| |
2023 | | |
2022 | |
| |
September 30, | |
| |
2023 | | |
2022 | |
Warrants | |
| 779,052 | | |
| 1,489,702 | |
Options | |
| 20,577 | | |
| 14,470 | |
Unvested restricted common stock | |
| 417 | | |
| 667 | |
Anti-dilutive securities | |
| 800,046 | | |
| 1,504,839 | |
|
Schedule of Assets and Liabilities at Fair Value |
The
following table sets forth by level, within the fair value hierarchy, the Company’s financial assets and liabilities at fair value
as of September 30, 2023, and December 31, 2022:
Schedule of Assets and Liabilities at Fair Value
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
September 30, 2023 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 3,744,400 | | |
$ | 3,744,400 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
December 31, 2022 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Total assets | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant derivative liability | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
Total liabilities | |
$ | - | | |
$ | - | | |
$ | 6,438,000 | | |
$ | 6,438,000 | |
|
Schedule of Warrant Derivative Liability Measured at Fair Value |
The
following table provides a roll-forward of the warrant derivative liability measured at fair value on a recurring basis using unobservable
Level 3 inputs for the nine months ended September 30, 2023:
Schedule of Warrant Derivative Liability Measured at Fair Value
Warrant derivative liability | |
| | |
Balance as of beginning of period – December 31, 2022 | |
$ | 6,438,000 | |
Change in fair value of warrant derivative liability, during the period | |
| (2,693,600 | ) |
Balance as of end of period – September 30, 2023 | |
$ | 3,744,400 | |
|
X |
- DefinitionSchedule of revenues by product [Table Text Block]
+ References
+ Details
Name: |
GHSI_ScheduleOfRevenuesByProductTableTextBlock |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of all information related to the key inputs and assumptions used in measuring the fair value of assets obtained or liabilities incurred, as the result of a sale of financial assets, relating to the transferor's continuing involvement, if any, at the time of securitization, asset-backed financing arrangement, or similar transfer (including at a minimum, but not limited to, and if applicable, quantitative information about discount rates, expected prepayments including the expected weighted-average life of prepayable financial assets, and anticipated credit losses, including expected static pool losses).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481326/860-20-50-3
+ Details
Name: |
us-gaap_ScheduleOfAssumptionsForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Inventories (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Inventory Disclosure [Abstract] |
|
Schedule of Inventories |
Inventories
consist of the following:
Schedule of Inventories
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Raw materials | |
$ | 35,405 | | |
$ | 49,637 | |
Finished goods | |
| 2,415,245 | | |
| 3,069,784 | |
Inventories, net | |
$ | 2,450,650 | | |
$ | 3,119,421 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Warrant Derivative Liability (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
|
Schedule of Warrant Derivative Liability |
Schedule of Warrant Derivative Liability
| |
Series A Warrants | | |
Series B Warrants | |
| |
September 30, 2023 | | |
December 31, 2022 | | |
September 30, 2023 | | |
December 31, 2022 | |
Common stock market price | |
$ | 7.38 | | |
$ | 7.26 | | |
$ | - | | |
$ | 7.26 | |
Exercise price | |
| 7.57 | | |
| 7.88 | | |
| - | | |
| 7.88 | |
Expected term (in years) | |
| 3.40 | | |
| 4.15 | | |
| - | | |
| 0.65 | |
Expected volatility | |
| 102.40 | % | |
| 131.20 | % | |
| - | | |
| 104.50 | % |
Expected dividend yield | |
| - | | |
| - | | |
| - | | |
| - | |
Risk-free interest rate | |
| 4.75 | % | |
| 4.11 | % | |
| - | | |
| 4.75 | % |
Total fair value | |
$ | 3,744,400 | | |
$ | 4,506,600 | | |
$ | - | | |
$ | 1,931,400 | |
|
X |
- DefinitionSchedule Of Warrant Derivative Liability [Table Text Block]
+ References
+ Details
Name: |
GHSI_ScheduleOfWarrantDerivativeLiabilityTableTextBlock |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Redeemable Preferred Stock (Temporary Equity, redeemed in full in February 2023) (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
Schedule of Preferred Stock |
The
following table reconciles the Series C and Series D Preferred Stock reflected on the balance sheet at December 31, 2022:
Schedule of Preferred Stock
| |
Series C Preferred
Stock | | |
Series D Preferred
Stock | |
Gross Proceeds | |
$ | 4,702,500 | | |
$ | 47,500 | |
Less: | |
| | | |
| | |
Preferred stock issuance costs | |
| (437,169 | ) | |
| (4,416 | ) |
Plus: | |
| | | |
| | |
Accretion of carrying value to redemption value | |
| 932,169 | | |
| 9,416 | |
Preferred stock subject to possible redemption | |
$ | 5,197,500 | | |
$ | 52,500 | |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 5 -Subparagraph (SAB TOPIC 4.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5
+ Details
Name: |
us-gaap_ScheduleOfPreferredUnitsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stockholders’ Equity (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
Schedule of Warrants Activity |
A
summary of the Company’s warrant activity is as follows:
Schedule of Warrants Activity
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (Years) | |
December 31, 2022 | |
| 1,526,701 | | |
$ | 8.67 | | |
| 2.39 | |
Granted | |
| - | | |
| - | | |
| - | |
Forfeitures | |
| - | | |
| - | | |
| - | |
Expirations | |
| (740,000 | ) | |
| 7.57 | | |
| - | |
Exercised | |
| (7,649 | ) | |
| - | | |
| - | |
September 30, 2023, all exercisable | |
| 779,052 | | |
$ | 8.95 | | |
| 2.14 | |
|
Schedule of Exercise Price of Warrants Outstanding and Exercisable |
The
exercise prices of warrants outstanding and exercisable as of September 30, 2023, are as follows:
Schedule of Exercise Price of Warrants Outstanding and Exercisable
Warrants Outstanding and Exercisable (Shares) | |
Exercise Prices | |
769,351 | |
| 7.57 | |
9,701 | |
| 120.00 | |
779,052 | |
| | |
|
Schedule of Share-based Compensation, Stock Options, Activity |
A
summary of the Company’s stock option activity is as follows:
Schedule of Share-based Compensation, Stock Options, Activity
| |
Shares | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (Years) | |
December 31, 2022 | |
| 13,294 | | |
$ | 217.05 | | |
| 6.80 | |
Granted | |
| 11,336 | | |
| 6.22 | | |
| 9.05 | |
Forfeitures | |
| (595 | ) | |
| 197.70 | | |
| 7.50 | |
Expirations | |
| (3,458 | ) | |
| 357.53 | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
September 30, 2023, outstanding | |
| 20,577 | | |
| 77.72 | | |
| 7.89 | |
September 30, 2023, exercisable | |
| 10,096 | | |
| 149.26 | | |
| 6.80 | |
|
Schedule of Exercise Price of Options Outstanding and Exercisable |
The
exercise prices of options outstanding and exercisable as of September 30, 2023 are as follows:
Schedule of Exercise Price of Options Outstanding and Exercisable
Options Outstanding (Shares) | | |
Options Exercisable (Shares) | | |
Exercise Prices | |
10,000 | | |
| 1,250 | | |
$ | 6.01 | |
1,344 | | |
| 1,176 | | |
| 7.35 | |
1,344 | | |
| 168 | | |
| 7.78 | |
841 | | |
| 788 | | |
| 45.50 | |
1,002 | | |
| 668 | | |
| 80.50 | |
1,008 | | |
| 1,008 | | |
| 88.00 | |
840 | | |
| 840 | | |
| 116.70 | |
336 | | |
| 336 | | |
| 162.33 | |
3,862 | | |
| 3,862 | | |
| 300.00 | |
20,577 | | |
| 10,096 | | |
| | |
|
Schedule of Non Vested Restricted Common Stock Activity |
The
following table summarizes restricted common stock activity for the nine months ended September 30, 2023:
Schedule of Non Vested Restricted Common Stock Activity
| |
Number of shares | | |
Fair value of shares | |
Non-vested shares, December 31, 2022 | |
| 667 | | |
$ | 80.50 | |
Granted | |
| - | | |
| - | |
Vested | |
| 250 | | |
| - | |
Forfeited | |
| - | | |
| - | |
Non-vested shares, September 30, 2023 | |
| 417 | | |
| 80.50 | |
|
X |
- DefinitionSchedule of Exercise Price of Warrants Outstanding and Exercisable [Table Text Block]
+ References
+ Details
Name: |
GHSI_ScheduleOfExercisePriceOfWarrantsOutstandingAndExercisableTableTextBlock |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Organization and Business Operations (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
|
|
|
Net loss |
$ 772,914
|
$ 1,739,394
|
$ 3,249,567
|
$ 6,071,020
|
|
Net cash used in operating activities |
|
|
3,052,293
|
$ 6,082,906
|
|
Cash and cash equivalents balance |
$ 7,657,309
|
|
$ 7,657,309
|
|
$ 10,655,490
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Schedule of Revenues by Product (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Product Information [Line Items] |
|
|
|
|
Revenue |
$ 3,337,190
|
$ 2,663,550
|
$ 9,312,695
|
$ 8,323,382
|
Clinical Nutrition [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
3,337,190
|
2,663,550
|
9,312,695
|
8,304,663
|
Other [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Revenue |
|
|
|
$ 18,719
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=GHSI_ClinicalNutritionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=GHSI_OtherMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Revenue by Geographical Area (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Total revenue |
$ 3,337,190
|
$ 2,663,550
|
$ 9,312,695
|
$ 8,323,382
|
North America [Member] |
|
|
|
|
Total revenue |
3,337,190
|
2,663,550
|
9,312,695
|
8,304,483
|
Europe [Member] |
|
|
|
|
Total revenue |
|
|
|
$ 18,899
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=srt_NorthAmericaMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=srt_EuropeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share (Details) - shares
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Anti-dilutive securities |
800,046
|
1,504,839
|
Warrant [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Anti-dilutive securities |
779,052
|
1,489,702
|
Options [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Anti-dilutive securities |
20,577
|
14,470
|
Unvested Restricted Common Stock [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Anti-dilutive securities |
417
|
667
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GHSI_OptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GHSI_UnvestedRestrictedCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Assets and Liabilities at Fair Value (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
|
|
Total liabilities |
3,744,400
|
6,438,000
|
Warrant Liability [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total liabilities |
3,744,400
|
6,438,000
|
Fair Value, Inputs, Level 1 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
|
|
Total liabilities |
|
|
Fair Value, Inputs, Level 1 [Member] | Warrant Liability [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total liabilities |
|
|
Fair Value, Inputs, Level 2 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
|
|
Total liabilities |
|
|
Fair Value, Inputs, Level 2 [Member] | Warrant Liability [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total liabilities |
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
|
|
Total liabilities |
3,744,400
|
6,438,000
|
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total liabilities |
$ 3,744,400
|
$ 6,438,000
|
X |
- DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_AssetsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value of financial and nonfinancial obligations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=GHSI_WarrantLiabilityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Warrant Derivative Liability Measured at Fair Value (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Accounting Policies [Abstract] |
|
|
|
|
Warrant derivative liability, beginning balance |
|
|
$ 6,438,000
|
|
Gain on change in fair value of warrant derivate liability |
$ (1,050,800)
|
$ (873,200)
|
(2,693,600)
|
$ (3,548,300)
|
Warrant derivative liability,ending balance |
$ 3,744,400
|
|
$ 3,744,400
|
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.
+ References
+ Details
Name: |
us-gaap_LiabilitiesFairValueAdjustment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial and nonfinancial obligations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Summary of Significant Accounting Policies (Details Narrative)
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Jan. 06, 2023
shares
|
Sep. 30, 2023
USD ($)
shares
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2023
USD ($)
Segment
shares
|
Sep. 30, 2022
USD ($)
|
Dec. 31, 2022
USD ($)
shares
|
Product Information [Line Items] |
|
|
|
|
|
|
Number of reporting units | Segment |
|
|
|
1
|
|
|
Stockholders' equity, reverse stock split |
one-for-fifty (1:50) reverse stock split
|
|
|
|
|
|
Common stock shares issued | shares |
|
1,275,239
|
|
1,275,239
|
|
1,267,340
|
Allowance for doubtful accounts |
|
$ 0
|
|
$ 0
|
|
$ 1,996
|
Third party outsourcing |
|
1,759,260
|
$ 1,876,259
|
4,339,388
|
$ 1,932,967
|
|
Cost of goods sold |
|
1,876,938
|
1,575,366
|
5,267,874
|
4,739,197
|
|
Advertising expense |
|
279,457
|
$ 385,010
|
1,109,310
|
$ 1,264,740
|
|
Cash and cash equivalents balance |
|
7,657,309
|
|
7,657,309
|
|
10,655,490
|
Cash FDIC insured amount |
|
250,000
|
|
250,000
|
|
|
Cash SIPC insured amount |
|
500,000
|
|
500,000
|
|
|
Warrant derivative liability - long-term |
|
3,744,400
|
|
3,744,400
|
|
4,506,600
|
Warrant derivative liability - current |
|
|
|
|
|
$ 1,931,400
|
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
68.00%
|
|
64.00%
|
|
|
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
47.00%
|
57.00%
|
50.00%
|
56.00%
|
|
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Second Largest Customer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
21.00%
|
|
14.00%
|
|
|
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Other Customers [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
10.00%
|
10.00%
|
10.00%
|
10.00%
|
|
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
|
|
|
|
88.00%
|
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | One Manufacturer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
59.00%
|
49.00%
|
47.00%
|
46.00%
|
|
Accounts Payable [Member] | Customer Concentration Risk [Member] | One Vendor [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
|
|
84.00%
|
|
88.00%
|
Shipping and Handling [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Cost of goods sold |
|
$ 135,059
|
$ 209,804
|
$ 416,101
|
$ 622,178
|
|
Maximum [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Common stock shares issued | shares |
35,281
|
|
|
|
|
|
Maximum [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
|
|
61.00%
|
|
|
Minimum [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
|
|
13.00%
|
|
|
Minimum [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Other Customers [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
|
|
10.00%
|
|
10.00%
|
Minimum [Member] | Accounts Payable [Member] | Customer Concentration Risk [Member] | Other Vendor [Member] |
|
|
|
|
|
|
Product Information [Line Items] |
|
|
|
|
|
|
Concentration risk, percentage |
|
|
|
13.00%
|
|
10.00%
|
X |
- DefinitionCash SIPC insured amount.
+ References
+ Details
Name: |
GHSI_CashSIPCInsuredAmount |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Definition
+ References
+ Details
Name: |
GHSI_ThirdPartyOutsourcing |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionWarrant derivative liability current.
+ References
+ Details
Name: |
GHSI_WarrantDerivativeLiabilityCurrent |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionWarrant derivative liability non current.
+ References
+ Details
Name: |
GHSI_WarrantDerivativeLiabilityNonCurrent |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of allowance for credit loss on accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
+ Details
Name: |
us-gaap_CashFDICInsuredAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20
+ Details
Name: |
us-gaap_ConcentrationRiskPercentage1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.
+ References
+ Details
Name: |
us-gaap_NumberOfReportingUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_TwoCustomerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_OneCustomerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_SecondLargestCustomerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_OtherCustomersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_OneManufacturerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_OneVendorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=GHSI_OtherVendorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Inventories (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Inventory Disclosure [Abstract] |
|
|
Raw materials |
$ 35,405
|
$ 49,637
|
Finished goods |
2,415,245
|
3,069,784
|
Inventories, net |
$ 2,450,650
|
$ 3,119,421
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregated amount of merchandise or goods held by the entity and readily available for future sale plus items held by the entity which are partially complete or in the process of being readied for future sale. This amount is net of valuation reserves and adjustments.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryFinishedGoodsAndWorkInProcessNetOfReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryRawMaterialsNetOfReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.3
Intangible Assets, Net (Details Narrative) - USD ($)
|
12 Months Ended |
|
|
|
Dec. 31, 2022 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
|
|
|
Intangible assets, gross |
|
|
|
$ 11,900,000
|
Impairment loss |
$ 10,065,833
|
|
|
|
Amortization expense |
|
$ 892,500
|
$ 297,500
|
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2
+ Details
Name: |
us-gaap_GoodwillImpairmentLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.3
Operating Leases (Details Narrative) - USD ($)
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
12 Months Ended |
Jul. 31, 2021 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Operating Leases |
|
|
|
|
|
|
Payments for operating lease liability |
$ 2,700
|
|
|
|
|
$ 22,221
|
Operating lease right of use asset |
|
|
|
|
$ 24,257
|
24,257
|
Operating lease liability current |
|
|
|
|
|
$ 3,807
|
X |
- References
+ Details
Name: |
GHSI_DisclosureOperatingLeasesAbstract |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from impairment of right-of-use asset from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6
+ Details
Name: |
us-gaap_OperatingLeaseImpairmentLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.3
Schedule of Warrant Derivative Liability (Details)
|
Sep. 30, 2023
USD ($)
$ / shares
|
Dec. 31, 2022
USD ($)
$ / shares
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Total fair value | $ |
$ 3,744,400
|
$ 4,506,600
|
Series A Warrants [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Total fair value | $ |
$ 3,744,400
|
$ 4,506,600
|
Series A Warrants [Member] | Measurement Input, Share Price [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Exercise price |
$ 7.38
|
$ 7.26
|
Series A Warrants [Member] | Measurement Input, Exercise Price [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Exercise price |
$ 7.57
|
$ 7.88
|
Series A Warrants [Member] | Measurement Input, Expected Term [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input, expected life (years) |
3 years 4 months 24 days
|
4 years 1 month 24 days
|
Series A Warrants [Member] | Measurement Input, Price Volatility [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input |
102.40
|
131.20
|
Series A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input |
|
|
Series A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input |
4.75
|
4.11
|
Series B Warrants [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Total fair value | $ |
|
$ 1,931,400
|
Series B Warrants [Member] | Measurement Input, Share Price [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Exercise price |
|
$ 7.26
|
Series B Warrants [Member] | Measurement Input, Exercise Price [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Exercise price |
|
$ 7.88
|
Series B Warrants [Member] | Measurement Input, Expected Term [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input, expected life (years) |
|
7 months 24 days
|
Series B Warrants [Member] | Measurement Input, Price Volatility [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input |
|
104.50
|
Series B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input |
|
|
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
Warrant liability, measurement input |
|
4.75
|
X |
- DefinitionWarrant derivative liability non current.
+ References
+ Details
Name: |
GHSI_WarrantDerivativeLiabilityNonCurrent |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
+ Details
Name: |
us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_SeriesAWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_SeriesBWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Warrant Derivative Liability (Details Narrative) - USD ($)
|
|
|
3 Months Ended |
9 Months Ended |
|
|
Nov. 30, 2022 |
Feb. 18, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Jan. 31, 2023 |
Dec. 31, 2022 |
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Fair value of the warrant liability |
|
|
|
$ 3,744,400
|
|
|
$ 6,438,000
|
Fair value of warrants |
|
|
|
$ (2,693,600)
|
$ (3,548,300)
|
|
|
Series C Preferred Stock [Member] |
|
|
|
|
|
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Exercise price |
$ 7.88
|
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Common stock issued for cash, net of offering costs, shares |
|
|
651,000
|
|
|
|
|
Series B Warrant [Member] |
|
|
|
|
|
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Number of warrants |
|
|
|
740,000
|
|
|
|
Warrants expiration |
|
|
|
Aug. 24, 2023
|
|
|
|
Fair value of warrants |
|
|
|
$ 0
|
|
|
|
Securities Purchase Agreement [Member] | Series A Warrant [Member] |
|
|
|
|
|
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Sale of common stock, shares |
|
740,000
|
|
|
|
|
|
Exercise price |
|
$ 18.50
|
|
|
|
$ 7.57
|
|
Securities Purchase Agreement [Member] | Series B Warrant [Member] |
|
|
|
|
|
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Sale of common stock, shares |
|
740,000
|
|
|
|
|
|
Exercise price |
|
$ 18.50
|
|
|
|
$ 7.57
|
|
Securities Purchase Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
|
|
|
|
|
|
Common stock issued for cash, net of offering costs, shares |
|
651,000
|
|
|
|
|
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial and nonfinancial obligations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
+ Details
Name: |
us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_WarrantExercisePriceDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_SeriesBWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=GHSI_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesAWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesBWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Preferred Stock (Details)
|
12 Months Ended |
Dec. 31, 2022
USD ($)
|
Series C Preferred Stock [Member] |
|
Class of Stock [Line Items] |
|
Gross Proceeds |
$ 4,702,500
|
Preferred stock issuance costs |
(437,169)
|
Accretion of carrying value to redemption value |
932,169
|
Preferred stock subject to possible redemption |
5,197,500
|
Series D Preferred Stock [Member] |
|
Class of Stock [Line Items] |
|
Gross Proceeds |
47,500
|
Preferred stock issuance costs |
(4,416)
|
Accretion of carrying value to redemption value |
9,416
|
Preferred stock subject to possible redemption |
$ 52,500
|
X |
- DefinitionPreferred stock subject to possible redemption.
+ References
+ Details
Name: |
GHSI_PreferredStockSubjectToPossibleRedemption |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsOfStockIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionValue of accretion of temporary equity to its redemption value during the period.
+ References
+ Details
Name: |
us-gaap_TemporaryEquityAccretionToRedemptionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Redeemable Preferred Stock (Temporary Equity, redeemed in full in February 2023) (Details Narrative) - USD ($)
|
|
12 Months Ended |
Nov. 29, 2022 |
Dec. 31, 2022 |
Class of Stock [Line Items] |
|
|
Voting rights description |
The Certificates
of Designation for the Preferred Stock provided that the Preferred Stock had no voting rights other than the right to vote on the Amendment
and as a class on certain other specified matters, and, with respect to the Series D Certificate of Designation, the right to cast 1,000,000
votes per share of Series D Preferred Stock on the Reverse Stock Split proposal. The Amendment required the approval of the majority
of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. On January 5, 2023, the Amendment
to authorize a reverse split of the Common Stock was approved at a special meeting of the Company’s stockholders. Following the
meeting, the board of directors approved a one-for-fifty (1-for-50) reverse split of the Company’s issued and outstanding shares
of common stock (see Note 2).
|
|
Proceeds from issuance of private placement |
|
$ 4,750,000
|
Proceeds from issuance of private placement additional |
|
$ 500,000
|
Redemption price percentage |
|
105.00%
|
Series C Convertible Redeemable Preferred Stock [Member] | Private Placement [Member] |
|
|
Class of Stock [Line Items] |
|
|
Series D convertible redeemable preferred stock, shares |
495,000
|
|
Series D Redeemable Preferred Stock [Member] | Private Placement [Member] |
|
|
Class of Stock [Line Items] |
|
|
Series D convertible redeemable preferred stock, shares |
5,000
|
|
X |
- DefinitionProceeds from issuance of private placement additional.
+ References
+ Details
Name: |
GHSI_ProceedsFromIssuanceOfPrivatePlacementAdditional |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph e -SubTopic 470 -Topic 942 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentRedemptionPricePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of units sold in a private placement of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5
+ Details
Name: |
us-gaap_PartnersCapitalAccountUnitsSoldInPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_PreferredStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesCConvertibleRedeemablePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=GHSI_SeriesDRedeemablePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Warrants Activity (Details)
|
9 Months Ended |
Sep. 30, 2023
$ / shares
shares
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Shares, Ending Balance |
779,052
|
Warrant [Member] |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Shares, Beginning Balance |
1,526,701
|
Weighted Average Exercise Price, Beginning Balance | $ / shares |
$ 8.67
|
Weighted Average Remaining Contractual Term (Years), Beginning Balance |
2 years 4 months 20 days
|
Shares, Granted |
|
Weighted Average Exercise Price, Granted | $ / shares |
|
Shares, Forfeitures |
|
Weighted Average Exercise Price, Forfeitures | $ / shares |
|
Shares, Expirations |
(740,000)
|
Weighted Average Exercise Price, Expirations | $ / shares |
$ 7.57
|
Shares, Exercised |
(7,649)
|
Weighted Average Exercise Price, Exercised | $ / shares |
|
Shares, Ending Balance |
779,052
|
Weighted Average Exercise Price, Ending Balance | $ / shares |
$ 8.95
|
Weighted Average Remaining Contractual Term (Years), Ending Balance |
2 years 1 month 20 days
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, exercised in period, weighted average exercise price.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, expirations in period, weighted average exercise price.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures in period, weighted average exercise price.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, grants in period, weighted average exercise price.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, weighted average exercise price.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, weighted average remaining contractual term.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, weighted average remaining contractual term.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of non-option equity instruments granted to participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_WarrantOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_WarrantTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Equity [Abstract] |
|
|
Shares Outstanding, Beginning Balance |
13,294
|
|
Weighted Average Exercise Price Outstanding, Beginning Balance |
$ 217.05
|
|
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance |
7 years 10 months 20 days
|
6 years 9 months 18 days
|
Shares, Granted |
11,336
|
|
Weighted Average Exercise Price, Granted |
$ 6.22
|
|
Weighted Average Remaining Contractual Term (Years) Outstanding, Beginning Balance |
9 years 18 days
|
|
Shares, Forfeitures |
(595)
|
|
Weighted Average Exercise Price, Forfeitures |
$ 197.70
|
|
Weighted Average Remaining Contractual Term (Years) Outstanding, Beginning Balance |
7 years 6 months
|
|
Shares, Expirations |
(3,458)
|
|
Weighted Average Exercise Price, Expirations |
$ 357.53
|
|
Shares, Exercised |
|
|
Weighted Average Exercise Price, Exercised |
|
|
Shares Outstanding, Ending Balance |
20,577
|
13,294
|
Weighted Average Exercise Price Outstanding, Ending Balance |
$ 77.72
|
$ 217.05
|
Shares Exercisable, Ending Balance |
10,096
|
|
Weighted Average Exercise Price Exercisable, Ending Balance |
$ 149.26
|
|
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance |
6 years 9 months 18 days
|
|
X |
- DefinitionSharebased compensation arrangement by sharebased payment award options forfeiture weighted average remaining contractual term 1.
+ References
+ Details
Name: |
GHSI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSharebased compensation arrangement by sharebased payment award options granted weighted average remaining contractual term 1.
+ References
+ Details
Name: |
GHSI_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Schedule of Exercise Price of Options Outstanding and Exercisable (Details) - $ / shares
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
20,577
|
13,294
|
Options Exercisable (Shares) |
10,096
|
|
Exercise Price One [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
10,000
|
|
Options Exercisable (Shares) |
1,250
|
|
Exercise Prices |
$ 6.01
|
|
Exercise Price Two [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
1,344
|
|
Options Exercisable (Shares) |
1,176
|
|
Exercise Prices |
$ 7.35
|
|
Exercise Price Three [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
1,344
|
|
Options Exercisable (Shares) |
168
|
|
Exercise Prices |
$ 7.78
|
|
Exercise Price Four [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
841
|
|
Options Exercisable (Shares) |
788
|
|
Exercise Prices |
$ 45.50
|
|
Exercise Price Five [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
1,002
|
|
Options Exercisable (Shares) |
668
|
|
Exercise Prices |
$ 80.50
|
|
Exercise Price Six [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
1,008
|
|
Options Exercisable (Shares) |
1,008
|
|
Exercise Prices |
$ 88.00
|
|
Exercise Price Seven [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
840
|
|
Options Exercisable (Shares) |
840
|
|
Exercise Prices |
$ 116.70
|
|
Exercise Price Eight [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
336
|
|
Options Exercisable (Shares) |
336
|
|
Exercise Prices |
$ 162.33
|
|
Exercise Price Nine [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Options Outstanding (Shares) |
3,862
|
|
Options Exercisable (Shares) |
3,862
|
|
Exercise Prices |
$ 300.00
|
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GHSI_ExercisePriceNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Non Vested Restricted Common Stock Activity (Details)
|
9 Months Ended |
Sep. 30, 2023
$ / shares
shares
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
Number of shares, Non-vested shares, ending |
10,096
|
Restricted Common Stock [Member] |
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
Number of shares, Non-vested shares, beginning |
667
|
Fair value of shares, Non-vested shares, beginning | $ / shares |
$ 80.50
|
Number of shares, Granted |
|
Fair value of shares, Granted | $ / shares |
|
Number of shares, Vested |
250
|
Fair value of shares, Vested | $ / shares |
|
Number of shares, Forfeited |
|
Fair value of shares, Forfeited | $ / shares |
|
Number of shares, Non-vested shares, ending |
417
|
Fair value of shares, Non-vested shares, ending | $ / shares |
$ 80.50
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=GHSI_RestrictedCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Stockholders’ Equity (Details Narrative) - USD ($)
|
|
|
|
3 Months Ended |
9 Months Ended |
Nov. 23, 2022 |
Feb. 23, 2022 |
Feb. 18, 2022 |
Sep. 30, 2023 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock issued during period value other |
|
|
|
|
$ 8,834,898
|
|
|
Proceeds from warrant exercises |
|
|
|
|
|
$ 57,903
|
$ 1,134,040
|
Granted options purchase |
|
|
|
|
|
11,336
|
|
Grand date fair value |
|
|
|
|
|
$ 153,000
|
|
Share based compensation |
|
|
|
|
|
$ 20,331
|
191,882
|
Unvested option |
|
|
|
10,096
|
|
10,096
|
|
Amortized period |
|
|
|
|
|
5 years
|
|
Intrinsic value |
|
|
|
$ 7.38
|
|
$ 7.38
|
|
Unvested options outstanding |
|
|
|
$ 13,700
|
|
$ 13,700
|
|
Restricted Stock [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Share-based compensation expense |
|
|
|
|
|
12,911
|
$ 76,938
|
Unvested compensation award |
|
|
|
6,534
|
|
$ 6,534
|
|
Unvested options, amortized year |
|
|
|
|
|
1 year
|
|
February 2022 Offering [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Net proceeds, after deduction |
$ 11,100,000
|
|
|
|
|
|
|
Net proceeds, after deduction |
9,969,000
|
|
|
|
|
|
|
Proceeds from warrant exercises |
$ 1,134,000
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Number of common stock issued |
|
|
|
|
|
7,649
|
|
Intrinsic value of warrants outstanding |
|
|
|
$ 318,570
|
|
$ 318,570
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock issued during period value other, units |
|
|
|
|
651,000
|
|
|
Stock issued during period value other |
|
|
|
|
$ 651
|
|
|
Series A Warrant [Member] | February 2022 Offering [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Warrants purchase shares of common stock series B |
|
740,000
|
|
|
|
|
|
Series B Warrant [Member] | February 2022 Offering [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Warrants purchase shares of common stock series B |
|
740,000
|
|
|
|
|
|
Warrants [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock price |
|
|
|
$ 7.38
|
|
$ 7.38
|
|
Number of common stock issued |
|
|
|
|
|
7,649
|
|
Issue of common stock |
|
|
|
|
|
$ 57,903
|
|
Investor [Member] | Warrant [Member] | February 2022 Offering [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Number of common stock issued |
|
89,000
|
|
|
|
|
|
Investor [Member] | Common Stock [Member] | February 2022 Offering [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock issued during period value other |
|
$ 651,000
|
|
|
|
|
|
Director [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Granted options purchase |
|
|
|
|
|
1,344
|
1,344
|
Grand date fair value |
|
|
|
|
|
$ 8,454
|
$ 7,793
|
Volatility rate |
|
|
|
|
|
146.00%
|
146.00%
|
Volatility rate |
|
|
|
|
|
3.81%
|
3.35%
|
Dividend yield |
|
|
|
|
|
0.00%
|
0.00%
|
Expected life |
|
|
|
|
|
3 years
|
3 years
|
Exercise price |
|
|
|
$ 7.78
|
|
$ 7.78
|
$ 7.35
|
option vest period |
|
|
|
|
|
2 years
|
2 years
|
Chief Executive Officer [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Granted options purchase |
|
|
|
|
|
10,000
|
|
Grand date fair value |
|
|
|
|
|
$ 65,000
|
|
Volatility rate |
|
|
|
|
|
146.00%
|
|
Volatility rate |
|
|
|
|
|
3.80%
|
|
Dividend yield |
|
|
|
|
|
0.00%
|
|
Expected life |
|
|
|
|
|
6 years
|
|
option vest period |
|
|
|
|
|
2 years
|
|
Share based compensation |
|
|
|
$ 92,412
|
|
$ 92,412
|
|
Securities Purchase Agreement [Member] | Series A Warrants [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock price |
|
|
$ 18.50
|
|
|
|
|
Securities Purchase Agreement [Member] | Series B Warrants [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock price |
|
|
$ 18.50
|
|
|
|
|
Securities Purchase Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock issued during period value other, units |
|
|
651,000
|
|
|
|
|
Securities Purchase Agreement [Member] | Investor [Member] | Warrant [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock issued during period value other, units |
|
|
651,000
|
|
|
|
|
Stock price |
|
|
$ 15.00
|
|
|
|
|
Number of common stock issued |
|
|
89,000
|
|
|
|
|
Securities Purchase Agreement [Member] | Investor [Member] | Series B Warrants [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock price |
|
|
$ 14.995
|
|
|
|
|
Securities Purchase Agreement [Member] | Investor [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock price |
|
|
0.005
|
|
|
|
|
Placement Agency Agreement [Member] | Roth Capital Partners LLC [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Stock price |
|
|
$ 18.50
|
|
|
|
|
Reimbursed expenses incurred |
|
|
$ 100,000
|
|
|
|
|
Placement Agency Agreement [Member] | Roth Capital Partners LLC [Member] | Maximum [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Warrants issued, shares |
|
|
37,000
|
|
|
|
|
Placement Agency Agreement [Member] | February 2022 Offering [Member] |
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
Number of stock sold percentage |
|
|
7.00%
|
|
|
|
|
X |
- DefinitionOffering expenses payable.
+ References
+ Details
Name: |
GHSI_OfferingExpensesPayable |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from issuance of preferred stock after deducting.
+ References
+ Details
Name: |
GHSI_ProceedsFromIssuanceOfPreferredStockAfterDeducting |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionReimbursed expenses incurred.
+ References
+ Details
Name: |
GHSI_ReimbursedExpensesIncurred |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation amortized period.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationAmortizedPeriod |
Namespace Prefix: |
GHSI_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSharebased compensation arrangement by share based payment award fairvalue assumptions expected discount rate.
+ References
+ Details
Name: |
GHSI_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate |
Namespace Prefix: |
GHSI_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPercentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIntrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480513/718-10-30-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480843/718-30-35-1
+ Details
Name: |
us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=GHSI_FebruaryTwoThousandTwentyTwoOfferingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_SeriesAWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_SeriesBWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=us-gaap_InvestorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_DirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=GHSI_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=GHSI_SeriesAWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=GHSI_SeriesBWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=GHSI_SeriesBWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=GHSI_PlacementAgencyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=GHSI_RothCapitalPartnersLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=GHSI_EmploymentAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=GHSI_JanetHallMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2023 to Aug 2024